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Abstract
In the de novo design of antibody specificity the aim is to define a set of 
complementarity determining region (CDR) residues which is able to bind a pre­
defined antigen. The starting point for this project was a monoclonal antibody 
(Gloop2) raised against residues 57-84 (the loop peptide) of hen-egg lysozyme (HEL) 
and the new target antigen was enkephalin. Both Gloop2 and enkephalin are 
structurally well characterised molecules through x-ray, and x-ray and NMR studies 
respectively.
Using a theoretical design procedure a docked complex between an all-alanine version of 
the Gloop2 combining site and enkephalin was constructed and, after reconstruction of 
side chains, twelve contact residues (7 in the heavy and 5 in the light chain) were 
identified as candidate positions for mutations. Each position was mutated to residue 
types, selected on the basis of both chemical redundancy and allowing for the fact that 
certain residues occur with high frequency in antibody combining sites. The resulting 
library was computationally screened using a simple force field and ten low energy 
complexes were selected.
The ten candidate antibodies were expressed as scFv fragments on the surface of 
filamentous phage creating a mini-library. The library was screened for binding to 
biotinylated enkephalin. After three rounds of selection, binding was observed and, DNA 
from the eluted binding phage was prepared and sequenced. It was found that the 
sequence matched one of the predicted mutation set. The scFv DNA of this selected 
design (GlaMor; Gk>op2 originated antibody with specificity for the Morphine family 
molecules) was subcloned as a cassette from the phage to an expression vector. Different 
expression vectors were tested for efficient expression of soluble scFv in the periplasmic 
extract of E. coli cells. Gloop2 and GlaMor scFv’s were purified from the periplasmic 
extract using immobilised metal affinity chromatography. The binding properties and 
specificity of Gloop2 against the loop peptide and enkephalin were studied using the 
surface plasmon resonance technology. However, severe problems in the expression of 
Glamor in any system explored prevented its full characterisation. The numerous attempts 
to resolve this expression problem are described in some detail.
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1Introduction
1.1 The Immune System
Most infections in normal individuals are of limited duration and leave little 
permanent damage due to the individual’s immune system that combats infectious 
agents. The immune system has two defence mechanisms:
a. natural (or innate) mechanisms that are present prior to exposure to infectious 
microbes or other foreign macromolecules and act as a first line of defense and,
b. adaptive (or specific) mechanisms that are activated when the innate response is 
not sufficient.
The term antigen is widely used to indicate any molecule, which can be specifically 
recognised by the adaptive elements of the immune system. The specificity of the 
immune response is due to lymphocytes, which are the only cells in the body capable 
of recognising and distinguishing different antigenic determinants. Lymphocytes
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consist of distinct subsets of cells that are quite different in their functions and protein 
products, even though they all appear morphologically similar.
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Fig. 1.1: The cells of the immune system
Two major categories of cells are derived from the common stem cell precursor: myeloid and 
lymphoid. Stem cells that differentiate to generate B cells reside in the bone marrow, and those that 
produce T cells reside in the thymus (From “Introducing Immunology”, Mosby Edition)
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T cells and B cells constitute the two important sets of lymphocytes that respond to 
antigens. B-lymphocytes express membrane bound and soluble antibodies while T 
lymphocytes express only membrane bound T cell receptor. The antigenic receptors 
carried, as membrane molecules on T lymphocytes are distinct but structurally related 
to antibodies, and bind to cell surface associated, but not soluble, antigens.
Antibodies are the major protecting agents of higher eukaryotes against foreign 
pathogens. A large repertoire of antibodies produced by B-cells provides recognition 
of almost all antigens and orchestrates their removal from the blood stream with the 
participation of the complement system and other immune system cells (T-cells, 
macrophages, phagocytes) (Fig. 1.1).
In the immune system the diverse repertoire of antibody molecules is generated by 
gene rearrangement, and is expressed (displayed) on the surface of B-cells, with each 
cell displaying a single-antibody species. Single B-cells proliferate on binding of 
antigen and differentiate to short-lived cells (plasma cells) making soluble antibody or 
to long-lived cells (memory cells) with surface antibody (Fig. 1.2).
First, the antigen encounters the pool of B cells, comprising of memory cells and 
naive cells, expressing a continuously changing portion of the potential germline gene 
repertoire. Primary responses (affinities 105-107 M'1) start largely on the naive portion 
of the repertoire, which is a much more diverse repertoire, whereas secondary 
responses start with the cells of the memory pool. Somatic hypermutation provides 
further variation (10- to 200- fold), from which antigen selects proliferative cells with 
improved binding characteristics. As immunisation proceeds, antibodies arise that
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come quite late in the immunization and which do not seem to be related to the pool 
of the initially reacting ones. It can be that these are very uncommon components of 
the naive pool, which eventually appear by pure chance, and having such high affinity 
for antigen, are able to survive and compete with already mature high affinity cells 
from the memory pool.
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Figure 1.2: The development of B cell
It starts with stem cell in the bone marrow. These cells reproduce themselves and also spawn lineage 
that pass through pro-B and pre-B stages to become B cells. B cell development culminates in the 
plasma cell, which secretes antibodies or to long-live memory cells (not shown), which retain their 
surface Ig and are involved in future immune response to the same or cross reactive antigen (From 
Scientific American, September 1993)
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1.2 Antibodies
1.2.1 Antibody Structure
The immunoglobulin G (IgG) molecule consists of a tetramer of two identical 25kDa 
polypeptides (the light chain, L) and two identical 50kDa polypeptides (the heavy 
chain, H). Crystal structures of IgG and IgG fragments have shown the antibody 
combining site (ACS) to be formed by the juxtaposition of six hypervariable loops or 
complementarity determining regions (CDRs), three from the light chain variable 
(VL) and three from the heavy chain variable (VH) domain. The CDRs of each chain 
are supported on a framework region (FR1, FR2, FR3, and FR4) which consists of 
conserved (3-strands that fold to form a (3-sandwich. When a light and heavy chain 
come together, one surface of each sandwich associates to form a (3-barrel structure. 
Supported on this (3-barrel scaffold the six CDRs, pack together in a tertiary structure 
to form a relatively flat platform with a surface area of about 700A (Fig. 1.3). The 
variable domains (VH and VL) contain all the determinants of antigen recognition 
they represent two of six domains in the IgG molecule, the remaining four being 
Constant or C-type domains (CH1-CH3 and CL). The relative positions of these 
domains form the characteristic Y-shaped IgG molecule (Fig. 1.4). The smallest 
antigen-binding fragment is the Fv (fragment variable), which consists of the VH and 
VL domains while the constant domains comprise the Fc (fragments crystallisable) 
fragment that has effector functions. The Fab (fragments antigen binding) fragment 
consists of the VH-CH1 and VL-CL domains covalently linked by a disulphide bond 
and more recently, the scFv (single chain Fv) antibody fragment (the VH and VL 
domains linked by a flexible peptide chain) was developed to overcome the tendency
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of the non-covalently linked VH and VL domains to dissociate during expression 
studies (Bird et al., 1988 and Huston et al., 1988). The polypeptide can link either the 
C-terminus of the VH to the N-terminus of the VL or the C-terminus of the VL to the 
N-terminus of the VH. As long as the linker is of adequate length, a wide range of 
different linker sequences can be tolerated (Huston et al., 1991). scFvs typically have 
affinities similar to the antibody from which they are derived (Bird and Walker, 1991, 
Fig. 1.5).
Porter (1958) and Edelman (1970) established the four-chain structure of antibodies 
for an IgG in the early 1960s. The three-dimensional arrangement of the heavy and 
light chain sequences as constant and variable domains was established for the Fab 
fragment in 1973 by Poljak et al. and for the Fc by Diesenhofer et al. 1976.
The six CDR loops forming the immunoglobulin binding site have different sequences 
in different antibodies; the remainder of the V domain exhibits less sequence variation 
and forms the framework regions (Fig. 1.6). The affinity and the specificity of a 
binding site is determined by the residues in both the hypervariable regions and the 
adjacent framework regions (Jones et al., 1986). The main chain conformations of the 
six hypervariable regions are determined to some extent by loop length (de la Paz et 
al., 1986) and by the interactions of a few residues at specific sites in the 
hypervariable regions and for certain loops in the framework regions. Hypervariable 
regions, that have the same conformations in different immunoglobulins have the 
same or very similar residues at these sites (Chothia et al., 1989). An examination of 
the library of the known immunoglobulin sequences showed that many 
immunoglobulins have hypervariable regions that are the same size as those in the
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known structures and contain the same or closely repeated residues at the sites 
responsible for the known conformations (Chothia and Lesk, 1987). These 
observations indicated that for at least five of the hypervariable regions there is a 
small repertoire of canonical main-chain conformations and that the conformation 
actually present can be predicted from the sequence by the presence of specific 
residues.
The antigen-binding activity can be grafted from one antibody to another by 
transplanting the CDRs (Jones et al. 1986, Verhoyen et al. 1988), showing that the 
p-sheet is a structural framework for the CDRs, that the CDRs are responsible for 
binding to antigen, and that the same p-sheet framework can provide a scaffold for 
mounting different antigen loops. CDR grafting has been used to humanise rodent 
antibodies for human therapy (Riechman et al., 1988).
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1.2.2 Antibody diversity and Gene Organisation
The domain structure of the antibodies is mirrored at the level of the gene, as the 
individual domains are encoded by separate exons. As we know today the variable 
region of antibodies (and similarly for T-cell receptors) is the result of the 
combinatorial recombination of three families of gene fragments (V, D, and J). The 
first and second hypervariable loops (HI, H2 and LI, L2) are encoded by the germ- 
line V genes, but the third hypervariable loop by the combination of V, D and J 
elements (H3 for the VH domain) and V and J elements (L3 for the VL domain). The 
third hypervariable loop of VH is accordingly the most diverse and is often the longest 
of the loops. The joining DNA fragment is not precise, and this gives rise to variations 
in length, particularly around the D segment which explains why the H3 hypervariable 
region is so variable. L2 is often not used in binding to smaller antigens even when all 
the other loops are used for binding (Tormo et a l, 1994)
The potential diversity of the mouse primary repertoire is huge (>1010) as a 
consequence of the combinatorial arrangements of the genetic elements with only a 
fraction of the potential repertoire available through the limited number of clones 
(107-108) expressing antibodies. In the secondary response genes used from the 
primary pool undergo hypermutation followed by selection and resulting in higher 
affinities antibodies. The rate of mutation approaches 10'3 or 3x1 O'4 mutations per base 
pair per cell division and is localised to the segment coding for the variable portion of 
the antibody genes. As immunisation proceeds, additional high-affinity antibodies
Chapter I: Introduction 10
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Fig. 1.4: The antibody molecule
Genes that consist of different DNA segments encode the chains. These segments rearrange to make 
genes for chains that are different in each B cell. The joining is so variable, so that only a few gene 
segments generate the estimated 100 million distinct antibodies the body is capable of producing (From 
Scientific American, September 1993).
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Figure 1.5: Antibody fragments
Antibody model showing the subunit composition and domain distribution along the polypeptide 
chains. Fragments generated by the proteolytic cleavage and/or recombinant technology appear on the 
















Fig. 1.6: Plot of amino acid variability in the variable region of immunoglobulin heavy and light chains.
The sequences from a large number of myeloma monoclonal proteins are compared and variability at each position 
is computed as the number of different amino acids found divided by the frequency of the most common amino 
acid; the higher the number the greater the variability. The three CDRs in the heavy (a) and light (b) chains are 
shown in blue, while the intervening peptide sequences are termed framework regions (in gray).
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1.2.2 Antibody diversity and Gene Organisation
The domain structure of the antibodies is mirrored at the level of the gene, as the 
individual domains are encoded by separate exons. As we know today the variable 
region of antibodies (and similarly for T-cell receptors) is the result of the 
combinatorial recombination of three families of gene fragments (V, D, and J). The 
first and second hypervariable loops (HI, H2 and LI, L2) are encoded by the germ- 
line V genes, but the third hypervariable loop by the combination of V, D and J 
elements (H3 for the VH domain) and V and J elements (L3 for the VL domain). The 
third hypervariable loop of VH is accordingly the most diverse and is often the longest 
of the loops. The joining DNA fragment is not precise, and this gives rise to variations 
in length, particularly around the D segment which explains why the H3 hypervariable 
region is so variable. L2 is often not used in binding to smaller antigens even when all 
the other loops are used for binding (Torino et al., 1994)
The potential diversity of the mouse primary repertoire is huge (>1010) as a 
consequence of the combinatorial arrangements of the genetic elements with only a 
fraction of the potential repertoire available through the limited number of clones 
(107-108) expressing antibodies. In the secondary response genes used from the 
primary pool undergo hypermutation followed by selection and resulting in higher 
affinities antibodies. The rate of mutation approaches 10'3 or 3x1 O'4 mutations per base 
pair per cell division and is localised to the segment coding for the variable portion of 
the antibody genes. As immunisation proceeds, additional high-affinity antibodies
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gradually emerge with V-D-J combinations, which are rarely found in the primary 
repertoire (repertoire shift).
1.2.3 Combining site topography and CDR conformation
The CDR residues number only around 70 of the total approximately 230 residues of 
the Fv antibody fragment and for some CDRs adopt only a limited number of 
canonical backbone conformations (Chothia et al.t 1989), determined by their loop 
length (de la Paz et al., 1986) and certain key, “structurally determining” residues 
(canonical residues). Chothia (1991) suggested that there is only a small repertoire of 
main-chain conformations (canonical structures) for at least five of the six 
hypervariable regions, that sequence variations within the hypervariable regions 
modulate the surface that these canonical structures present to the antigen and, that 
sequence variations within the hypervariable and the framework regions shift the 
canonical structures relative to each other by small but significant amounts. The 
adaptability of the antibody framework has been well illustrated, as variations in loop 
size, amino acid composition and relative domain disposition can tailor the antibody 
binding site to obtain the specificity and affinity in the immune recognition process 
(Wilson and Stanfield, 1993). The essential validity of the canonical concept has been 
demonstrated by the reasonable success with which it has been used to predict the 
structure of the antibody binding site, for up to 5 of the 6 CDRs, before the 
experimental determination (Chothia et al., 1989).
Webster et al. (1994) suggested three types of combining site: cavity (hapten), groove 
(peptide, DNA, carbohydrate) and planar (protein) and this topographic classification
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was based on the analysis of 20 X-ray structures. The amount of Fab surface buried on 
complex formation increases in the order cavity<groove<planar while the percentage 
of antigen surface area buried in the interface area buried decreases as the size of the 
antigen increases.
There is no totally satisfactory way of predicting which CDR combinations give rise 
to which surface topography. Analysis of antigen contacting residues for ten pairs of 
complexed and uncomplexed antibody-antigen crystal structures clustered the 
antibody combining site surfaces into four topographic classes: concave and 
moderately concave (mostly hapten binders), ridged (mostly peptide binders) and 
planar (mostly protein binders). However, when the whole antibody combining site 
was subjected to the same analysis the trend was much less marked, due to an increase 
in the noise resulting from the inclusion of non-accessible (or non contacting residues) 
of the non-interface surfaces in the calculations (MacCallum et a l , 1996). The non­
contacting residues within the CDRs coincided with residues identified by Chothia et 
al (1989) in defining canonical backbone conformations.
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1.2.4 Antibody-Antigen Interactions
The Thermodynamic View
In general two macromolecules in solution have to overcome large entropic barriers 
before they can form a tight association. There is the loss of the entropy of free 
rotation and translation of the separate molecules, and there is the loss of 
conformational entropy of mobile segments and of side chains upon binding. On the 
other hand, entropy is gained when water molecules are displaced from the surfaces 
that become the new interface.
Enthalpic contributions arise from van der Waals interactions together with the more 
specific hydrogen bonds and salt bridges. As one would expect, the larger the ligand 
the more surface area is involved on both molecules, although the surface area does 
not increase proportionally to the total surface area of the ligand (Davies and Padlan,
1990).
The Role of Water
The effect of water displacement from the antibody-antigen interface and the entropy 
gain is quite significant. In the structures observed by X-ray analysis, at 2.5A 
resolution water molecules have been identified at the interfaces (Tulip et al., 1992) of 
Fab complexes unfortunately with limitations in the certainty with which ordered 
molecules could be located. In other studies at 1.8A resolution it was demonstrated 
that when comparing structures of free and bound Fv fragment of D 1.3 several of the 
water molecules in the free antibody combining site were retained and that additional
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water molecules linked antigen and antibody upon complex formation Bhat et al 
(1994).
It has also been suggested that water molecules present at the interface, may mediate 
antibody-antigen interactions by increasing the packing density and contributing to 
charge complementarity (Tulip et al., 1992). Water molecules have been found in the 
interface of the anti-lysozyme antibody D1.3 (Mariuzza and Poljak, 1993), around the 
periphery of some anti-protein interfaces (Tulip et a l , 1992) and in the combining site 
of some anti-peptide antibodies (Shoham, 1993). It is a reasonable speculation that, 
where complementarity is imperfect, filling-in by water molecules might occur. 
Recently, Corell and Mallqvist (1997), calculated that interfacial crystal water 
molecules contributed 25% of the total calculated binding strength when assessing the 
origins of binding strength and specificity for three crystal determinants. They 
calculated changes in binding free energy (calculated value) and the experimental 
values (observed) for single and double mutations of these complexes. They proposed 
a model where the observed differences in the binding strength (between the 
experimental and the calculated values) were attributed to indirect changes due to 
released crystallographic water molecules that were near the mutation sites.
The antieen-bindine site
The specificity of the antibody-antigen interaction might be regarded as a paradigm of 
molecular recognition in general and is believed to result from the complementarity of 
the interaction surfaces. The investigations reviewed here confirm that there is 
remarkable shape complementarity; depressions on one surface are filled by 
protuberances from the other, often leaving no holes large enough for even water
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molecules. Hydrogen bonding is another factor that makes the interaction specific. Of 
particular relevance here is the directionality of the hydrogen bonds, necessitating a 
hydrogen bond receptor within a certain distance and within a certain solid angle of 
the hydrogen bond donor in order to form a strong bond.
When the antibody-antigen interfaces are inspected, a high degree of shape 
complementarity is often seen, particularly for protein complexes. In an analysis of 
the interface of the influenza virus N9 neuraminidase-NC41 Fab complex it was found 
that the average packing density of atoms at the interface was lower than for a typical 
protein core (Tulip et a l , 1992). However, a second analysis by Walls and Sternberg 
(1992) found that the packing densities of the three anti-hen egg-lysozyme antibody 
interfaces were as high as the protein cores. In contrast, electrostatic complementarity 
is not always as high (Novotny and Sharp, 1992).
Antibodv-antigen interactions
Affinity constants (KD or KA) and kinetic binding constants (kon and kof£) are used to 
quantitate the antibody-antigen (Ab Ag) interaction. Two approaches are typically 
used to measure affinity constants.:
• the determination at equilibrium of the ratio of the concentrations of the antibody 
(or antigen) free and engaged in complex and
• measurement of the kinetic dissociation and association constants, after which IQ 
can be obtained from the ratio koff/kon.
Amino acid substitutions in antibody-antigen interfaces play an important role in 
affinity maturation of antibody responses and in antigenic variation. These changes
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have the capacity to drive the affinity towards more tightly bound complexes or can 
effectively abolish the interaction entirely, providing a mechanism for antigenic 
variation. In studies on the effects of point changes in the binding for the influenza 
virus neuraminidase (Tulip et al., 1992) shown that two separate mutations located 
near the edge of the combining site had the same effect on the antibody-antigen 
interface as the amino acid substitutions within the interior of protein molecules 
(Matthews, 1991). Folding could be considered to be more tolerant of amino acid 
substitutions because of the cooperative effects caused by the interactants being 
convalently linked to each other.
In other studies Padlan (1990) showed that Tyr residues are unusually common in the 
regions of antibodies responsible for contact with antigens. Tsumoto et al. (1995) 
clarified this by studying the interaction between hen egg lysozyme (HEL) and its 
monoclonal antibody HyHELlO, both having well-characterised structures. Four Tyr 
residues in the VH chain were replaced by Ala, Leu, Phe, or Trp making in total 16 
mutated constructs. Twelve of them could be expressed, but two mutants could not be 
obtained in E. coli expression system and a further two mutants could not be purified 
by affinity chromatography. The Tyr residues at each mutated site made positive 
contributions to the interaction to different degrees.
Studies on antibodies against various haptens concluded that residue 96L interacts 
directly with the antigen (Roberts et al., 1994, Riechmann and Weill, 1993) while an 
Arg at position 96 correlates with ds DNA binding by autoantibodies to DNA (Marion 
e ta l , 1992).
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Conformational Changes
One of the more controversial issues in the antibody field has been the question of 
whether conformational changes occur in the antibody or antigen upon binding 
(Webster et al., 1994). This issue has been touted as a lock-and-key versus an induced 
fit contest. Two Fab structures, an anti-DNA (Herron et al., 1991) and an anti-peptide 
(Rini et al., 1992), illustrated the extensive nature of the conformational changes that 
can occur in an antibody following the ‘induced fit’ theory. These might range from 
small changes in side chain orientation (Stanfield et al., 1990), to segmental changes 
in the main chain (Stanfield et al., 1990), to CDR loop rearrangements (Herron et al.,
1991), to the more extensive alterations in the relative disposition of the VL and VH 
domains which form the antibody combining site (Herron et al., 1991).
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1.3 Antibody Engineering
1.3.1 Production of Polyclonal and Monoclonal Antibodies
The blood of an immunised individual contains many different antibodies, each 
derived from a particular clone of B cells and each having a distinct structure and 
specificity for antigen. Nevertheless, during early immunological experiments 
antibodies were sufficiently similar to each other that it was possible to purify 
mixtures of antibodies away from other blood proteins. Working with these mixtures, 
immunologists were able to deduce the overall structure of antibody molecules. 
However, the molecular heterogeneity of these polyclonal antibodies interfered with 
more detailed analysis of antibody structure, such as amino acid sequence 
determination. The key methodological breakthrough in this endeavour was the 
discovery that patients or animals with multiple myeloma, a monoclonal tumour of 
antibody-secreting plasma cells, often have high levels of biochemically identical 
antibodies or portions of antibodies in their blood or urine. These immortalised cells 
provide a source of individual antibody-secreting cells from an immunised animal, 
permitting the selection of individual monoclonal antibodies of predetermined 
specificity.
The monoclonal antibody method subsequently developed involved cell fusion or 
somatic cell hybridisation between a normal antibody-producing B cell and a 
myeloma line using a fusogenic agent such as polyethylene glycol. If the conditions 
are carefully controlled, some cells fuse and some of these both make specific
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antibody and will survive indefinitely in culture. The unfused myeloma cells 
eventually die under the genetic selection conditions used to favour the fused progeny, 
while the unfused primary B-cells die within a few days. Eventually hybridoma cells 
can be grown individually and the clones used to establish permanent large cultures 
from which the monoclonal antibodies can be harvested (Kohler and Milstein, 1975)
1.3.2 Antibody Display Technology
The polymerase chain reaction, described in 1988 (Suggs et al., 1988), greatly 
simplified the task of obtaining and cloning immunoglobulin DNA and has made it 
possible to reproduce antibody gene repertoires present in vivo. Design of primers for 
the 3* end of immunoglobulin variable region genes was straightforward since primers 
could be based on the constant regions, all of which have been sequenced. Design of 
primers for the 5’ end of the V gene was less straightforward due to the sequence 
variability of different V-genes, although it was known that primers did not have to be 
a perfect match for the template DNA. In the earliest attempt to use PCR to amplify 
V-genes, N terminal protein sequencing was done on purified antibody from a 
hybridoma and the sequence used to assign the VH and VL gene families. The VH 
and VL gene assignments were used to design degenerate primers based on FR1.
A more generally applicable approach was taken by Orlandi et al. (1989) where the 
nucleotide sequences of murine VH and VL genes were extracted from the Kabat 
database (Kabat et al., 1987) aligned and the frequencies of the most common 
nucleotide regions plotted for each position. Conserved regions were identified at the 
5’ and 3’ regions of the VH and VL genes, and the sequences of these regions were
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used to design oligonucleotide primers. Restriction sites were incorporated into these 
primers to permit cloning directly into vectors for sequencing and expression in 
eukaryotic cells. VH and VL genes amplified from a hybridoma were expressed in 
eukaryotic cells, and functional recombinant antibody was produced, verifying this 
method (Orlandi et a l , 1989). PCR with immunoglobulin specific primers could also 
be used to amplify genomic VH and VL gene repertoires from DNA or RNA prepared 
from mouse spleens (Huse et al., 1989, Gussow et a l, 1989, Ward et a l, 1989). 
Sequence analysis of the amplified VH and VL genes indicated that a diverse gene 
repertoire could be produced (Gussow et a l, 1989).
When these gene libraries are displayed on filamentous bacteriophages, antibodies can 
be made completely in vitro, by-passing the immune system and the immunisation 
procedure, and allowing in vitro tailoring of the affinity and specificity of the 
antibody. VH and VL genes can be fused to the amino terminus of the phage minor 
coat protein pin. The technology has been used to display both scFv and Fab antibody 
fragments. McCafferty et al (1990) demonstrated the feasibility of displaying 
fragments of antibodies on the surface of a bacteriophage and that these fragments 
folded correctly and bound antigen. Antibody variable-region genes were cloned into 
the gene encoding the minor coat protein (gene3) of the filamentous bacteriophage fd 
(Fig. 1.7). The fusion protein created, consisting of the antibody fragment at the N- 
terminus of the coat protein is incorporated into the phage particle (a “phage 
antibody”). Each recombinant phage genome contains the DNA encoding the specific 
antibody displayed on its surface, allowing the phage particle carrying antibody gene 
to be selected directly using the binding properties of the expressed protein. This 
discovery opened a novel route for antibody isolation.







Fig. 1.7: Phage antibody particle
The filamentous bacteriophage (fd) contains a 6.4Kb single-stranded, circular DNA molecule 
associated with 2800 copies of the major coat protein encoded by gene 8. At the end of the 
phage particle there are three copies of the minor coat protein encoded by gene 3. Antibody- 
gene sequences have been inserted at 5’ end of the gene 3 protein. This fusion protein is 
assembled into phage particles which display antibody fragments on the surface (Chiswell and 
McCafferty, 1992).
Repertoires of antibody genes are amplified using PCR and cloned into phage, thus 
creating a large library of phage each displaying a specific antibody. Within these 
large libraries of phage antibodies (potentially representing between 106 and 109 
different antigen-binding specificities) each phage expresses an individual heavy-and 
light-chain combination (Fig 1.8), although these combinations do not necessarily 
reflect the in vivo pairings since VH/VL scrambling occurs during the library 
construction. The linkage between antibody genotype and phenotype allows the 
enrichment of antigen-specific phage antibodies, using immobilised or labelled 
antigen (e.g via antigen bound to a solid surface such as a Sepharose column or a 
coated tube). Phages that display a relevant antibody are retained on a surface coated 
with antigen, while non-adherent phage are washed away. Bound phages can be 
recovered from the surface, reinfected into bacteria and re-grown for further 
enrichment and, eventually, for binding analysis. The phage antibody can be both
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analysed and used directly from the culture supernatant as a reagent in techniques 
such as ELISA (Fig 1.9).
The success of antibody phage display hinges on the combination of this display and 
enrichment method, with the creation of large combinatorial repertoires of phage 
antibodies. Each of these antibodies has a different combining site, generated by a 
PCR-based amplification of antibody V-genes (Winter et al., 1994). An antigen- 
driven enrichment procedure can be used to isolate even the rarest phage antibody, for 
example where only one in 107 phage in a population is specific for the antigen. This 
basic technique has been applied to construct very large and highly diverse 
combinatorial repertoires of antibody fragments, from which antigen-specific 
antibodies to any chosen antigen can be selected (Griffiths et al., 1994). It has also 
been possible to use antibody-gene VIII protein fusion in which, theoretically, over 
2000 copies/phage particle could exist (in practice much less than this), leading to a 
multivalent selection system. This latter approach involves the display of greater 
numbers of antibodies on each phage particle as well as a variable number of 
antibodies on different phage particles produced by the same cell. Selection would 
therefore be a function of avidity (i.e. a combination of affinity and valency) rather 
than affinity alone, limiting the usefulness of this approach, particularly when 
selecting high affinity antibodies. Antibody fragments using a display system based 
on the gene VIII product have been engineered onto phages for Fab fragments by 
Kang et a l , 1991, Chang et a l , 1991 and Huse et al, 1992)
Other groups have used gene3- display to isolate antibodies derived from libraries 
originally constructed on X bacteriophage (Huse et a l, 1989). Plaques expressing
Chapter 1: Introduction 25
Other groups have used gene3- display to isolate antibodies derived from libraries 
originally constructed on X bacteriophage (Huse et a l, 1989). Plaques expressing 
antigen binding antibody fragments were identified by obtaining plaque lifts that were 
then probed with labelled antigen. This type of antibody expression system has also 
been successfully applied to the isolation of murine antibodies specific for influenza 
virus hematoglutin (Caton and Koprowski, 1990) and for human Fab fragments 
specific for tetanus toxoid (Persson et a l, 1991).
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Fig. 1.8: The strategy of the immune system in vivo (left) and using phage (right)
Step 1: rearrangement or assembly of germ line V-genes; Step 2: surface display of antibody; Step 
3: antigen-driven or affinity selection; Step 4: affinity maturation; Step 5: production of soluble 
antibody (or antibody fragment) (Hoogenboom et a l, 1992).
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Fig. 1.9: Selection methods
Phages displaying antigen-specific antibodies (white) are usually separated from non-binding 
phages (black) using the above procedures (Hoogenboom, 1997)
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A recent application of selectively infective phage (SIP) (Fig. 1.10) has been devised, 
in which cognate pairs of peptidic antigen and antibody can be selected at the same 
time (Krebber et al., 1995 and for a Review, Spada et a l, 1997). In the SIP system, 
the antibody-displaying phage is itself non-infectious and acquires the ability to infect 
cells only upon the occurrence of a cognate interaction between antibody and antigen 











Fig.1.10: Selectively Infective Phage (SIP)
(Top) wt fd phage in infective
(Middle) Multivalent antibody-displaying phage, devoid of N1-N2, is non-infective
(Bottom) Infectivity is restored by the cognate interaction between antibody and antigen, reconstituting
of glllp functions (Krebber et al., 1995).
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1.3.3 Expression of Recombinant Antibody Fragments.
Different expression systems have been studied for the production of recombinant 
antibodies. These range from bacteria, insect cells and plants to transgenic anim als, 
with each system having its own advantages and problems. Different antibody 
fragments (Fab, Fv and scFv) have been expressed in all of these systems as well as 
whole chimeriG antibodies.
E. coli offers an attractive system for the expression of antibody fragments and has 
major advantages overproduction in eukaryotic cells since, yields are higher, costs are 
lower and the system is more easily regulated and manipulated. However, in other 
studies the mammalian expression systems appear to be more successful for the 
production of correctly folded intact antibodies or antibody derivatives (Gilliland et 
al., 1996).
Various fragments that retain antigen-binding activity can be created. An Fab 
construct most closely resembles the native binding site structure, retaining the 
adjacent constant region domain for both heavy and light chain. However, the variable 
region domains can also be expressed separately and still associate to form an Fv 
fragment. It has also been demonstrated that the variable regions can be joined by a 
short linker segment, thereby providing a single chain binding site or scFv.
For some biotechnological applications, scFv’s are better suited than whole antibodies 
because they are smaller in size yet they retain their antigen binding specificity. For 
example, in tumour targeting studies they have been shown to exhibit increased
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tumour penetration and localisation in comparison to intact mAb or Fab fragments 
(Colcher et al., 1990). In addition, scFvs can be made “immunosilent” by CDR 
grafting (Verhoeyen et al., 1988) or "resurfacing" (Roguska et al 1994) that reduce 
the foreign nature of the proteins
Fab and Fv fragments have also been expressed infs, coli (Field et al., 1988; 1989) and 
the final choice of structure, depends on the specificity requirements and the proposed 
use. For example, an Fv fragment has been shown to have a half life of only 1.3 hours 
at 37°C rendering it unsuitable for most studies. The addition of a flexible linker 
segment (scFv) has been shown to increase the thermostability to 15 hours 
(Glockshuber et al., 1990). This significant increase in stability is thought to be a 
function of limiting the dissociation of VH and VL. However, the constant regions in 
an Fab also limit dissociation, such that an indefinite half-life is observed at 37°C. 
Other structural modifications to increase the stability of smaller fragments, such as 
introduction of additional disulphide bonds, may prove useful for increasing the 
thermostability (Glockshuber et al., 1990).
The affinity of the expressed antibody fragment can also vary with respect to 
structure. No difference in affinity has yet been observed between chemically cleaved 
Fab and genetically constructed, bacterially expressed Fab (Buchner et a l , 1991). 
Similarly Skerra and Pliinkthun reported that their Fv directed against 
phosphorylcholine retained the same affinity as that of the parent antibody (Skerra and 
Pliinkthun, 1988). In contrast the addition of a linker to one Fv to form a scFv was 
found to result in a 2-4-fold decrease in the apparent affinity (Glockshuber et al., 
1990). Other scFv’s have also been shown to have affinities as low as one tenth of
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their Fab counterparts (Huston et al., 1988a). Such is not always the case and may be 
a function of the specific linker construct utilised hindering the proper formation of, or 
access to, a particular binding site (Bird and Walker, 1991). It would seem reasonable 
to expect that this may be less of a concern for binding sites directed toward small 
haptenic determinants. Interestingly, however there are examples of scFvs directed 
against small chemically defined haptens which have one tenth the binding affinity of 
an Fab (Huston et al., 1988b) and several examples of scFv’s that recognise a 
complex protein structure with affinities only 2-4 fold less than that of their Fab 
counterparts. A caveat with some of these measurements is that they may have been 
influenced by the presence of incorrectly folded material (Pantoliano et al., 1991).
Recombinant chimeric antibodies are based on the transplantation of murine CDRs 
onto human variable-chain frameworks and are intended as tools for diagnostics in 
situ and for therapy, since murine antibodies are recognised as foreign causing an 
immune response on secondary challenge. While the widely used method of achieving 
humanisation is the reshaping technology of Winter and Milstein (1991), there are 
additional alterations of individual amino acid residues within the framework that are 
usually necessary to restore full activity for antigen.
In a novel approach, Fv surface analysis of 12 Fab X-ray crystallographic structures 
has been used to exhaustively characterise the surface of different V-regions 
(Pedersen, 1993). This resulted in the development of a novel method termed 
Resurfacing. Three major observations were made; first, that for the residue 
frequencies at certain positions of the sequence were particularly conserved. Second 
that the amino acid positions identified none of the entire combinations of surface
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residues in the human sequences were found in the murine sequences and vice versa. 
Third, only at two of the positions were different distributions of amino acids found 
(Roguska et al, 1997). This method is now becoming widely used since in all 
instances so far tested full activity is retained after the resurfacing procedure (Roguska 
etal., 1997).
Plant based expression systems present a cost-effective means for the productions of 
recombinant antibodies and proteins in general. It is possible to produce whole Fab 
and IgG molecules in a functional form in various organs of the plant (seeds or 
tubers). Plants have been shown to be capable of expressing functional engineered 
forms of antibody such as “single domain antibodies” (VH fragment alone) 
(Benvenuto et al., 1991) or scFvs (Owen et al., 1992 and Tavladoraki et al. 1993). 
These genes may have derived from hybridomas or from phage display libraries. This 
technology has implications not only for plant pathology but could be of general 
utility when other plant functions or activities are permanently modulated.
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1.3.4 Gloop2: An anti-lysozyme antibody and a model for re-design
Hen egg lysozyme (HEL) is an ideal model antigen as its three dimensional structure 
has been determined to high resolution (Blake et al., 1965). In addition, the structures 
of lysozymes from other species are known, for example human (Artimiuk and Blake, 
1981), turkey (Bott and Sarma, 1976), hen (Smith et al., 1993) and goose (Grutter et 
al., 1983). A panel of primary sequences from closely related and more distantly 
related lysozymes is also available (Grutter et al., 1983).
The antigenic response to HEL has been the subject of considerable study. Atassi 
(1978) proposed that the entire structure of lysozyme consisted of only three antigenic 
sites. However, subsequent studies have shown that most, if not all, of the surface of 
HEL is potentially antigenic (Smith-Gill et al., 1984; Harper et al., 1987). Structures 
of three anti-lysozyme antibodies have been solved by X-ray crystallography, D1.3 
(Amit et al., 1986; Bentley at al., 1989; Bentley et al., 1990), HyHEL-5 (Sherrif et al., 
1987), HyHEL-10 (Padlan et al., 1989). In addition, the structure of an anti-peptide 
antibody that cross reacts with native HEL, Gloop2, has been determined (Jeffrey, 
1989). Gloop2 is one of a group of five mAbs (Gloopl to 5) specific for the loop 
region of HEL, which comprises residues 57-84 (loop peptide). The antibodies were 
raised against a peptide-bovine serum albumin conjugate and cross react with native 
HEL (Darsley and Rees 1985a and b). The isotype of Gloop2 is y2bk (Darsley and 
Rees 1985a). It binds the loop antigen with a dissociation constant (KD) of 2xl0'8M 
and HEL with a Kd of 10'7M (determined by solid phase RIA; Roberts et al., 1987). 
Serological mapping of Gloop2 using a panel of avian lysozymes indicated that the 
epitope on HEL comprises of the majority of the loop region and includes at least
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eight residues (Darsley and Rees, 1985a). The epitope has been further refined by 
NMR studies of the Gloopl-loop complex (Cheetham et al., 1991) - the epitopes 
recognised by Gloop2 and Gloopl are virtually indistinguishable, as shown by 
Darsley and Rees (1985a). Studies on main chain mobility by NMR indicated that 
residues in the centre of the loop (e.g. Ser 72, Arg73) are not involved in direct 
contact with antibody as was originally assumed from the serological results. The 
epitope is now recognised to be discontinuous, consisting of residues 59 to 70 and 74 
to 79 (Cheetham et al., 1991).
The structure of Gloop2 Fv has been modelled by two different methods. The early 
molecular modelling studies (de la Paz et al., 1986) used a maximum overlap method 
to build the combining site onto NEW framework, selecting the CDRs from available 
antibody structure according to length and sequence homology. The resulting model 
was then manually docked onto the serologically defined epitope of HEL and 
subjected to energy minimisation to relax any bad contacts between antibody and 
antigen (de la Paz et al., 1986; Roberts et al., 1987). This model was used to guide 
protein engineering experiments designed to test loop/HEL cross reactivity. Since 
then, the structure of the native Gloop2 Fab has been determined by X-ray 
crystallography (Jeffrey, 1989). Comparison of the structure with the model showed 
good agreement on four CDRs (r.m.s. difference 0.64 A to 0.8 A for the backbone). 
The other two CDRs, H2 and H3 were modelled incorrectly (r.m.s. difference on 
backbone 1.77A to 3.61 A) which prevented identification of a prominent groove in 
the centre of the combining site. Because of this difference in the modelled structure, 
the proposed docking with the HEL epitope was almost certainly incorrect. The 
Gloop2 crystal structure has been used for the development of novel modelling
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methods which use a combination of both knowledge-based and ab initio algorithms. 
Two models of the combining site were generated, one in which each CDR was 
modelled individually in the presence of the other five (Martin et al., 1989), and the 
other modelled ab initio (Martin, 1990). Both models had good agreement with the 
structure (r.m.s. difference 0.63A to 1.36A and 0.73 to 1.41 A respectively).
The native Gloop2 structure was solved to 2.8A resolution in two different crystal 
forms, enabling a comparison of two independently solved structures (Jeffrey, 1989). 
The combining site structures are similar with the only significant difference being the 
side chain positions of Phe52 and Tyr59 in H2, although this could be explained by 
the crystal packing interactions (Jeffrey, 1989). At the centre of the combining site 
there is a groove 12A long, 9A wide and 7A deep which is defined by L3, H2 and H3.
The cDNAs for Gloop2 heavy and light chain have been cloned and a mutagenesis 
system was developed (Roberts and Rees, 1986). The mutant antibodies were 
expressed in Xenopus laevis oocytes after microinjection of synthetic RNA. The 
secreted antibody was tested directly for antigen binding affinity. Results from the 
early mutagenesis experiments show that removal of two charged side chains from the 
combining site (Glu28Ser (LI) and Lys56Gln(H2)) increased the affinity to HEL by 
10 fold, making it equivalent to the affinity for peptide (Roberts et a l, 1987). Since 
then, extensive mutagenesis has surveyed the complete area of the combining site in 
order to define regions crucial for crossreactivity between peptide and native HEL 
(Roberts, S. pers. com.).
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The E. coli expression system for Gloop2 Fv has been developed for the production of 
antibody fragments for structural analysis by NMR and crystallography (Field, 1988; 
Field et a l, 1989). The VH and VL polypeptides were expressed separately as 
insoluble cytoplasmic products. Partial purification and refolding in vitro to form the 
Fv heterodimer in large losses of material (90%) (Field et a l, 1989).
The Gloop2 system has been well defined by structural techniques (such as X-ray 
crystallography and NMR), molecular biology and protein chemistry. It therefore 
represents an ideal system to study antibody function and to attempt to create antibody 
molecules with novel properties.
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1.4 Antibody Design
1.4.1 Modelling and Design of the Antibody Combining Site
The aim of antibody modelling is to be able to suggest a three-dimensional model 
corresponding to a given sequence.
Modelling of the antibody combining site was first attempted by Padlan and Davies 
(1976) at a time when very few antibody structures were known. It was recognised 
that the key lay in the structural homology that existed within the (3-sheet framework 
regions of different antibody variable domains. Chothia’s “canonical” families of 
residues for CDRs LI, L2, L3, HI and H2 (Chothia and Lesk, 1987) were useful for 
those CDRs that obey the rules exactly while further development was necessary for 
those CDRs that lack the appropriate key residues and also neighbouring CDRs that 
might hinder correct domain assembly of an otherwise canonical conformation.
In the de novo design the goal is to suggest a sequence of aminoacids which is able to 
bind a pre-defined antigen, using three-dimensional information. There are three 
different approaches to the design problem:
1. From the known three-dimensional structure of antigen search the database to 
define surface matching with complementary shapes.
2. Starting form a known antibody-antigen complex structure a homologous antigen 
structure is docked at the same orientation and minimal changes are made in the 
antibody in order to retain the binding.
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3. Using small peptide/hapten antigens (peptide ab initio method) in complex with a 
large range of homologous compounds leads to mapping of the individual 
interactions assuming the paratope shape and orientation. This method, because of 
the small antigen size limits the number of interactions, increases the size of 
database of structures and facilitates the synthesis and use of many different 
analogues. It also keeps open the possibility of using proteins at a later stage.
1.4.2 The Design Process
The design process starts with a known antigen and an antibody of known structure 
that is chosen randomly. It is assumed that the specificity of anti-hapten antibodies 
will not be dependent on particular combinations of CDR lengths using the antigen 
molecular weight as a descriptor of the antigen shape. This length independency 
hypothesis is substantiated by crystal structure data that show the formation of similar 
grooves in binding sites by both long and short CDRs (Rudikoff et al., 1981, Jeffrey 
P., pers. com. Webster et al., 1994). For larger antigens (MW> 10,000) it is not 
possible to deduce anything from these data as the molecular weight does not 
accurately describe the shape of the binding epitope.
From the randomly selected antibody combining site the side chains that do not 
influence the backbone structure (non-canonical residues) or are not buried by the 
CDR backbone and framework are truncated to alanine residues and the resulting 
structure is termed ”the alanine cushion”.
The next step is to dock the antigen in a reasonable initial orientation in the combining 
site in order to obtain maximum interaction area and maximum satisfaction of
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electrostatic interactions using a Monte Carlo simulated annealing method (Goodsell 
and Olson, 1990). After the antigen has been docked all the residue positions which 
can potentially interact with the antigen are reconstructed. Evaluation of this 
reconstruction is obtained by selecting only those residue positions for which a 
favourable side chain rotamer exists and is capable of interacting with the antigen. 
Otherwise the original sidechain is retained. All sidechain conformations for each 
position are ranked based on energy data of the sidechain conformers and the antigen 
alone. By this procedure the sidechains that interact best with the antigen, and have 
the lowest electrostatic interactions are scored highest (Pedersen, 1993 Fig. 1.11).
The final residue rank for each sequence position is obtained from the estimation of 
the binding energy of antibody-antigen complexes and the accessibility of the solvent 
surface area lost by the antigen (see formula below). According to Novotny (1991) the 
total free energy of binding (AGT0I) is a function of the hydrophobic effect (AGF) upon 
antigen binding, the electrostatic interactions (AGEL), the loss of sidechain 
conformational entropy upon antigen binding (TASCF), the loss of overall rotational 
and translational entropy (TAS^) and a correction term that accounts for dilute 
concentrations of proteins in biological systems (TASCR).
AG tot — A Gf + A Gel - TAScf- TAStr - TASCR
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Fig. 1.11: The design process
Cartoon of the process described in the text by which an antibody specific for one antigen can be 
remodelled to fit a different antigen. In the example shown the new antigen is morphine, and the 
binding site is being created within the existing combining site of the anti-peptide antibody Gloop2. 
The process shown is as follows:
(a) the new antigen is selected for which an X-ray (and preferably and NMR) structure is known
(b) the side chains from all the CDR residues that are not required to define backbone structure are 
removed
(c) the ‘alanine cushion’ is generated
(d) and the new antigen is docked and the predicted contact chains are reconstructed
(e) the candidate side-chains are evaluated using knowledge based and conformational search 
methods. (Hydrogen bonds are shown in blue) (Rees et al., 1994).
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1.5 The aims and scope of this thesis
The scope of this thesis is to test experimentally the ab-initio design of antibodies (changing 
specificity) using the anti-peptide antibody Gloop2 (raised against a peptide, part of 
lysozyme, (Geffrey et al., 1991) as a model system. The Gloop2 combining site has been re­
designed using a genetic algorithm and computational methods to form a new, anti-opioid 
antibody GlaMor (Pedersen, 1993).
The design process presented in Chapter 3, predicted residues candidate for mutation that 
would change the Gloop2 specificity resulting in a novel anti-opioid combining site 
(GlaMor). Starting with Gloop2 and the set of mutations the experimental test had a dual 
aim.
First, to create the repertoire of mutations as phage displayed antibody fragments and select 
the “best” combination of these mutations on the basis of specificity against the opioid 
enkephalin. The Recombinant Phage Antibody Technology, described in Chapter 4, was used 
as a tool for this first test of the design.
Second, to express Gloop2 and GlaMor in a soluble form in E. coli and again test and 
compare their specificity for the lysozyme peptide and enkephalin respectively. In Chapter 5 
different vectors are tested for their efficiency to express soluble form of scFv antibody 
fragments. The periplasmic expression in E. coli and purification of scFv antibody fragments 
together with optimisation studies is described in Chapter 6.
At a rather late stage, the Fv sequence selected on the basis of its binding to enkephalin as a 
phage construct when subjected to expression as a single chain Fv showed signs of 
significant instability. The analysis of this Fv and the attempts to obtain protein from it, are 
discussed in Chapter 6 and further extensive attempts to correct its sequence and expression 
problems are discussed in Chapter 7.
Finally Chapter 8 presents the qualitative assays for testing the binding properties of antibody 
fragments exploiting the Surface Plasmon Resonance technology.
Materials and Methods
This chapter describes the standard methods that were used as well as any 




Escherichia coli strains used are listed in table 2.1. Strains like XL-1 Blue, DH5a and 
JM109 were used routinely for cloning and general DNA manipulation while TOPP2 
and TGI strains were used for protein expression work.
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Strain Name Genotype Reference
XL-1 BLUE
[F’::TnlO (TcR) proA+ 
proB+ laclq /acZAM15] 
recAl endAl gyrA96 
(NaIR) thi hsdR.ll (rkmk+) 
supE44 relAl lac
Bullock, W.O. et al., 
(1987)
DH5ct
endAl hsdRll (rkmk+) 
supE44 th i1 recAl gyr A  




thil rpsL end AX sbcE 15 
hsdR.4 supE D {lac- 
proAB)fF ’ [traD36,proABX 
laclq lacZAMlS]
Yanisch-Perron, C. et al., 
(1985)
TOPP2 Rif [F’ proAB proAB+, 
TnlO (Tef)l
Hatt, J., et al (1992)
TGI sue hsd DS ^z*S[/ac- 
proAS] F’ [traD2>6 
proABX laclq lacZ AM 15
Gibson, T., (1984)
Table 2.1: The different E.coli strains used in for DNA manipulations and expression studies.
2.1.2 Bacterial cell culture media
All cell culture media were purchased from Difco.
LB (1 Litre) lOg Tryptone, 5g Yeast Extract, 5g NaCl (BDH) 
2 x YT (1 Litre) 16g Tryptone, lOg Yeast Extract, lOg NaCl 
XL (1 Litre) 16g Tryptone, 15g Yeast Extract, lOg NaCl
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2.1.3 Plasmid Vectors
All plasmid vectors used are listed in table 2.2.
Plasmid Obtained from Reference
pKK322 IGEN Ltd. Amann, E. & Brosisus, J., 
1985
pTrc 99 A Pharmacia Amann, E. et al. (1988)
pUC119/
His6mycXba
Prof. R. Hawkins 
Dpt. of Oncology 
University of 
Bristol
Griffiths, A. et al. (1994)
fd-tet-DOGl
Greg. Winter, 




Hoogenboom et al. (1991)
Table 2.2: Plasmid Vectors used in cloning and expression studies
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2.2 DNA Manipulations
2.2.1 DNA preparation
DNA for cloning, sequencing and transformation was prepared using the QIAprep
Spin Plasmid Kit by QIAGEN Ltd. This protocol gives yields of 5pg of plasmid DNA
from 5ml overnight cultures of E. coli.
Protocol:
1. 5ml cultures of E.coli grown overnight at 37°Cin LB (Luria-Bertani) medium 
were pelleted by centrifugation at 5,000 RPM, at room-temperature forlO min.
2. the pelleted bacterial cells were resuspended in 250 \i\ of buffer PI and 
transfered to a microfuge tube.
3. 250fd of buffer P2 was added and the tube was inverted gently 4-6 times.
4. 350|fr of buffer N3 was added and the tube was inverted immediately but 
gently 4-6 times.
5. the lysed cells were centrifuged in a minifuge at 13,000RPM at room- 
temperature for 10 min.
6. the supernatants were applied by pipetting on a QIAprep spin column already 
placed in a 2ml collection tube.
7. the columns were centrifuged in a microfuge at 13,000 RPM at room- 
temperature for 60sec and the flow-throughs were discarded.
8. the QIAprep spin columns were washed by adding 0.75ml of Buffer PE and 
centrifuged as in step 7.
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9. the flow-throughs were discarded and the columns were centrifuged for an 
additional 1 min to remove residual wash buffer.
10. the QIAprep column was placed in a clean 1.5 centrifuge tube and the DNA 
was eluted by adding 50gl of H20  to each QIAprep column, let stand for lmin. 
and centrifuged as in step 7.
Medium scale preparation of plasmid DNA
Medium sized preparations up to lmg of plasmid DNA were obtained using the 
Wizard Maxiprep DNA Purification System (Promega). The method required 500ml 
of overnight culture and the protocol was followed exactly as described by the 
manufacturer.
Large scale preparation of plasmid DNA: LiCl Method
This method gives yields between 25-100mg of plasmid DNA and was used when 
large quantities of DNA were needed for cloning manipulations. The plasmid DNA 
prepared with this method is ultimately treated with RNase to remove any RNA 
contamination offers the purity and high yields of the CsCl preparation without the 
ultracentrifugation step.
Protocol:
1. 150ml of 2xYT medium containing appropriate antibiotic(s) and 2% w/v glucose 
was inoculated with a bacterial plaque containing the desired plasmid. The culture 
was grown at 37°C, 250 RPM overnight in a shaker incubator to an A600 of >1.5.
2. The cells were harvested at 4,000RPM for 15 minutes and the pellet resuspended in 
50ml STE (lOOmM NaCl, lOmM Tris-HCl pH 8.0, ImM EDTA) and centrifuged 
again as before.
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3. The pellet was resuspended in 9ml of solution I  (50mM Glucose, 25mM Tris-HCl 
pH 8.0), 1ml of fresh lysozyme (lOmg/ml) was added and the suspension gently 
mixed for 2 minutes.
4. 20ml of solution I I  (0.2N NaOH, 1% w/v SDS) was added and the suspension 
gently mixed and incubated at room temperature for 10 minutes.
5. 10ml of ice-cold solution I I I  (4M KOH pH 5.5, 11.5% v/v acetic acid) was added 
to the flask and the mixture inverted several times and incubated on ice for 10 
minutes.
6. the lysed cells were centrifuged at 4,000RPM for 15 minutes with no brake to 
avoid disturbing the pellet.
7. the supernatant was filtered through gauze and 0.6 volumes of isopropanol was 
added and the solution left to incubate at room temperature for 10 minutes. This 
solution was centrifuged at 5,000RPM for 15 minutes at room temperature.
8. the supernatant was discarded and the precipitated DNA allowed to air dry. The 
pellet was resuspended in 2ml TE buffer (lOmM Tris-HCl pH 8.0, ImM EDTA).
9. 2ml of 6M LiCl2 was added and the solution was incubated on ice for 10 minutes 
followed by centrifugation at 6,000RPM at 4°C for 10 minutes. The supernatant 
was decanted to a sterile COREX tube and the DNA ethanol precipitated (2.2.5).
10. the solution was centrifuged at 13,000RPM at 4°C for 30 minutes and the DNA 
pellet resuspended in 1ml TE buffer. 10pl RNase (lOmg/ml in lOmM Tris-HCl pH 
7.5,15mM NaCl) was added and incubated at 37°C for one hour.
11. the RNase was inactivated by the addition of 50pl 10% w/v SDS and incubation at 
75°C for 10 minutes. The DNA was ethanol precipitated and resuspended in 0.5ml 
TE buffer (2.2.5).
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2.2.2 Agarose gel electrophoresis
DNA can be analysed using agarose gel electrophoresis followed by staining with 
ethidium bromide and visualisation by ultraviolet (UV) irradiation of the gel. The 
following protocol describes a typical minigel analysis; however, a variety of gel sizes 
may be used, depending on the specific application. TBE running buffer was used for 
ordinary DNA visualisation while TAE running buffer was used for DNA gel 
purification.
Protocol:
1. The minigel apparatus was assembled (spacers, comb etc.).
2. the required amount of agarose was preweighed and added to the appropriate 
amount of TAE or TBE IX buffer in a flask. For example, to prepare an 1% 
agarose gel, l.Og of agarose was added to 100ml of buffer.
3. the mixture was heated in a microwave oven for the minimum time required to 
allow all the agarose to dissolve. The heating was interrupted at regular intervals 
and the container was swirled to mix the contents. The solution should not be 
allowed to boil over.
4. the solution was allowed to cool to 50-60°C and ethidium bromide was added at a 
concentration of 0.5pg/ml before the gel was poured. The gel was allowed to form 
completely (typically, 30min at room temperature). The comb was removed from 
the gel, and a sufficient volume of TBE or TAE IX buffer added to just cover the 
surface of the gel.
5. Blue loading dye 6X was added to the DNA samples before they were loaded into 
the wells
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6. the gel apparatus was connected to an electrical power supply and an appropriate 
voltage was applied. For minigels, typical gradients used were between 1- 
5volts/cm
7. after electrophoresis was completed, the gel was removed and placed on a U.V. 
light box and photographed according to specifications recommended for the 
camera and film type used.
2.2.3 DNA Amplification; The Polymerase Chain Reaction (PCR)
PCR was developed in the mid-1980s, thanks to the discovery of DNA polymerases 
that are stable at high temperatures. PCR enables specified DNA fragments to be 
amplified from minute amounts of starting material (theoretically just a single 
molecule). The only limitation is that the region of DNA to be amplified must be 
already known or at least must be predictable with 90% certainty in the boundary 
regions where the oligonucleotides (primers) will anneal and prime the amplification.
Basic procedure for PCR amplification.
All PCR’s were performed in the Perkin-Elmer, Model: PTC-100 thermo-cycling 
machine. Vent DNA polymerase (NEB) was used that ensures high fidelity 
amplification and utilises its 3’-5’ exonuclease activity for proof-reading of the 
extension product.
Protocol:
1. The PCR reaction was set up in 0.2 ml thin-walled eppendorfs by adding:
• 5jil of a lOx stock of dNTPs (dATP, dCTP, dGTP, dTTP at 3mM)
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• 5^ 1 of NEB lOx ThermoPol buffer (lOOmM KC1, 200mM Tris-HCl pH 8.8, 
lOOmM (NH4)2S04, 0.1% Triton X100)
• 0.5^1 of BSA (lOmg/ml) was 0.2ml thin-walled tubes.
• 1 pi of each oligonucleotide primer (50pmoles/pl)
• lOng of template DNA
• 0.5jil of Vent DNA polymerase (2 U/pl)
• Sterile Milli-Q water to 50pl total Volume
2. one drop of mineral oil was added to the tube to cover the reaction and prevent 
evaporation.
3. all PCR’s performed included a negative control (no DNA template added) to test 
for the absence of contamination in the reagents and a positive control on a known 
template to test the performance of the buffers, enzyme, and the temperature cycle 
parameters.
Olieonucleotide primers
All oligonucleotides used were custom made by Perkin-Elmer and had been HPLC 
purified and lyophilised.
Successful amplification requires two primers about 20-30 nucleotides long that 
anneal stably to sites bordering the target DNA region that will be amplified. There 
were a few factors taken into consideration when designing an oligonucleotide primer,
a. The length of the primer should be a compromise between specificity and affinity. 
Longer primers raise the stringency of the PCR, and ultimately allow amplification 
with high specificity while shorter primers (e.g. 7-mers) might yield a number of 
different products. On the other hand, at a given stringency of annealing, shorter
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primers should give fewest products because they will not be long enough to 
anneal stably to sites of low homology.
b. the base composition of the primers has to be as heterogeneous as possible, with an 
even mixture of all four bases. Whenever possible, an imbalanced distribution of 
G/C and A/T-rich domains must be avoided.
c. primers that are used in combination should have similar Tm values.
d. internal and self-complementarities of primers that could lead to primer-dimer” 
formation and reduce the efficiency of the PCR were checked using computer 
software (Amplify, Bill Engels 1992. University of Wisconsin).
Temperature cycling
Each cycle of PCR consisted of three separate steps:
a. denaturation at 94°C for 2min to separate any double-stranded DNA
b. annealing (hybridisation) of primers to DNA template for 2min.
For complementary oligonucleotides of 11-20 bases the annealing temperature was 
calculated using the Wallace equation: Tm= 4(G + C) + 2(A + T) (Thein and 
Wallace, 1986). PCR optimisation experiments should start with annealing 
temperatures approximately 5°C above the calulated Tm.
c. extension of primer by Vent polymerase at 72°C.
1 minute per kilobase of expected extension product was allowed; longer extension 
times may lead to degradation of the extended product due to the polymerases 
exonuclease activity.
d. the reaction was cycled back between the annealing, extension and denaturing steps 
28 times. The final step involved cooling to 72°C and maintaining this temperature 
for 2 minutes to ensure all extension products were double-stranded.
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2.2.4 Restriction Enzyme Digestions.
Restriction endonucleases recognise and digest specific palindromic nucleotide 
sequences leaving a 5’ protruding sequence, a 3’ protruding sequence or blunt ends. 
Because of the palindromic nature of the restriction enzyme sites, fragments generated 
have complementary or ‘sticky ’ ends which ultimately can be linked (ligated) to vector 
DNA. Plasmid DNA and PCR products may be digested with restriction enzymes. 
PCR products with restriction sites placed very close to the end of the DNA may 
require varying amounts of flanking DNA around the recognition site. Therefore, if an 
oligonucleotide primer is designed with a cut site that is too close to the end of the 
DNA, the site may cut poorly or not at all after amplification. All digests were 
performed in the appropriate NEB buffer described in the NEB product catalogue. 
Digestion of plasmid DNA required enzyme at 1 unit per 1 mg DNA whereas 
digestion of PCR extension products required 3 units per 1 mg DNA. Digestions were 
generally performed at 37°C overnight and inactivated by heating at 65-80°C for 15- 
30 minutes.
Double Digestions
The reaction mixture should be appropriate for the restriction enzyme requiring the 
lower salt concentration of the two enzymes to be used. Some NEB enzymes required 
the addition of BSA to a concentration of lOOpg/ml. If BSA was a buffer requirement 
for either enzyme, it was added to the double digest reaction since it does not inhibit 
any restriction enzyme. If the reaction buffers of both enzymes are similar, the DNA 
may simply be incubated in the presence of both enzymes.
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Protocol:
1. 100-200ng of DNA was added in a 49pl total reaction volume, made up with 5pi 
lOx reaction enzyme buffer and sterile water.
2. lpl of the restriction enzyme (diluted in water if high unit title) was added to 
reaction and mixed gently with the pipette tip.
3. the tube was incubated in a water bath routinely at 37°C (unless stated otherwise in 
the product guide) overnight.
4. the enzyme was then heat inactivated at 65-80°C for 15-30min and a 5pi aliquot of 
the reaction was analysed by gel electrophoresis.
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2.2.5 DNA purification
B-agarase digestion of LMP agarose
The B-agarase digestion of LMP agarose was used as a general method for purifying
digested vectors and DNA fragments prior to cloning. The digested DNA was
analysed on an 1% (w/v) LMP agarose gel in TAE. The gel was cast and run at 4°C
for lhour at 40mA.
Protocol:
1. The DNA containing LMP agarose was cut out with a scalpel under low frequency 
UV light.
2. the agarose was incubated at 60°C to melt and 10% total volume of lOx Agarase 
buffer was added.
3. the reaction was allowed to cool to 40°C before adding B-agarase (lu/pl):
2pl enzyme per 200pl 1% (w/v) agarose gel.
3pl enzyme per 200pl 1.5% 9w/v) agarose gel.
4. the reaction was incubated at 40°C for 2hrs, 10%v/v of 3M NaOAc. pH 5.5 was 
added and chilled on ice for 15min.
5. the undigested agarose was spun at 13,000RPM at room temperature for 15min and 
the supernatant was decanted.
6. two Volumes of iso-propanol (pre-chilled at -20°C) were added and DNA was 
precipitated after 30min at -20°C.
7. the DNA was pelleted at 13,000RPM at 4°C for 15min and the iso-propanol was 
carefully aspirated off leaving about 50pl.
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8. 1ml of 70% (v/v) ethanol was added and the tube was inverted 2-3 times and spun 
again as in step 7.
9. the ethanol was carefully aspirated and remaining traces of alcohol were left to 
evaporate on the bench for lOmin.
10. DNA was recovered in lOpl of TE pH 7.5 or sterile H20.
Spin-column chromatography
Spin-column chromatography was used post-PCR for the removal of primers, and 
between sequential reactions in cloning for buffer exchange and desalting. MiroSpin 
S400 columns (Pharmacia Biotech Inc.) are pre-packed with Sepharyl S-400 HR resin 
and equilibrated in TE buffer (pH 7.6).
Protocol (Based on the general protocol described in the Instruction Handbook):
1. The resin in the column was resuspended by vortexing, the cup was loosened and 
the bottom closure was snapped off.
2. The column was placed in an 1.5ml Eppendorf tube and pre-spun in a minifuge at 
3,000RPM at room-temperature for 2min.
3. the column was placed in a new tube and the DNA sample was applied to the top- 
centre of the resin.
4. the column was spun as in step 2 for 3min. The purified sample was collected at 
the bottom of the support tube.
Purification of DNA bv phenol extraction and ethanol precipitation 
In many cases, DNA prepared from a bacterial cell extract contains significant 
quantities of proteins and RNA. The standard way to deproteinise the cell extract is to 
add phenol or a 1:1 mixture of phenol: chloroform. Phenol denatures and dissolves 
proteins leaving nucleic acid in aqueous solution. Samples of DNA which have been
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treated with phenol are routinely then extracted with 24:1 (v/v) chloroform: isoamyl 
alcohol to precipitate remaining protein and reduce the amount of dissolved phenol 
which is in the aqueous phase. DNA in the aqueous solution can be precipitated by 
adding ethanol or iso-propanol in the presence of sodium or ammonium acetate and 
cooling to -20°C.
Protocol:
1. Equal volume of phenol, prepared as described in Maniatis (Maniatis and 
Sambrook, 1989) was added to the DNA mixture and vortexed gently.
2. the aqueous phase, which contains the DNA, was separated from the organic phase 
by centrifugation in the microfuge, at 10,000RPM for 1 min at room temperature.
3. the aqueous phase was transferred carefully into a fresh microfuge tube and an 
equal amount of chloroform: isoamyl alcohol (24:1) was added and step 2 was 
repeated.
4. in order to precipitate the DNA, 10% of 3M NaOH pH 5.5 and then 2 volumes 
absolute ethanol (chilled at -20°C) was added to the aqueous phase and the tube 
was incubated at -20°C overnight or for 30min at -80°C.
5. the precipitated DNA was pelleted by centrifugation in a microfuge at 13,000RPM 
at 4°C for 30min. The ethanol was removed with care and the pellet was dried in a 
desiccator for lOmin.An extra wash with 70% (v/v) ethanol was included to 
remove excess salt from the pellet. The dried DNA was resuspended in sterile TE 
pH 8.0 or water, and stored at 4°C for further manipulation.
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Spectrophotometric determination of DNA
Small quantities of DNA can be assessed by electrophoresing samples in an 
agarose gel with known standards, but samples from large-scale plasmid 
preparations were usually determined spectrophotometrically.
Protocol:
1. 5pi of DNA sample was transferred to 995pl of H20  in a 1ml quartz cuvette, the 
contents were mixed thoroughly and absorbance readings were taken at 260nm and 
280nm. The ratio 260:280nm absorbance ratio should be more than 1.9. If the ratio 
is less than 1.9 then contamination with protein should be suspected.
2. the quantity of DNA was calculated using the guide that 1ml of a solution with an 
A260 of 1.0 is equivalent to 50pg of double-stranded or 35pg of single-stranded 
DNA.
2.2.6 Ligations
Appropriately digested and purified vector and insert DNA can be linked together in a 
final ligation step prior to transfer to E. coli competent cells. DNA ligase covalently 
links, fragments of DNA to each other provided that a 5*-phosphate is in close 
proximity to a 3’-hydroxyl group. When protruding complementary termini (sticky 
ends) are present on the vector and insert DNA molecules they provide an obvious 
docking mechanism to bring the 5*- and 3’- ends of molecules together. However, 
ligation can also occur when there is no obvious mechanism for prior adhesion of 
fragments. Blunt- end ligation is not as efficient as the sticky-end ligation but it occurs 
when a higher concentration of DNA insert and ligase are provided.
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Vector: Insert Ratio
After the vector and insert DNA have been prepared for ligation, the concentration of 
each was estimated by agarose gel electrophoresis along with molecular weight 
markers of a known concentration. In most cases, a 2:1 ratio of insert: vector was used 
for sticky-end ligations and a 10:1 ratio for blunt-end ligations. Approximately, 20ng 
of insert DNA (MW 750bp) was added to 50ng of digested vector (MW 3.5Kb) for 
sticky -end ligations. The amount of insert DNA was increased to 60ng for blunt-end 
ligations to ensure that enough ‘ends’ were present in the reaction mixture.
Ligation fusing the T4 DNA ligasel
Using the 2:1 (or 10:1) insert: vector ratio the ligation reactions were set up as 
follows:
Protocol:
1. 1.5pl of lOx ligation buffer (0.5M TrisHCl pH 5.5, lOOmM MgCl2> lOOmM 
dithiothreitol, lOmM ATP, 250mg/ml Bovine Serum Albumin) was mixed with the 
digested DNA and 1.0 pi of T4 DNA Ligase (diluted lOx before use to 4 U/pl). 
The reaction volume was made up to 15pi using sterile H20.
2. the reactions were incubated overnight at 16°C
3. T4 ligase was heat inactivated at 65°C for lOmin before setting up the 
transformations
4. all 15pi of the ligation reactions were used to transform competent bacterial E.coli 
cells.
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Protocol fusing the Fast link ligation kit. Epicentre Technologies Co.. WisconcinL
1. 1 .5j l i 1 of lOx ligation buffer (lOOmM NaCl, O.lmM EDTA, 0.1% v/v Triton X-100, 
lmM dithiothreitol (DTT), 50mM Tris-HCl pH 7.5) was mixed with 1.5pl of 
lOmM ATP, the digested DNA and 1.0 pi of T4 DNA Ligase (2 U/pl). The 
reaction volume was made up to 15pi using sterile H20.
2. the tubes were allowed to incubate at room temperature for at least 1 hour after 
which the reaction was heated at 70°C for 15 minutes to inactivate the DNA ligase 
(Michelsen, B.K., 1995).
3. 10% of the reaction mix was used directly to transform competent E. coli cells.
2.2.7 Preparation of competent cells
In the early 1970’s it was observed that E. coli cells that had been soaked in an ice- 
cold solution were more efficient at DNA uptake than unsoaked cells. A solution of 
50mM CaCl2 is traditionally used. Although the exact reason is not well understood a 
possible explanation is that CaCl2 causes the DNA to precipitate on the outside of the 
cells or improves binding of the DNA in the cell well. The actual movement of DNA 
(transformation) into competent cells is stimulated by briefly raising the temperature 
to 42°C. Competent cells were prepared using the CaCl2 method.
Protocol:
1. lOmls LB medium containing the appropriate antibiotics and 1% (w/v) glucose was 
inoculated with cells toothpicked from frozen glycerol stocks and grown overnight 
at 37°C.
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2. 500^1 of the overnight culture was transferred in 50ml fresh LB medium containing 
the appropriate antibiotics and 1% (w/v) glucose and grown at 37°C with shaking 
until OD at 550nm was 0.4.
3. the cells were centrifuged at 5,000RPM at 4°C for 5min.
4. the pellet was resuspended in 25ml ice-cold CaCl2 (50mM) and incubated on ice 
for 20min and repelleted as in step 3.
5. the new pellet was resuspended in 5ml ice cold CaCl2 (50mM)/15% (v/v) glycerol 
and dispensed in 200gl aliquots into pre-labelled Eppendorf tubes.
6. the aliquots were snap frozen in acetone/dry ice and stored at -70°C.
2.2.8 Transformations
Heat shock transformation was used to introduce plasmid DNA into competent E.coli
cells. This method yields more than 107 transformants per microgram of supercoiled
plasmid DNA which is satisfactory for most cloning procedures.
Protocol:
1. lOOng of plasmid DNA was added in 50fil pre-thawed E. coli competent cells and 
was incubated on ice for lhour. When a ligation reaction was used to transform 
bacterial cells the amount of DNA was determined by the volume of the ligation 
(i.e. normally for ligations less than 20pl all DNA was used in the transformation).
2. the transformation reaction was incubated at 42°C for exactly 2min
3. 450ml ice-cold LB medium containing 1% (w/v) glucose was added to the heat- 
shocked cells and incubated at 37°C for lhour.
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4. 200j.il of each transformation was plated on LB medium plates containing 1% (w/v) 
glucose and the appropriate antibiotics and incubated overnight at 37°C.
(For the ligation reactions the cells were centrifuged at 5,000RPM at room 
temperature for 5min, the pellet was resuspended in 200jil LB medium (1% (w/v) 
glucose) and plated as in step 4).
2.2.9 Screening for recombinant plasmids
PCR Colony Screening
Transformed E.coli cells toothpicked directly from a plate, were screened by PCR to 
identify clones carrying the recombinant plasmids. Different sets of primers were used 
depending on the vector and the cloned fragment.
Protocol:
Each toothpicked colony was transferred in 20\i\ sterile H20  and pre-incubated for 
lOmin at 94°C. 1 fil from each sample was added to the reaction mixture containing:
dNTP’s 2|d
lOx Buffer 2(il





Vent DNA pol. 0.25ul
Total Volume 20^1
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The reactions were cycled 30 times, programmed depending on the primers used and 
the DNA template size (see table and 2.2.3). 5pl aliquots from each reaction were 
analysed on an 1% (w/v) agarose gel.
In-well Lvsis Screening
In-well screening (Epicentre Technologies Co., Wisconsin), adapted from Sekar 
(Sekar,V., 1987), is useful for identifying recombinant-plasmids based on differential 
migration of supercoiled plasmids with and without inserts in agarose gels. The only 
limitation is that the inserts must be of a sufficient size to allow discrimination based 
upon migration. Initially protoplasts are generated from colonies that potentially 
contain recombinant plasmids. The protoplasts are subsequently lysed in the wells of 
an agarose gel and supercoiled DNA is detected by ethidium bromide staining 
following separation by gel electrophoresis.
Protocol:
1. 15 pi of Protoplast Buffer was pipetted at room temperature into a convenient 
number of wells of a round-bottom microtiter dish or microfuge tube.
2. the transformed colonies, 2-3mm in diameter, were removed from the agar plate 
using a sterile toothpick.
3. the toothpick was vigorously swirled in the well of the microtiter dish for 10-15 
seconds, to deposit a sufficient number of cells.
4. the microtiter dish was incubated at room temperature for lOmin to allow 
protoplast formation.
5. while the cells were incubated 8 pi of lysis buffer was added into the appropriate 
number of wells of a submerged agarose gel.
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6. the protoplast buffer containing the cells was carefully added to the wells of the 
agarose gel filled with the lysis buffer. The mixture was allowed to incubate in the 
gel well for 15min.
7. in separate wells of the gel, supercoiled molecular weight markers and a sample of 
the supercoiled plasmid (without insert) were added. The DNA molecules were 
separated by electrophoresis, stained with ethidium bromide and visualised. 
Samples containing plasmid with insert migrated more slowly that the plasmid 
without-insert control.
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2.2.10 DNA Sequencing
Manual DNA sequencing (Sanger-Coulson Method)
Manual DNA sequencing was performed using the Sequenase kit v.2.0 (US 
Biochemical, Ohio) based on the chain-termination method (Sanger et al., 1977).
The chain termination method requires approximately lpg of a purified single­
stranded DNA template,. Sequencing double-stranded DNA requires an extra step 
where the DNA template is denatured before being added in the sequencing reaction. 
The chain-termination method (or dideoxy-nucleotide method) utilises a DNA 
polymerase (Sequenase) to synthesise a radiolabelled complementary copy of the 
template DNA in the 5'-3' direction. Incorporation of a dideoxynucleotide terminated 
chain elongation selectively at A, C, G or T because of the absence of a 3'-OH group. 
This generates the ladder of oligonucleotides to be resolved on a high resolution 
denaturing polyacrylamide gel. The reactions are set up to include also a short 
synthetic oligonucleotide primer (homologous to a portion of the template) from 
which the DNA polymerase initiates synthesis, normal deoxynucleotides that are used 
to elongate the new strand and an 35S-dATP to label the growing strand. The reactions 
are subjected to electrophoresis on a high resolution denaturing polyacrylamide gel 
and autoradiographed to visualise the DNA sequence.
Protocol:
Plate Preparation:
1. Two glass plates, a front plate 48cm long and a back plate 50cm long were cleaned 
and polished with ethanol.
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2. the back plate was placed in a fume cupboard and covered with a layer of 20ml 
ethanol mixed with 0.6ml 10% acetic acid and 0.2ml Bind Silane (A-174). The 
plate was incubated for 5min and then rinsed with distilled water and polished with 
ethanol.
3. the front plate was treated with 5ml Repel ™ (dimethyldichloranesilane) solution 
for 5min and rinsed as in step 2.
4. the back plate was placed on a large beaker and the spacers were placed on the 
sides. The front plate was placed on top and the two plates were sealed together 
with yellow tape putting extra tape around the bottom of the plates.
Preparine and casting the gel.:
1. The acrylamide solution was prepared by mixing together 16ml 40% 
Acrylamide/bis solution (AccuGel), 33ml diluent and 5ml buffer.
2. when fully assembled including comb and bulldog clips 300ul of ammonium 
persulphate (16%(w/v)) and 25pi N \ N’, N \ N’- tetramethylethylene-diamine 
(TEMED) was added to the mixture and mixed well.
3. the gel mix was poured between the two plates, the comb was placed upside down 
about 0.5cm from the top and the edges near the comb were clipped together with 
the bulldog clip. The gel was allowed to set for 1-2 hours.
4. once the gel had set tissue soaked in TBE (890mM Tris-borate, 890mM Boric acid 
and 20mM EDTA) was placed over the top opening to prevent the gel from drying 
out.
The sequenase reaction:
1. Double stranded DNA was denatured with NaOH and then the alkali was removed 
using Pharmacia Spin Columns (see chapter 2.2.5).
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2. the annealing mixture containing the DNA, 2pl reaction buffer, lpl primer (50pM) 
in a total volume of lOjul was incubated at 65°C for 2min, allowed to cool down at 
room temperature over 20min and then chilled on ice.
3. 2.5pl of each termination tube was added to A, C, G and T prelabelled tubes and 
incubated at 37°C before use.
4. the labelling mix was diluted 1:5 to working concentration.
5. lpl DTT (0.1M), 2 pi Diluted Labelling Mix 0.5pl 35S-dATP and 2pl diluted
Sequenase polymerase were added to the ice cold annealed mixture from step 2 and 
the labelling reaction was incubated for 2min at room temperature.
6. 3.5pi of the labelling reaction was transferred to each termination tube (A, C, G, 
and T) and mixed well. The termination tubes were incubated at 37°C for 5min.
7. the reactions were stopped by adding 4pl stop solution to each termination tube.
8. samples were stored at -20°C until further use.
9. immediately before loading on to the sequencing gel the samples were heated at
75°C for 2min.
Loading and Running the Gel.
1. the comb, the clips and the bottom tape were removed and the plates were attached 
to the sequencing apparatus.
2. the upper and lower tanks were filled with TBE and the gel was pre-warmed using 
constant power 45W, 1700V for about 30min.
3. just before loading the samples the comb was placed no more than 2mm in to the 
gel surface.
4. 5pi of each reaction were loaded in the appropriate lanes marked A, C, G and T.
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5. the samples were run for 3-4 hours until the lower marker was near the bottom of 
the gel.
Autoradiography
1. The gel was removed from the apparatus and the plates were separated gently using 
a razor blade.
2. the gel, usually stuck to the back plate, was soaked in 10% methanol, 10% acetic 
acid for 5min and then in water for 15min.
3. the gel was dried on the plate in a drying cabinet at 80°C for 30min.
4. the plate with the gel was placed in a cassette with the X-ray film on top and 
allowed to expose for 2-3 days in the dark room at room temperature.
5. the film was processed using the automatic autoradiography processor.
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2.2.11 Automated DNA sequencing - Fluorescent DyeDeoxy 
terminator method
For Automated sequencing, the samples were sequenced on a 377 DNA Sequencer 
ABI Prism (Perkin-Elmer) using the fluorescent dye terminator method at the 
Automated DNA Sequencing Service, School of Biology and Biochemistry, Bath 
University. The principle of this method is briefly discussed in Appendix I.
Protocol:
1. Samples to be sequenced were placed in 12pl total volume in a 0.2ml thin-walled 
tube containing 300-500ng of double-stranded DNA or 30-90ng of PCR product 
DNA (purified from an LMP agarose gel, 2.2.5) and 3.2pM of HPLC purified 
primer
2. The primer concentration was determined using the following formula:
pmol  __________ 100(A26O)__________
pi (1.54i l 4 + 0.75wC+1.1 InG  + 0.92 nT)
[n = number of A , C, G or 7]
3. All DNA sequences were checked against the sequence chromatogram to ensure 
that each base had been correctly identified and called by the sequencing software.
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2.3 Protein Methods
2.3.1 SDS PAGE Electrophoresis
All analytical electrophoresis of proteins was carried out in sodium dodecyl sulphate 
(SDS) polyacrylamide gels. In this technique the proteins are denatured and coated 
with a detergent by heating in the presence of SDS and a reducing agent. The gels can 
then be fixed, stained with Coomassie brilliant blue or used to establish a western 
blot.
Preparing and Running the Gel.
Protocol:
1. The glass plates were assembled together according to the manufacturer’s 
instructions. The Mini-Protean II System (BIORAD) based on the method 
described by Laemmli (Laemmli, 1970) was routinely used.
2. a 12% w/v resolving gel was prepared by mixing 4ml 30% w/v bis-acrylamide 
solution (ProtoGel) with 3.40ml H20 and 1.5M Tris-HCl pH8.8. lOOpl of 10% w/v 
SDS, 40pl of 25% w/v ammonium peroxodisulphate (AMPS) and 4pl of N, N, N’, 
N’, - tetramethylethylene-diamine (TEMED) were added and briefly mixed.
3. 3.5ml of the gel was poured into the vertical plates of the Mini-Protean II system 
300pl of water was carefully added to ensure a smooth interface between the 
stacking and resolving gel and the gel allowed to set.
4. A 6% w/v stacking gel was prepared by mixing 1.7ml 30% w/v bis-acrylamide 
solution with 6.7ml H20, 1.25ml 1M Tris pH 6.8, lOOpl of 10% w/v SDS and 40pl
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of 25% w/v AMPS. lOpl of TEMED was added and the mixture poured onto the 
resolving gel, a comb was inserted and the gel was allowed to set.
5. samples were mixed with loading solution (50mM Tris-HCl, pH6.8, 25% v/v 
glycerol, 0.1% w/v bromophenol blue, 6% w/v SDS, 4% v/v p-mercaptoethanol) at 
a ratio of at 5:1 (sample: loading solution) and incubated at 95C for 5 minutes. 
Electrophoresis was performed in tank buffer (250mM Tris-HCl pH 8.3, 192mM 
glycine, 0.1% w/v SDS) at 200V until the bromophenol dye had moved to the 
bottom of the gel.
2.3.2 Staining SDS-polyacrylamide gels with Coomassie Brilliant 
Blue.
Proteins separated by SDS-polyacrylamide gels can be simultaneously fixed with
methanol:glacial acetic acid and stained with Coomassie Brilliant Blue R250. The gel
is submerged in a concentrated methanol/acetic acid solution of the dye, and excess
dye is then allowed to diffuse from the gel during a period of destaining.
Protocol:
1. The gel was submerged in Coomassie dye solution (0.1% w/v Coomassie Brilliant 
Blue R250, 50% v/v methanol, 10% v/v acetic acid) and left to stain on a rocking 
machine at room temperature for 2-3 hours.
2. the stain was then removed and saved for future use.
3. the gel was destained in a destain solution (10% v/v methanol, 10%v/v acetic acid) 
as in step 2 for 1-2 hours or until the background was clear.
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4. stained gels may be stored in water in a sealed plastic bag or wrapped in cellulose 
film (BIO-RAD) and dried under vacuum at 60°C.
2.3.3 Western Blot Analysis
In general, proteins immobilised on membranes are detected with antibodies in a 
three-step process. First, the primary antibody, an IgG directed against the protein in 
question, is added to bind to potential antigenic sites. In the second step, a secondary 
antibody-enzyme conjugate, which recognises general features of all IgGs (anti-IgG), 
is added to identify bands at which the primary antibody is bound. The enzyme (AP or 
HRP) conjugated to the secondary antibody catalyses a colorimetric reaction in the 
third step, when the appropriate substrate is added. The colour provides a visual 
indication of proteins recognised by the primary antibody.
Protocol:
1. Six pieces of 3MM filter paper (Whatmann) and one piece of Hybond-C 
Nitrocellulose membrane (Amersham) were cut to the size of the SDS-PAGE 
Mini-gel and soaked in transfer buffer (39mM glycine, 48mM Tris-HCl pH 8.3,
0.037% (w/v) SDS, 20% (v/v) methanol) for 10 minutes.
2. the SDS PAGE Mini gel after the end of the electrophoresis was briefly soaked in 
transfer buffer.
3. the proteins analysed on the mini gel were transferred (blotted) on the 
Nitrocellulose membrane electrophoretically using the 2117 Multiphore II 
Electrophoresis unit (LKB Bromma).
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4. a typical set-up for Western Blotting includes in order from the anode plate (+): 
three pieces of the filter paper, one nitro-cellulose paper, the mini-gel, the three 
remaining pieces of the blotting paper and the cathode plate (-). Any overlapping 
paper larger than the gel was cut to gel-size with a razor blade and the apparatus lid 
was secured.
5. electrophoresis was performed at 80mA, 10 volts for 30minutes for one blot or at 
160mA for two.
6. after blotting the nitro-cellulose was washed briefly in phosphate buffered saline 
(PBS: 108mM NaCl, 2.7mM KC1, lOmM NajHPO* 1.75mM KH2P04) and the 
Mini-gel was Coomassie stained to check the efficiency of the transfer (see section 
2.3.2).
7. the membrane was placed in a glass dish and incubated in 30ml PBS, 2% w/v non­
fat dried milk (Marvel) for 1 hour at room temperature to block non-specific 
absorption sites. The membrane was washed twice with 30ml PBS for 3 minutes 
and immersed in 30ml PBS/Milk containing 0.1% (v/v) primary antibody and 
incubated at 4°C overnight. Alternatively, the blocking step was performed 
overnight at 4°C and the membrane was incubated with the primary antibody for 
2hs at room temperature.
8. the membrane was twice washed in 30 ml PBS, 0.05% (v/v) Tween-20 for 3 
minutes and washed twice in 30ml PBS for 3 minutes.
9. the membrane was incubated in 30ml PBS/Milk containing 0.1% (v/v) secondary 
antibody (conjugated to horseradish peroxidase HRP) for 45 minutes at 4°C.
10. the membrane was washed as in step8.
11. the antigen-antibody complex was located by immersing the membrane in 60ml 
HRP developing solution (0.3% (w/v) 4-chloro-l-napthol, 8mM Tris-HCl pH 7.5,
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125mM NaCl, 0.015% (v/v) H20 2) and incubation at room-temperature until an 
intense purple colour developed.
(All the incubations and washing steps were carried out under low agitation on a 
rocking apparatus).
3Redesigning the Antibody Combining Site
The design process outlined in section 1.4 was tested using enkephalin/morphine 
as the target antigen and Gloop2 as the antibody scaffold. The work presented in 
this chapter has been described in the Ph.D thesis of Dr. Jan Pedersen (1993), 
although the text has been modified and added to in places.
3.1 The design of an opioid antibody (GlaMor)
3.1.1 Antigen selection
The opioids were chosen as the primary target for the design project out of three 
candidate molecular classes sampled from Cambridge Crystallographic database 
(Kennard, 1991). The three candidate molecular classes namely, non-peptide 
antigens caffeine and theophyllin, opioid peptide antigens and the non-peptide 
opioid morphine and helical peptides containing the sterically constraint amino- 
acid a-amino-isobutiric-acid (Fig. 3.1). The rationale behind these selections is to




Leu Enkephaline Aib peptide
Fig. 3.1: Monte Carlo (Neumann and Ulam, 1945) plots of the three compounds chosen for 
the design an antibody.
The Monte Carlo programme is a general tool for molecular modelling targeting the prediction of 
side chain conformations in proteins. A. caffeine (Sutor, 1958a and b), B. morphine (Bye, 1976) 
and P-tum conformation of Leu-enkephalin (Aubry et al., 1988), C. Aib helical peptide (Karle et 
al., 1991).
The enkephalins, and related opiods have the most structural information available (From 
Pedersen, Ph.D thesis, 1993)
provide a spectrum of antigen types, a small non-peptide hapten, a small peptide 
hapten and a large peptide antigen.
The reason for choosing the enkephalins was that there exists the most structural 
information with structures determined by X-ray crystallography and refined to a 
resolution of <0.5A (Aubry et al., 1988). The N-terminal tyrosine residue of 
enkephalin -the one component of the enkephalin structure essential for biological 
activity-(see Fig.3.3) contains a phenolic ring separated by two carbon atoms from 
a nitrogen, which is also a feature of the morphine structure (Henderson and 
McFadzean, 1986).
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Docking the antigen in the generic combining site as described in section 1.4.2 
and finding the initial orientation requires data from known functional groups of 
the antigen. These date allow the determination of distance constraints for optimal 
liganding geometry.
The opiates have been extensively analysed in terms of their agonist/antagonist 
activities by QSAR methods (see Casy & Roberts, 1986 for a review); A 












Fig. 3.2: Schematic Representation of the Opioid Receptor Binding Site.
Numbers indicate the putative positions of the liganding groups in the receptor. This mapping was 
the basis for the calculation of distance constraints (see text and Pedersen, 1993).
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The putative receptor sites corresponding to the ligand features are indicated. 
Since the seven sights shown will have a defined distance relationship (a sine qua 
non of a pharmacophore model), the distance map derived from the 
pharmacophore was applied to each of the five opioid agonists, morphine, leu- 
enkephalin, naloxone, methadone and nalorphine. The structures of the agonists 
were obtained from the Cambridge Crystallographic Database (Kennard, 1991) 
and are shown overlapped in Fig3.3 (overlapping carried out using INSIGHT, 
MSI,US A). Average distances were then calculated and the final set of inter-site 
distances were used as constarints to search the combining site of the target 
antibody (see section 3.1.2) for potential complementary positions. Once found the 
selected set of seven contact positions would be mutated to a residue type most 
likely to provide the ideal complementarity to each of the opioid features. Since 
equally probable solutions for a given site might be allowed (given the inexactness 
of pairwise contact matching, either by energetics methods or docking), several 
sets of mutants at each position were generated.
Fig: 3.3: Structures of morphine , nalorphine and naloxone overlapped, with leu-enkephalin 
and methadone in the likely equivalent conformation shown alongside
Chapter 3: Redesigning the Antibody Combining Site 77
3.1.2 Antibody selection
The antibody selection process makes use of antigen topology information and the 
antibody classification as outlined in section 1.2.3. According to Webster et al. 
(1994) there are three groups namely cavity, groove and planar antibodies 
referring to the overall topography of the antibody combining site (Fig. 3.4). There 
are some indications (Rini et al., 1992; Novotny, 1991; Herron et al., 1989) that 
smaller antigens bind best when they are almost buried in the surface of the 
combining site, usually in a hydrophobic hole. Larger protein antigen prefer less 
curved surfaces and appear to bind over a larger surface area (Amit et al., 1986 ; 
Sherrif, 1987), often with many charge-charge interactions.
MacCallum’s recent classification (1996) clusters antibody combining sites into 
four topographic classes; concave and moderately concave (mostly hapten 
binders), ridged (mostly peptide binders) and planar (mostly protein binders).
The antibody platform chosen was the anti-lysozyme antibody Gloop2 (Darsley 
and Rees, 1985a and b). The specificity of this antibody for certain residues of the 
“loop” peptide of hen egg lysozyme was determined by serological mapping 
(Darsley & Rees, op.cit), by site-directed mutagenesis (Roberts et al 1987) and by 
NMR (Cheetham et al, 1991). The x-ray structure of Gloop 2, determined for the 
uncomplexed Fab only (Jeffreys, 1989), shows a truncated groove (see Fig.3.5a) 
formed at the centre of the combining site of dimensions ~12A (long) by ~ 
9A(wide) by ~ 7A (deep). It is lined predominantly by side chains although there
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are a few contributions to the groove surface from main chain atoms. A list of the 




L3 L89, Y91, L92, Y94, L96
HI F32, G33, T35
H2 E50, F52, Y59
H3 E99,1100, R101
Table 3.1: List of residues of the Gloop2 groove
Fig. 3.5a: Space filling model of GIoop2 showing the groove type of combining 
site
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Fig. 3.5b: The Loop peptide backbone structure with the side chains built in.
The polypeptide sequence and the important residues (in bold) is shown below:
Gln-Ile-Asn-Ser-Arg-Trp-Trp-Cys-Asn-Asp-Gly-Arg-Thr-Pro-Gly-Ser-Arg-
Asn-Leu-Ala-Asn-Ile-Pro-Cys-Ser-Ala-Leu-Leu
Fig. 3.5c: The initial (loop peptide-left) and the target (enkephalin-right) 
antigens in space filling models with the contact residues marked.
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Of the six CDRs, LI is almost completely excluded from the groove by L3 except 
for the sidechain of Y32, while L2 performs a secondary packing role. The groove 
of Gloop 2 is an extension of the hapten binding type pocket and is caused by the 
conformation of the unusually short H3 (4 residues). The Fab HyHEL-5 (Sheriff et 
al, 1987) has a small groove in this region also, except that it is terminated at both 
ends -  by CDRs L3 and H3. Also, a fully formed groove is found in the NC41- 
neuraminidase complex (Tulip et al, 1989) which spans the combining site due to 
the packing of CDRs L3 and H3 against the VL and VH domains, respectively.
Of particular significance in the Gloop 2 groove is the presence of two partially 
buried Glu residues, E50 and E99. When mutated, binding to the loop peptide is 
lost, implicating charge-charge interactions in the binding of the parent antigen 
(Roberts & Rees, unpublished; Jeffreys, 1989). Confirmation of the likely role of 
the salt bridges in the Gloop 2-loop peptide interaction was obtained by NMR 
experiments in which line broadening (COSY experiments) was measured for 
each peptide residue during binding to the Fab (Cheetham et al, 1991). These 
studies clearly identified the roles of residues R61, W62,W63 and 178 in the 
interaction. The conformation of these residues in the crystal structure of 
lysozyme (Phillips et al, 1967) is shown in Fig3.5b where the loop peptide region 
only is shown; Residues implicated in the Gloop 2 binding are highlighted. For 
comparison, the structure of leu-enkephalin is shown alongside the loop peptide in 
Fig.3.5c. Of particular importance to note is that leu-enkephalin has no Arg 
residues, the roles of which are central to the specificity of the loop peptide for the 
Gloop 2 antibody.
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Fig. 3.4: The three antibody binding site types.
A. Planar, B. Cavity and C. Groove. In this picture the Fv framework is shown as the magenta 
ribbon, and the antigen is shown in a space filling model (Webster et a l, 1994)
Against this structural backdrop, the re-design of the Gloop 2 combining site was 
initiated. The groove of Gloop 2 was taken as the ‘platform’ and the following 
procedure adopted:
i) Map the positions of all canonical class ‘key’ residues in the CDRs 
(see Table 3.2) and retain the existing residue
ii) Convert the remaining residues to alanine
iii) Construct a distance map in which the distance constriants of the 
pharmacophore model (see Fig.3.2) are used to find the best fit to 
the C13 positions of the groove residues. This will now be 
described.
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3.1.3 Search and Selection
The Gloop2 combining site was searched in the following way in order to find the 
initial orientation of the ligand. First, all non-canonical residues (see Table 3.2) 
were removed from Gloop2 CDRs’ (retaining the canonical residues) and replaced 
by alanine, still accommodating the complementarity and retaining the original 
backbone conformation.
Loop Sequence
HI 31-p 32p  33q  34j-jj 35j
H2 ^50p 51 j  5 p  52ap 53q  5 4 ^  55 g  56j^ 5 7 p  58Y J
H3 | 9 5 p  96j 101j^ 102Y J
LI 24R 25[A] 26S 27Q 28E 29[I] 30S 31G 32Y 33[L] 34s
L2 50A 51A 52S 53T 54L 55D 56S
L3 89L 90rOl 91Y 92L 93S 94Y 95[P196L 97T
Table 3.2: Canonical classification of Gloop2
Canonical residues are in bold and in [ ] brackets. For H2, all residues are in square brackets since 
at the time of the design, no canonical class was known. For H3, no canonical classes are known. 
Numbering is according to Kabat. (Kabat et al., 1987)
A distance map of the Cj5 positions was generated and the distance matrix was 
then searched against the distance constraints determined previously for the new 
antigen (actually, the pharmacophore). If a hit was found within the allowed 
variation of the distance constraint, the next constraint was searched for, and so 
on. If all the constraints were satisfied a hit was scored. The hits were ranked 
according to deviation from mean values obtained from the distances of the seven 
positions of the liganding groups in the opioid receptor binding site.
In the second search, all the non-canonical (or defined as being changeable) CDR 
residues (twenty six positions from Table 3.2) which could potentially participate
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in specific ligand interactions were retained. These residue positions were then 
searched with the distance searching procedure described above. Identifying an 
initial orientation by this procedure reduces the number of residues that have to be 
changed and determines the maximum number of ligand requirements that can be 
satisfied by the original antibody sidechains.
In the starting orientation, where enkephalin was placed in the centre of the 
binding site in an orientation dictated by the constraint procedure above,, it was 
only possible to make contacts with thirteen of the original set of twenty six 
residues; The positions of those thirteen residues in the Gloop 2 structure are 
shown in Fig.3.6. After conversion of these thirteen positions to alanine, the 
enkephalin molecule was repeatedly ‘thrown’ into this site using a Monte Carlo 
algorithm (Neumann and Ulam, 1945) until a low energy set of docked structures 
was obtained (illustrated in Fig.3.7). Then, side chain replacement was carried out 
at each position and the lowest energy conformations of all the possible side chain 
types were extracted. The ten lowest energy residue combinations for all the 
residues in the construct are shown in Table 3.3, and formed the basis of the 
library to be constructed.
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Residue Position Number
Sequence
L32 L89 L91 L94 L96 H32 H35 H50 H52 H56 H95 H96 H101
1 F W D F N K F H F W H D F
2 F W D F D K F H F W H D F
3 F W D F N K F H F W H D Y
4 F W D F D K F H F W H D Y
5 F W D F N K F H F W H N F
6 F W D F D K F H F W H N F
7 F W D F N K F H F W H N Y
8 F W D F D K F H F W H N Y
9 F Y D F N K F H F w H D F
10 F Y D F D K F H F w H D F
Original Y L Y Y L F T E F K E I R
Table 3.3: The ten lowest energy conformations of the complete construct
The original Gloop2 residues are shown in the bottom row
Fig. 3.6: The Gloop2 combining site with highlighted the proposed contact residues.
The heavy chain is on the left and the light chain is on the right.
Chapter 3: Redesigning the Antibody Combining Site 85
A
B
Fig. 3.7: Pictures showing the initial (Ala) and final binding site of the GlaMor antibody 
(Best construct)
Ala site, B. After side chain reconstruction (side view), C. After side chain reconstruction (front 
view).
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The final ten best models were subjected to further energy minimisation cycles in 
order to validate the conformations. All the opioid ligands extracted from the 
crystallographic database were overlapped (Fig.3.3) in the GlaMor combining site 
and were able to assume the same orientation as the docked morphine (not 
shown). None of the non-peptide ligands clashed with the backbone of the model, 
though Leu-enkephalin exhibited some overlap of terminal sidechains with the 
sidechains of the reconstructed antibody combining site (Fig. 3.7).
3.3 Experimental test of the design
In order to determine how the design process performed, two experimental 
systems were devised and implemented in the laboratory. Gloop2 was built as a 
scFv construct. The ten GlaMor constructs were generated by PCR mutagenesis of 
the Gloop2 scFv, displayed on phage and screened for binding to leu-enkephalin 
using a phage display library. Binders from this library were sequenced and the 
sequences were compared with the ten predicted sequences. The second 
experimental strategy was to express soluble GlaMor scFv in E. coli and 
investigate its binding to leu-enkephalin using the Biacore technology. This will 
be described in the following chapters.
4Phage display and selection of Gloop2 and 
GlaMor scFv
4.1 Introduction
Computational predictions on the effect of mutations on antibody affinity and 
specificity can be experimentally tested by mutagenizing residues in one or more of 
the six complementarity determining regions (CDRs) by site-directed mutagenesis. 
Using the M l3 filamentous phage system, antibody gene fragments can be cloned in a 
phage vector expressed as a coat protein fusion and screened for novel antibody 
binding properties. Several libraries of phage displaying single-chain Fv fragments 
randomised at CDR positions have been constructed and selected for hapten affinity 
(Schier etal., 1996).
The size of the library is directly influenced by the efficiency of transformation of the 
DNA into bacterial cells. Random libraries need to be of considerable size to contain a 
clone with the desired properties. If on the basis of structural information, 
randomising is restricted to a few residues, the number of possible mutations can be
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adjusted so that the size of a library, covering all of them, is no longer a technical 
obstacle (Fig.4.1).

















Fig. 4.1 Representation of sequences in the library
The amino acid positions on the protein sequence shown on X axis and the percentage of 
representation of different combinations of these mutations by a specific library size are shown on the 
Y axis.
Each o f the labelled lines represents the different codon possibilities (amino acids) that are allowed. 
For example the (first on the left) shows that if all 30 codon (all amino acids) are allowed then 
only 4 positions (304 combinations) can be mutated to get 100% representation (assuming the library 
size>304) and it requires 5xl06 transformants. If 5 positions are mutated then only 1% of the sequences 
will be represented by the above library size.
Antibody fragments are selected by subjecting the population of phage antibodies to 
antigen-affinity selection. Depending on availability of the antigen, and the type of 
binding desired, this can be accomplished by using columns of antigen immobilised 
on Sepharose (McCafferty et a l , 1990) or by ‘panning’ the library using plastic tubes 
or petri dishes which have been coated with antigen (Clackson et a l, 1991). After 
washing, binding phages can be specifically eluted, using for example an excess of
antigen (Clackson et a l, 1991), or non-specifically eluted by changing the pH using,
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for example, triethylamine (McCafferty et a l, 1990). Phages eluted from the affinity 
matrix are then used to infect E. coli. Since this particular phage genome carries a 
gene conferring drug resistance, infected cells can be selected on bacterial plates 
carrying an antibiotic. Phage antibodies are prepared from individual clones by 
growth in liquid culture and harvesting of the supernatant.
Phage antibody particles in the culture media can be used directly for subsequent 
analysis (e.g. by ELISA) and single- or double stranded DNA from selected clones 
can easily be prepared for sequencing or further mutagenesis. Soluble fragments can 
be produced without the phage particle by using vectors that contain an amber codon 
between the antibody and gene3. These vectors produce soluble or phage antibodies 
depending on the bacterial strain infected. Alternatively, soluble fragments can be 
produced by sub-cloning of the antibody genes into normal expression vectors (see 
Chapter 5).
4.2 PCR Mutagenesis
The approach of a restricted site-directed randomisation was used to design 
degenerate primers in order to introduce the predicted sets of mutations; Four 
positions in the sequence were randomised. The Gloop2 scfv gene was used as 
template. Gloop2 scFv (full sequence shown in Appendix I) was constructed by Dr. G. 
Elliott based on Gloop2 VH and VL genes (Roberts and Rees, 1986) and D1.3 scFv 
(generous gift from Dr. G. Winter, MRC, Cambridge) The VH and VL genes on the 
D1.3 scFv were replaced by the VH and VL genes from the Gloop2 Fv maintaining 
the linker sequence of the D1.3 construct intact. The sequences of the degenerate
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primers synthesised with the mutations they carry are summarised in Table 4.1, while 
Figure 4.2a illustrates the basic mechanism of PCR site-directed mutagenesis.
Splice assembly PCR olieos for semi-random mutagenesis
For all reactions to generate fragment PCRs were performed with 30 cycles of 92°C 
(lmin), 44°C (2min) and 72°C (2min).
Splice assembly PCR was performed with Vent DNA polymerase (strand 
displacement but no nick translation activity). Annealing temperature of the splice
overlaps was 60°C for all fragments using the same programme.
Name Sequence No of bases Mutations/
Sites
IFOR ggt gca get gca g 13 Pst I  site
2BACK cca etc aag gcc ctg tcc agt tct ctg ctt 
cac cca aaa tat acc aaa ggt tgt g
55 T35F
3FOR gga cag ggc ctt gag tgg att gga cat att 
ttt cct gga aat agt tgg act tac tac get ga
62 E50H, K56W
4BACK t ggt gcc ttg gcc cca gta g(a/t)a gt(c/t) 




5FOR act ggg gcc aag g 13
6BACK ttt ctg ctg aag cca get taa gaa acc act 
aat ttc ttg ac
41 Y32F
7FOR ctg get tea gca gaa 15
8BACK ttt cae etc eae ctt eet ccc acc acc eaa 
cgt gt(c/t) egg aaa act aag ate ttg 
(c/g)(c/t)a aca ata ata gtc tgc aaa




Table 4.1: The primer sequences used for the site-directed mutagenesis.
The last column shows the mutations and the sites that are contained in each primer.
The library that will be constructed using the above primers will be semi-randomised at 4 positions and 
will contain 2x2x2x4=32 different sequence combinations.
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Fig. 4.2a: The basic mechanism of site-directed mutagenesis using PCR
Gloop2 scFv construct is shown at the top with the various degenerate oligonoucleotides (spiked 
arrows) used to introduce the mutations predicted by the Design process (Chapter 3). All possible 
combinations of mutations could be introduced resulting in the bottom scFv construct, which was 
cloned as a Pst VXho I cassette in the fd-tet-DOGl phage vector.
A B C D AB BC CD ABCD M
Fig. 4.2b: Agarose Gel of Mutagenised DNA fragments
DNA fragments after mutagenesis were analysed on an 1% (w/v) agarose gel. Sizes correspond to the 
ones described above. M; DNA markers
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4.3 Library construction and multiple pannings
DNA Technology
PCR products were cloned as PstI (in the VH)/XhoI fragments into the fd-tet-DOGl 
(Hoogenboom et al., 1991) for fusion with g3p (Fig. 4.3). Ligated DNA was 
electroporated (Dower et a l , 1988) into TGI E. coli cells resulting in a mini library 
with 108 colonies/jig of DNA (Fig.4.5).
Titration of Phage 
Protocol:
1. 10ml TGI cell culture in 2xYT was set up overnight at 37°C
2. IOOjj.1 of the overnight culture was transferred in 10ml fresh 2xYT grown to log 
phase (OD600: 0.5) and tranferred in 200pl aliquots to pre-warmed eppendorfs
3. serial dilutions of phage were prepared in water ranging normally between 10 2 to 
1014
4. 50pl from each phage dilution was added to each aliquot of TGI and incubated 
without shaking at 37°C
5. 200pl from each aliquot was transferred on 2xYT+15pg/ml Tetracyclin plates and 
incubated overnight at 37°C
6. colonies grown were counted and the original phage titre was estimated.








f d-gene V III
fd - te t-D O G  1
9290  bp
T e t R
II
fd-gene I I I  fd-tet-DOG 1 polylinker fd-genelll
' H S A ' Q V Q L Q E L E I  K K ’ A A  ~A k  T V 
CACAGTGCACAGGTCCAACTGCAGGAGCTCGAGATCAAACGGGCGGCCGCAGAAACTGTT
ApaU Psti Saci xhol Notl
III Psti Xhol
M13 VH VL ■g
Fig. 4.3: Cloning the scFv genes in the fd-tet-Dogl phage vector
I. Structure of the phage vector fd-tet-DOG 1
II.. Sequence of fd-tet-DOG 1 cloning sites
III scFv (Gloop or GlaMor) cloning cassette in the fd-tet-DOG 1 phage vector
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Pannine library on streptavidin coated beads
Protocol:
1. Phage was diluted in sterile blocking buffer (1% casein/PBS/0.1% Tween 20) to a 
final concentration of 109TU/ml and preblocked by incubating for 1 hour at room 
temperature
2. Biotinylated enkephalin was added to a final concentration of 50ug/ml to 1ml of 
preblocked phage in a sterile eppendorf mixed on end-over-end shaker for 2hrs at 
37°C. Meanwhile magnetic beads were preblocked:
• Streptavidin coated magnesphere particles (Promega) were resuspended by 
vortexing. 0.5ml (0.5mg) of beads were transfered to an eppendorf tube and 
pelleted by spinning briefly (lOsec, 2,000rpm). The tubes were placed into 
a DYNAL stand with the pellet towards the back. The supernatant was 
aspirated and the beads were centrifuged for lOsec at 2,000rpm to remove 
any residual preservative.
3. The beads were washed this way three times in 1ml of blocking buffer and finally 
were left to stand in lOOpl of blocking buffer until the phage incubation was 
completed.
4. The beads were added to the phage/enkephalin solution and the incubation was 
continued for half an hour.
5. The beads were washed six times in 1ml PBS/Tween as before
6. The beads were resuspended in freshly prepared elution buffer (50mM 
triethylamine) and left rotating end-over-end for lOmin. Meanwhile, for each pan 
50pl of Tris HC1 pH 7.4 was aliquotted into an eppendorf. The phage should not be 
left in the elution buffer for more than lOmin.
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7. The beads were pelleted, the phage supernatant was transferred to the Tris 
containing tubes and mixed immediately to neutralise.
8. Titre serial dilutions of lOpl aliquots were used to infect 200pl of exponential TGI, 
incubated for half an hour and then plated onto 2xYT+ 15pg/ml Tetracyclin plates. 
A PCR screen and/or sequencing of the resulting colonies was used to check the 
ratio of recombinant to parental vectors.
9. The eluted phages were reamplified by doing a large scale phage prep and then 
titrated as described above (Fig. 4.3).
10. Phages after three rounds of panning were used in a phage ELISA over a range of 
BSA-enkephalin concentrations, PCR screened and sequenced. The library panning 
and selection procedure is illustrated in Fig. 4.4.
M utant Phage 
D isplay Library
1. B ind b iotinylated 
target antigen




2. Isolate binders 
on m agnetic beads
Fig. 4.4: Panning for anti-enkephalin mutants
Biotinylated enkephalin was added to phage from the mutant display library and any binders were 
captured on streptavidin coated beads. The binders were then washed, reamplified and panned again 
following the same cycle.
Chapter 4: Phage display and selection o f Gloop2 and GlaMor scFv 96



















Fig.4.5: Construction of the mutation phage library.
The scFv DNA fragments (carrying different sets of mutations) were cloned into the fd-tet-DOG 1 
phage vector and electroporated into E.coli competent cells creating a phage library. Phage produced 
was panned against enkephalin to select for potential binders. The library efficiency was always 
checked to secure that all possible combinations of mutations were represented.
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Preparation of Phage Supernatants, growth of cultures and reamplification of library
Protocol:
1. Each colony was transferred to 10ml of 2xYT containing tetracycline and grown at 
37°C overnight.
2. The cells were centrifuged at 13,000rpm for 5min a room temperature and the 
pellets were resuspended in 2xYT+15% (v/v) glycerol and stored at -70°C.




1. BSA-enkephalin conjugate was serially diluted over a range of lOOug/ml to 
lOng/ml in fresh 50mM NaHC03 pH 9.6 using eppendorfs
2. lOOpl per well of each dilution was pipetted onto a 96well Nunc maxisorb plate in 
duplicates
3. lOOpg/ml of BSA was used a negative control and was put onto the end wells of 
the dilution series
4. The plate was incubated in a plastic box containing a little water overnight in the 
cold room. The plate was covered to prevent any drops of water falling in.
5. The samples were flicked out from the wells and washed by filling a sandwich box 
with wash buffer (PBS/0.1% Tween-20) and submerging the plate. The plate was 
tapped side to side to remove bubbles and then flicked to remove any wash buffer.
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6. The plate was placed upside down on blue roll and tapped on the bench a few times 
to remove any remaining drops/bubbles. The plate was left to drain for a few 
minutes.
7. Each well was filled with 200pl of blocking buffer (3% BSA (w/v) 
/PBS/0. l%Tween-20 (v/v)) using a multichannel pipette.
8. The plate was covered and incubated in a humidified sandwich box at 37°C for 1 
hour to block. For the last half-hour of the incubation, phage was preblocked.
9. Phage was diluted in blocking buffer to 109TU/ml of blocking buffer and incubated 
at room temperature for half-hour. Wild type Gloop2 phage and fd-tet-DOGl were 
also tested as control samples.
10. The plate was rinsed by submerging in wash buffer and tapped dry. lOOpl of 
preblocked phage was added in each well in duplicate for each row and for each 
phage type.
11. The plate was incubated at 37°C for two hours in a humidified container. For the 
last half-hour, HRP-linked anti-M13 conjugate was preblocked at room 
temperature. This was diluted 1/5000 with blocking buffer and lOOpl was added to 
each well.
12. After the incubation, the plate was washed six times with wash buffer and drained 
by tapping onto tissue.
13. lOOjul of preblocked HRP-linked anti-M13 conjugate was added per well and 
incubated for 1 hour at 37°C in a humidified box. Meanwhile lOmM sodium citrate 
solution pH 5 was made up
14. The plate was washed six times with PBS/0.1% (v/v) Tween-20 and once in citrate 
solution and was allowed to dry on blue roll
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15. IOOjliI of developing solution (lOmg ABTS in 45ml citrate buffer) was added to 
each well. Just before adding the developing solution to the plate, hydrogen 
peroxide was added (36pi hydrogen peroxide/42ml developing solution). After the 
colour has developed the plate was read at 414nm
16. The absorbance was plotted against the log of the conjugate concentration.
Results
1012 phage particles (titrated as described earlier) were prepared and panned against 
biotinylated enkephalin on streptavidin coated beads. Phage displaying the Gloop2 
scFv were used as a control and were panned against the biotinylated loop peptide 
against streptavidin coated beads. Three rounds of panning were carried out each time 
checking the phage titre and the presence of Gloop2 mutants by a PCR screen.
Phage after the third pan were screened for specific binding against enkephalin by 
phage ELISA (as described earlier). The control assay was set up using Gloop2 scFv 
displaying phage. Both phage constructs (Gloop2 and mutant) were screened against 
both the peptides (loop peptide and enkephalin). Binding was determined with a 
chromogenic reaction between the anti-M13 HRP conjugate phage and its substrate 
and measurement of the absorbance at 414nm. The absorbance was plotted against the 
log of serial concentrations of the peptides (Fig. 4.6). The binding of the library and 
Gloop2 displaying phage against the loop peptide first, and enkephalin second was 
compared. Tighter binding against enkephalin was indicated by a clear shift of the 
binding curve of the library to the left (about 1 log) of the binding curve of the Gloop2 
displaying phage. The binding curves against the loop peptide showed that Gloop2 
phage bound tighter than the mutant library (about a 1.5 log shift). These results
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indicated that the phage population in the library was expressing a construct that was 
responsible for the tighter binding. To identify the nucleotide sequence of this 
construct DNA from several clones was prepared and sequenced (as described later).
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Fig.4.6: Specificity of the GlaMor phage library to enkephalin
After three rounds of panning and selection phage from the mutant library and Gloop2 scFv displaying 
phage were used in phage Elisa against BSA-enkephalin (bottom graph) and BSA-loop peptide (top 
graph). The peptide antigens, coating the wells, were serially diluted and were used to determine 
specific binding of the mutant display phage library to BSA enkephalin. The tighter binding o f the 
library to BSA-enkephalin is shown with a shift o f the curve to the left of the binding curve of the 
Gloop2 phage to BSA-enkephalin peptide.
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4.5 Colony screening of panned library and 
sequences of positive clones
PCR aided colony screen
Eight colonies infected with phage after the third panning (titre:2.58xl012) were PCR 
screened using oligos 5FOR and 8BACK to identify positive clones carrying the 
GlaMor scFv insert. Gloop2/fd-tet-DOGl transformed TGI was used as a positive 
control for the screen.
Each colony was toothpicked in a 30pl reaction set up with 0.6pl 5FOR (lOpM),
0.6.l 8BACK (lOpM), 6pl Buffer (5X) and 22.5pl H20  and the reactions were heated 
for lOminutes at 94C before 0.3pi Taq DNA polymerase (Bioline) was added. PCR 
was performed with 25 cycles of 94°C (lmin), 55°C (lmin) and 72°C (2min) and then 
an extra step at 72°C for lOmin. 5pi of dye was added to lOpl from each reaction and 
analysed on an 1% (w/v) agarose gel. Four colonies (50%) with scFv GlaMor inserts 
were identified and used to prepare ssDNA for sequencing (Fig.4.7a,b)
Preparation of ssDNA 
Protocol:
1. 10ml overnight culture grown as above was used to innoculate 100ml of 2xYT 
containing 15pg/ml tetracyclin and was incubated at 37°C overnight
2. The cells were centrifuged at 3,000rpm for lOmin at room temperature
3. The pellets were resuspended at 2xYT+15% (v/v) glycerol and stored at -70°C and 
5ml of the supernatant was filtered using an 0.45pm filter and stored at 4°C
Chapter 4: Phage display and selection o f Gloop2 and GlaMor scFv 102
4. 1ml of 20% (w/v) PEG 6000 in NaCl was added to the rest 5ml of supernatant and 
incubated at 4°C for 1 hour or alternatively the cell pellet was resuspended in 1ml 
of 85% 2xYT (v/v) containing 15%(v/v) glycerol frozen on dry ice and stored at - 
70°C
5. The supernatants were centrifuged at 6,000rpm for lOmin and the pellets were 
resuspended in 200pl of TE and purified twice using phenol chloroform and then 
ethanol precipitated. The final pellet was resuspended in lOpl of TE.
6. 3pi was analysed on an 1% (w/v) agarose gel and 7pl was added to the sequencing 
reactions
All four clones were sequenced manually using different sets of primers so as to 
obtain the full-length sequence. The sequences read were compared with the Gloop2 
scFv sequence to identify any matches to the ten predicted mutation sets. All four 
clones gave the same sequence (Fig. 4.8 for the CDR sequences and Appendix I for 
the full-length scFv sequences) and this matched with the fourth ranked predicted 
construct but which contained the additional mutation I138R in CDRH1 (Fig. 3.2).
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Fig. 4.7a: PCR screen of positive GlaMor/fd-tet-DOGl clones
After the third panning eight colonies were PCR screened using oligos 5FOR and 8BACK. 10pl of 
each PCR reaction was loaded per well. Colonies 1, 3, 5,and 7 carry the right size construct that 
corresponds to the Gloop2 +ve control.
Colonies 1 3  5 7
Fig. 4.7b: ssDNA preparation of mutant GlaMor/fd-tet-DOGl positive clones
The four positive colonies (1, 3, 5, and 7) identified by the PCR screen were used to prepare ssDNA
and used consequently for sequencing. 3pl of each DNA preparation was loaded per well.
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Fig. 4.8: Amino acid sequences of the Gloop2 and GlaMor complementarity determining regions in heavy 
and light chains.
Residues different between the fourth GlaMor design (see Table 3.2) and the phage-selected construct are marked 
with asterisks. The additional mutation is shadowed in grey. Residues are numbered according to Kabat et al. 
(1991). Details o f the protein and DNA sequence of Gloop2 and GlaMor CDRs are described in Chapter 5 (Fig. 
5.8a and b).
4.6 Discussion
The design process outlined in Chapter 3 identified twenty-six amino acid positions in 
the CDRs of Gloop2 combining site that were known not to be critical for CDR 
backbone conformation (CDRs LI-3 and HI). The absense of a canonical structure 
for CDR H2 (at the time of the design and construction) led to a conservative 
substitution for this CDR (2 positions only included), while three of the four residues 
in H3 were included in the design. From these 26 positions, only 13 survived the 
docking procedure (see Chapter 3). The all-alanine version of Gloop2 combining site 
and enkephalin was constructed and, after reconstruction of the side chains, twelve 
residues from these thirteen contact residues (7 in the heavy and 5 in the light chain) 
were taken as candidate positions for mutation. The resulting library with the different
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combinations of these mutations was computationally screened, with a positive 
weighting applied to certain residues that occur with high frequency in antibody 
combining sites, and the ten lowest energy Glamor-enkephalin complexes were 
selected.
To assess the effectiveness of the design process, four of the twelve positions were 
semi-randomised (but also including the designed residue as part of the population). If 
one of the designed sequences was then selected during phage panning against a 
background of more diverse sequences, this would go some way towards validating 
the design process.
Mutagenesis of antibodies derived from phage display libraries has often given rise to 
drastic improvements in affinity (Marks et al., 1992 and Schier et al., 1996), as well 
as in neutralisation capacity (Burton, 1994). The advantages of generating a panel of 
mutagenised antibodies from a single starting clone was to fulfil the aim of assessing 
the de novo design of antibody specificity by defining a set of residues which is able 
to bind a pre-defined antigen (enkephalin).
There are a number of options available for introducing diversity into a clone prior to 
selection. Complete randomisation using degenerate oligonucleotides is restricted to a 
few residues by the library size governed by the efficiency of transformation in E. 
coli. While improved binders may be isolated, it is not always possible to pinpoint the 
residues responsible or determine whether the optimal clone has been identified.
Partial randomisation, incorporating low redundancy codon usage (Balint and Larrick, 
1993), is one way of extending the range of a mutagenesis scheme while ensuring that
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all possible sequence combinations are cloned. For example, partial randomisation, 
which introduces eight different amino acids over a stretch of eight residues 
(assuming one codon per amino acid), will generate lx l07 variants, which can be 
easily cloned in E. coli. Total randomisation of the same eight residues would require 
an excess of 1012 clones (328).
In the Gloop2 scFv DNA sequence, four residues were semi-randomised using the 
codons ag(a/t), (c/t)at, gt(c/t) and (c/g)(c/t)a and assuming an unbiased nucleotide 
incorporation which will result in 32 different combinations. The transformations 
resulted in 108 colonies and therefore all possible mutants, or combinations of them, 
were covered with this library size.
Phage prepared from this library were panned three times using biotinylated 
enkephalin and streptavidin coated beads. After the third round of selection the eluted 
phage were used in phage ELISA against BSA conjugated enkephalin and BSA 
conjugated loop peptide. Gloop2 phage was prepared in parallel with the library and 
used in the same ELISA assays. Serial dilutions of the antigens were used to 
determine specific binding. Fig.4.6 shows the results from the phage ELISA of the 
library and Gloop2 phage against BSA-enkephalin and BSA-loop peptide. From these 
graphs it is easily concluded that the library shows tighter binding to BSA enkephalin 
than to BSA loop peptide and this is indicated by the shift of the curve about one log 
to the left. On the other hand the binding of Gloop2 phage shows no significant 
difference between the two antigens and an apparent non-specific binding to BSA- 
enkephalin.
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There are a number of possible explanations for the non-specific binding of the loop 
peptide to GlaMor. For example, it may have been due to the existence of 
multivalency, which would cause even weak binding to show up. To a first 
approximation, this means that if there are 3 sites each at 20% occupancy the affinity 
of any trivalent phage particle will appear as though it is one site with 60% 
occupancy, so that even intrinsically low affinity binding will show up. Alternatively, 
it may have originated in the non-specific binding of phage particles. However, this 
would require that the loop peptide has a particularly ‘sticky* surface and 
consequently a similar effect should have been seen with the wild type phage binding 
to loop peptide.
A more likely explanation is that there are residual recognition motifs for the loop 
peptide present in the Glamor constructs. The retention of all but two of the H2 
residues (for reasons previously explained) and of other CDR residues is a weakness 
of the design, since at least some residues responsible for the loop peptide specificity 
may have been retained. At the time of writing, the ability of computer programs for 
modelling antibody combining sites (eg AbM, developed by the Rees group and 
marketed by Oxford Molecular pic) is much more effective than at the time of the 
design, so that more extensive changes to H2 (and H3) could now be made while 
ensuring retention of the overall groove topography.
PCR screening of eight mutant clones from this library identified four clones (50%) 
carrying inserts of the right size and after sequencing all four clones shared the same 
sequence. When this was compared with the Gloop2 wild-type scFv sequence it was 
found that it carried the set of mutations shown in Fig. 4.8. Interestingly this set of 
mutations matched with the fourth ranked predicted construct from the design process
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(Chapter 3). The sequences of the mutant clones carried one additional mutation in 
CDRH1, position I34R and a PCR error (probably) mutation at position 89 of the light 
chain where the designed tryptophan was actually a cysteine. At this stage no further 
mutagenesis was carried out and the GlaMor clone was used to produce soluble scFv.
5Cloning of scFv genes in expression vectors
5.1 Expression Vectors
All antibody expression strategies (described in Chapter 6), require the use of 
appropriately designed expression vectors. The main reason is the stress imposed on 
E. coli by expressing the antibody and therefore the protein expression must be 
carefully controlled to the right level.
Vectors constructed for the functional expression of antibody fragments carry a 
regulatable promoter and its cognate repressor gene, efficient ribosomal binding sites, 
structural genes encoding the corresponding antibody fragments fused to bacterial
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signal sequences, a transcription terminator, and a high copy number replication 
origin.
The vectors described here have been tested in expression studies of the Gloop2 and 
GlaMor scFv fragments in E. coli. All the primer sequences used for cloning are 
summarised in Table 5.1 at the end of this chapter.
5.1.1 pKK322
The vector map of pKK322 and the multiple cloning site are illustrated in Fig. 5.1. 
Subcloning of GlaMor scFv gene in pKK322 vector
GlaMor/fd-tet-DOGl DNA was prepared as described in Chapter 4 from log phase E. 
coli TGI cells, infected with phage carrying the GlaMor/fd-tet-DOGl. Plasmid DNA 
was prepared following the LiCl method alongside the Gloop2/pKK322 DNA 
(provided by Dr. G.E.Elliott, Fig. 5.21). Both DNA’s were double digested with PstI 
and Xhol (reaction 1) and fragments of the appropriate size (GlaMor scFv insert and 
pKK322 vector fragment) were gel purified and extracted with agarase. The ligations 
(reaction 2) were set up and the reactions were used to transform E. coli TGI 
competent cells.
Ten randomly selected colonies were PCR screened using primers IFOR and 
XhoMutBACK (Table 5.1) and all showed the presence of the correct size cloned 
insert (Fig. 5.211). DNA was prepared from two of these clones and was sequenced to 
verify the cloning of the mutant sequence before commencing the expression trials.
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Reaction 1: Restriction digest of Gloop2/pKK233 and GlaMor/fd-tet-DOGl DNA
1. The following were mixed in order:
15 pi of Buffer 3 (New England Biolabs), approximately lpg of the GlaMor/fd-tet- 
DOGl DNA or Gloop/pKK233, lpl of Pstl (diluted to lOunits/pl), ljLtl of Xhol 
(diluted to lOunits/pl) 1.5pl 100X BSA (lOmg/ml) and H20  to a final volume of 
150pl.
2. The mixtures were incubated overnight at 37°C
3. The enzymes were heat inactivated at 65°C for 20 minutes.
4. The fragments of the desired size were purified on an 1% (w/v) LMP agarose 
gel and extracted with agarase.
5. lpl of each fragment and digested vector was analysed on an 1% (w/v) agarose 
gel in order to determine the efficiency of the purification and the final 
concentrations before setting up the ligations.
Reaction 2: Ligation and transformation of competent E. coli cells
1. The following were mixed on ice:
2pi of 10X ligase buffer (containing lOmM ATP), 20ng of digested vector, 30ng of 
digested PCR fragments, lpl of diluted T4 DNA ligase (4units/pl, New England 
Biolabs) and H20  to a final volume of 20pl.
As a control the insert DNA was omitted (-ve control)
2. The mixtures were incubated at 16°C overnight
3. The enzyme was heat inactivated at 65°C for 10 minutes
4. All 20pl of each reaction was used to transform 50pl of thawed competent XL1- 
Blue cells
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5. The transformed cells were centrifuged, resuspended in approximately 200pl of 
the supernatant and spread onto LB agar plate containing 100pg/ml Ampicillin, 
15pg/ml Tetracyclin and 2% (w/v) Glucose
6. The agar cultures were incubated at 37°C for approximately 15 hours.
7. The transformant colonies were counted and are shown in the table below
Sample DNA Description No o f 
colonies
1 GlaMor/pKK322 139
2 negative control (no insert) 1
3 positive control (Gloop/pKK322) >1000
Sequencing of Gloop2 and GlaM positive clones
DNA was prepared for the ten GlaMor/pKK233 positive clones using the QIAprep 
Spin Plasmid Kit (QLAGEN Ltd.) as described in Materials and Methods.
Two samples were sequenced using the IFOR and XhoMutBACK primers. Sequences 
were analyzed on a 377 Automated DNA Sequencer ABI prism (Perkin-Elmer). 
Sequence analysis was performed using SeqEd (Applied Biosystems) (Appendix I) 
and verified the successful cloning of GlaMor scFv gene in the pKK322 vector.






















PelB VH L VL His6
Fig. 5.1: Cloning the scFv genes in the pKK322 expression vector
I. Structure of the pKK322 vector
II. scFv (Gloop2 or GlaMor) cloning cassette in the pKK322 expression vector
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vector
insert
Fig. 5 2: Subcloning of GlaMor scFv gene in the pKK322 vector
I. Double digests of Gloop2/fd-tet-DOGl (1) and GlaMor fd-tet-DOGl (2) plasmid DNA with Pstl and 
Xhol Both vector and insert DNA were gel purified and the GlaMor scFv gene was cloned as a cassette 
in the pKK322 vector. Ligated DNA was used to transform XL 1-Blue E. coli competent cells, 
n. Positive clones were identified first by PCR screen of 10 randomly selected colonies (1-10) using 
IFOR and XhoMutBACK primers followed by DNA sequencing, 
a, +ve control (Gloop/pKK322/TGl); b, +ve control (Gloop/pKK322 plasmid DNA)
All DNA fragments were analysed on 1% (w/v) agarose gels next to 1Kb ladder molecular weight DNA 
markers (numbers in bp shown on the left).
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5.1.2 p7>c99A
The p7rc99A contains a strong Trc promoter which is inducible by IPTG (l-5mM), 
the lacZ ribosome binding site, and the laclq repressor The Trc promoter contains the 
trp (-35) region and the lac UV5 (-10) region separated by 17 base pairs. The lac Iq on 
the plasmid controls the promoter and makes the plasmid inducible in any E. coli host 
strain. However, this is a very strong promoter and might show very low expression in 
the uninduced state. The plasmid confers resistance to lOOpg/ml ampicillin (Fig. 5.3).
Subcloning Gloop2 and GlaMor scFv genes in p7>c99A expression vector.
Gloop2 and GlaMor scFv genes were isolated by digestion with Nhel/Hindni 
ofGloop2 and GlaMor pKK322 pre-sequenced clones (reaction 1) followed by gel 
purification of the appropriate size fragments. Because the pTrc MCS lacks the Nhel 
site the wild type vector could not be used for cloning in this case. Instead, the 
NheVHindlll digested vector derived from the digestion of a control scFv fragment 
pre-cloned in the p7>c99A (reactionl) through the Ncol/HindlJl sites followed by gel 
purification (Fig. 5.41 and II).
The ligations (reaction 2) were set up and were used to transform competent XL1- 
Blue E. coli cells. Recombinant bacteria were screened for the presence of correctly 
inserted scFv by mini DNA preparations of randomly selected clones followed by 
restriction digests with Pstl/HindUl. Six clones (three for Gloop2 and three for 
GlaMor) were screened and all of them showed the presence of a scFv insert of the 
right size (Fig. 5.4III). DNA of the selected pTrc clones was sequenced using the 
pelSeqFOR and LS2BACK primers (Table 5.1).
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Expression studies using the pTrc vector were interrupted due to the presence of two 
ATG start codons (one in the Ncol site and one in the beginning of the pelB leader 
sequence) upstream of the scFv sequence in different reading frames. Experiments 
focused on knocking out the first of the two ATG codons (in the Ncol site).
Reaction 1: Restriction digest ofGloop2 and GlaMor pKK233 clones and 
control pTrc vector
1. The following were mixed in order:
5pl of Buffer 2 (New England Biolabs), approximately 500ng eachGloop2 and 
GlaMor pKK233 DNA or lpg of the vector with the pre-cloned control scFv, 2pi of 
Nhel (diluted to 1 unit/pl), lpl of Hindlll (diluted to 1 unit/pl), 0.5pl 100X BSA 
(lOmg/ml) and H20  to a final volume of 50pl.
2. The mixtures were incubated overnight at 37°C
3. The enzymes were heat inactivated at 65°C for 20 minutes.
4. The fragments of the desired size were purified on an 1% (w/v) LMP agarose gel 
and extracted with agarase.
5. 5pi of each fragment and digested vector was analysed on an 1% agarose gel in 
order to determine the efficiency of the purification and the final concentrations 
before setting up the ligations.
Reaction 2: Ligation of Gloop2 and GlaMor Nhel/Hindlll digested fragments in the 
pTrc vector and transformation of competent E. coli cells
1. The following were mixed on ice: 2pl of 10X ligase buffer (containing lOmM 
ATP), lOng of digested vector, 15ng of digested PCR fragments, lpl of diluted T4 
DNA ligase (4 units/pl, New England Biolabs) and H20  to a final volume of 20pl.
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As a control the PCR fragment was omitted (-ve control)
2. The mixtures were incubated at 16°C overnight
3. The enzyme was heat inactivated at 65°C for 10 minutes
4. All 20pl of each reaction was used to transform 50 j l l1 of thawed competent XL1- 
Blue cells
5. The transformed cells were centrifuged, resuspended in approximately 200pl of the 
supernatant and spread onto LB agar plates containing lOOpg/ml Ampicillin, 
15pg/ml Tetracycline and 2% (w/v) Glucose
6. The agar cultures were incubated at 37°C for approximately 15 hours.
7. The transformants grown on the plates were counted and are shown in the table
below.
Sample DNA Description No o f 
colonies
1 GlaMor/ pTrc99A 220
2 Gloop/pTrc99A 180
3 negative control (no insert) 9
4 positive control (wild type 
pTrc99A)
>1000
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Knocking out the Ncol site using Mung Bean Nuclease
Mung Bean Nuclease (New England Biolabs) is a single-strand specific DNA and 
RNA endonuclease isolated from mung bean sprouts. It degrades single-stranded 
extension from 3’ and 5’ ends of DNA and RNA molecules, leaving blunt, ligatable 
ends. SI nuclease functions in the same way but has a greater tendency to cleave 
single stranded DNA across from a nick.
DNA was prepared from previously sequencedGloop2 and GlaMor pTrc clones using 
the LiCl method and digested with Ncol (reactionl, Fig. 5.51). The digested DNA was 
ethanol precipitated and treated with Mung Bean Nuclease (reaction 2) for periods of 
10 and 30 minutes (Fig. 5.511). Mung bean treated DNA was ethanol precipitated, 
added in blunt end ligation reactions (reaction 3) and used to transform competent 
XL 1-Blue E. coli cells. DNA was prepared from 10 randomly selected colonies (5 for 
Gloop2 and 5 for GlaMor) and digested with Ncol to screen for the knock out of the 
ATG codon in the Ncol site (Ncol™) as described in reaction 1 (Fig.5.5III). DNA 
from the Ncol ™ clones was prepared and sequenced across the pelB leader sequence 
using the pelSeqFOR primer.
Reaction 1: Restriction digest of Gloop2 and GlaM pTrc DNA with Ncol
1. The following were mixed in order:
4 pi of Buffer 4 (New England Biolabs), approximately 1 pg of Gloop2 or GlaMor 
pTrc DNA, lpl of Ncol (diluted to 3 units/pl),) and H20  to a final volume of 40 pi.
2. The mixtures were incubated overnight at 37°C
3. The enzyme was heat inactivated at 65°C for 30 minutes.
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4. The reactions were ethanol precipitated and the final pellets were resuspended in 
5pi of H20. lpl from each reaction was analysed on an 1% (w/v) agarose gel.
Reaction 2: Mung Bean digest of Ncol digested DNA fragments
The following were mixed in order:
1. 5 pi of Buffer 2 (New England Biolabs), approximately 400ng of Gloop2 or
GlaMor pTrc DNA digested with Ncol, 1.6 pi of Mung Bean nuclease (diluted to 1
unit/pl),) and H20  to a final volume of 50pl.
2. The reactions were incubated at 30°C
3. Aftre lOmin, 25pi from each reaction was added to 0.01% (w/v) SDS and the rest 
of the reaction was incubated at 30°C for another 20 minutes before it was 
inactivated with SDS.
4. All four samples were ethanol precipitated and the final pellet was resuspended in 
5pl of H20. lpl from each sample was analysed on an 1% (w/v) agarose gel.
Reaction3: Blunt end ligation of the Mung Bean Nucleased DNA
1. The following were mixed on ice:
3pi of 10X ligase buffer (containing lOmM ATP), lOOng of Mung bean digested
DNA (Gloop2 or GlaMor), lpl of diluted T4 DNA ligase (4units/pl, New England
Biolabs) and H20  to a final volume of 30pl.
As a control the ligase was omitted (-ve control)
2. The mixtures were incubated at 16°C overnight
3. The enzyme was heat inactivated at 65°C for 10 minutes
4. 15pi of each reaction was used to transform 50pl of thawed competent XL 1-Blue 
cells
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5. The transformed cells were centrifuged, resuspended in approximately 200 pi of 
the supernatant and spread onto LB agar plate containing lOOpg/ml Ampicillin, 
15pg/ml Tetracyclin and 2% (w/v) Glucose
6. The agar cultures were incubated at 37°C for approximately 15 hours.
7. The transformants grown on the plates were counted and are shown on the table 
below.
Sample DNA Description No o f 
colonies
1 GlaMor/pTrc 24
2 Gloop/p Trc 15
3 negative control (no ligase) 0
4 positive control (wild type pTrc 
vector)
>1000
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Fig. 5.3 : Cloning the scFv genes in the p7rc 99A expression vector
I. Structure of the expression vector p7rc 99A
II. Sequence of pTrc 99A cloning sites
III. scFv (Gloop2 or GlaMor) cloning cassette in the pTrc 99 A  expression vector
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Fig. 5.4: SubcloningGloop2 and GlaMor scFv genes in the p7Vc99A expression vector
I Vector DNA (1) and II GlaMor scFv insert DNA (1) double digested with Nhel and Hindlll both after 
gel purification and before adding to the ligation reactions. The ligations were used to transform XL1- 
blue E. coli competent cells. The same procedure was followed for theGloop2 scFv DNA.
III. Positive clones were identified by plasmid mini-preparations of six randomly selected colonies 
followed by double digests with Nhel and HindHl.
1-3, Gloop2/pTrc and 4-6, GlaMor/pTrc DNA
All DNA fragments were analysed on 1% (w/v) agarose gels next to 1Kb ladder molecular weight DNA 
markers (numbers in bp shown on the left).
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Fig.5.5: Knocking out the ATG codon in the Ncol restriction site using Mung Bean Nuclease
1. Gloop2 and GlaMor pTrc DNA was linearised with Ncol
1 and 4 (+ve controls), Gloop2 and GlaMor p7>c DNA digested with Ncol and Hindlll
2, 3 and 5, 6, Gloop2/pTrc and GlaMor/p7rc respectively digested with Ncol (in duplicates)
II. Mung Bean Digest
1 and 3, Gloop2 and GlaMor p7Vc DNA linearised with Ncol and incubated with Mung Bean nuclease 
at 30°C for 10 minutes; 2 and 4, Gloop2 and GlaMor pTrc DNA linearised with Ncol and incubated 
with Mung Bean nuclease at 30°C for 30 minutes
5 (+ve control), Gloop2 p7rc DNA incubated with Mung Bean at 30°C for 30 minutes
6 (-ve control), Gloop2 p7>c plasmid DNA.
Gloop2 and GlaMor pTrc DNA was blunt-end ligated after the Mung Bean treatment and transformed 
JM109 competent E. coli cells. Ten colonies (1-10) were selected randomly, used to prepare DNA and 
incubated with Ncol, to identify positive clones that show deficiency to digest with Ncol. Further DNA 
sequencing was performed to confirm the knocking out of the ATG codon.
1-5, Gloop2 p7rc DNA; 6-10, GlaMor p7Vc DNA; a, (+ve control) Gloop2 p7rc DNA digested with 
Ncol; b, Gloop2 p7>c plasmid DNA. All DNA fragments were analysed on 1% (w/v) agarose gels next 
to 1Kb ladder molecular weight DNA markers (numbers in bp shown on the left).
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5.1.3 pUC119His6mycXba
This vector is a derivative of pUC119 (Vieira and Messing, 1987) in which the 
polylinker has been replaced by the sequence shown in Fig.5.6. It has been used 
successfully for the expression of antibody fragments in E. coli and was generously 
donated by Professor. R. Hawkins (University of Bristol).
This vector was extensively used for all the expression studies of Gloop2 and GlaMor 
soluble scFv described here.
SubcloningGloop2 and GlaMor scFv genes in pUCl 19His6mvcXba vector 
Gloop2 and GlaMor pTVc clones were used as template DNA and the scFv genes were 
PCR amplified (reaction 1) with Xba FOR and Not BACK primers (Table 5.1) that 
introduced the Xbal and Notl cloning sites at the 3’ and 5’ end of the scFv genes 
respectively (Fig.5.7II). The amplified inserts were column purified, digested with 
Xbal and Notl (reaction 2) and gel purified. pUC119His6MycXba vector DNA was 
prepared using the QIAprep Spin Plasmid Kit (QIAGEN), linearised using the same 
enzymes (reaction 2) and gel purified.
The ligations were set up (reaction 3) and the reactions were used to transform 
competent XL 1-Blue E. coli cells. Recombinant bacteria were screened for the 
presence of correctly inserted scFv through In-well lysis screening (Epicentre 
Technologies Co.). Out of the twenty randomly selected colonies, twelve (seven 
Gloop2 and five GlaMor) turned out to be positive and were used for sequencing prior 
to expression studies (Fig. 5.7III).
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Reaction 1: PCR amplification of Gloop2 and GlaMor scFv fragments
1. The following were mixed in order:
5 pi 10X PCR buffer, 0.5pl 100X BSA (lOmg/ml), 5pl of 10X dNTP, lpl Xbal 
primer (50pM), lpl Notl primer (50pM), lpl DNA, lpl Vent DNA polymerase 
(2u/pl) and 35.5pl H20  to a final volume of 50pl. The mixture was overlaid with 
approximately 50pl of mineral oil.
2. The PCR was performed with 30 cycles of 94°C (lmin), 55°C (lmin) and 72°C 
(2min)
3. 5pi from each reaction was analysed on an 1% (w/v) agarose gel .
Reaction 2: Restriction digest ofGloop2 and GlaMor PCR products and 
pUCl 19 Mvc His6 vector
1. The following were mixed in order:
6pl of Buffer 3 (New England Biolabs), approximately 600ng of the purified PCR 
products or lpg of the vector, 2pl of Xbal, 2pl of Notl, 0.6pl 100X BSA 
(lOmg/ml) and H20  to a final volume of 60pl.
2. The mixtures were incubated overnight at 37°C
3. The enzymes were heat inactivated at 65°C for 20 minutes.
4. The fragments of the desired size were purified on an 1% (w/v) LMP agarose gel 
and extracted with agarase.
5. 5pi of each fragment and digested vector was analysed on an 1% (w/v) agarose gel 
in order to determine the efficiency of the purification and the final concentrations 
before setting up the ligations.
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Reaction 3: Ligation and transformation of competent E. coli cells
1. The following were mixed on ice:
2jil of 10X ligase buffer (containing lOmM ATP), 16ng of digested vector, 32ng 
of digested PCR fragments, 1 jul of diluted T4 DNA ligase (4units/pl, New 
England Biolabs) and H20  to a final volume of 20jil.
As a control the PCR fragment was omitted (-ve control)
2. The mixtures were incubated at 16°C overnight
3. The enzyme was heat inactivated at 65°C for 10 minutes
4. All 20pl of each reaction was used to transform 50pl of thawed competent XL1- 
Blue cells
5. The transformed cells were centrifuged, resuspended in approximately 200pl of the 
supernatant and spread onto LB agar plate containing lOOpg/ml Ampicillin, 
15pg/ml Tetracyclin and 2% (w/v) Glucose
6. The agar cultures were incubated at 37°C for approximately 15 hours.
7. The transformants grown on the plates were counted and are shown on the table 
below.
Sample DNA Description No o f 
colonies
1 GlaMor/pUCl 19 200
2 Gloop/pUCl 19 200
3 -ve control (Xbal/Notl digested 
vector purified and ligated)
10
4 +ve control (wild type pUCl 19) >1000
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Sequencing of Gloop2 and GlaMor positive clones
DNA was prepared for all seven Gloop2 and GlaMor positive pucll9His6mycXba 
clones using the QIAprep Spin Plasmid Kit (QIAGEN Ltd.).
Four samples were sequenced (two for Gloop2 and two for GlaMor) using the 
lacBFOR and 5FOR primers (Table 5.1). Sequences were analyzed on a 377 
Automated DNA Sequencer ABI prism (Perkin-Elmer). Sequence analysis was 
performed using SeqEd (Applied Biosystems, Fig. 5.8).







XbaFOR tcactagtctaeaatgaaatacctattgcctac 33 Xbal





Table 5.1: The primer sequences used for the cloning experiments.
Sequences of the restriction sited that they are introduced are also shown (underlined sequences).
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Fig.5.6: Cloning the scFv gene in the pUC119His6mycXba expression vector
I. Structure of vector pUCl 19His6mycXba
II. Sequence of pUCl 19His6mycXba cloning site
III. scFv (Gloop2 or GlaMor) cloning cassette in the pUCl 19His6mycXba vector
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Fig.5.7: SubcIoningGloop2 and GlaMor scFv genes in pUC119His6mycXba expression vector
I.Gloop2 and GlaMor scFv genes were PCR amplified using pre-sequenced pTrc clones with the 
XbaFOR and NotBACK primers.
I,Gloop2 and 2, GlaMor scFv DNA PCR products
II. pUCl 19His6MycXba vector DNA (1) was prepared from TGI E. coli cells, double digested with 
Xbal and Notl, gel purified before it was added to the ligation reaction. Ligated DNA was used to 
tranform XL-1 Blue TGI E. coli competent cells.
IQ. Twenty colonies were randomly selected and screened by in-well lysis screening. Positive clones 
were identified by an increase in the M.W of plasmid DNA (top arrows) compared with the M.W of the 
pUCl 19His6MycXba wild-type plasmid DNA (lower arrows)
1-10, Gloop2/pUCl 19His6MycXba; 11-20; GlaMor/pUCl 19His6MycXba;a, +ve control 
pUCl 19His6MycXba plasmid DNA; b, +ve control pUCl 19His6MycXba/XL-lBlue. All DNA 
fragments were analysed on 1% agarose gels next to 1Kb ladder molecular weight DNA markers 
(numbers in bp shown on the left)
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Fig.5.8a: CDR sequences of (he VH domain of Gloop2 (left) and GlaMor (right)
The mutations are shown in the middle
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Gloop2 Sequence GlaMor Sequence
Mutation
CDRL1
C Q Q Q C A A Q T C A A Q A A A T T A Q T Q Q T T A C T T A A Q C
40 150 100 tac
Y 32 F
C GC. C C A A I I T C A A N  A A A T T  A Q T O G T T T C T  TA A Q C
1 C 150 100ttc
CDRL2
Q C C O C A T C C A C T T  T A N  A T 7 C - I  
> 220 230
: G C C U C A T C C A C T  T T A N  A T T C T 1  
0  220 230
CDRL3
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330
tfW
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340 380
Fig.5.8b: CDR sequences of the VL domain of Gloop2 (left) and GlaMor (right)
The mutations are shown in the middle
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5.2 Discussion
Vectors for antibody secretion have been in constant evolution aiming to optimize 
vector stability, minimize the promoter leak-rate and optimize the expression level in 
the induced state (Pluckthun et al., 1996).
The tight control of the promoter/operator system is one important feature when 
designing an expression vector. The “leakiness” of expression is responsible for all 
the unfavorable effects such as periplasmic leakage, plasmid loss, and rearrangement, 
because of the relatively long time cells spend in pre-cultures, or the main culture 
before induction. In general the promoter must have a “window” as wide as possible.
For phage display, a strong promoter is of lower importance. In contrast a low 
background before induction is important since fusion proteins of antibodies with 
gene3 impose enormous stress on the cell. Soluble expression and phage display have 
different optima, the latter requiring much stronger transcription and translation. Thus 
the use of phage-display vectors for soluble expression can be used for 
characterization but not for efficient production (Pluckthun et al., 1996).
Particularly important are tag sequences to follow and purify the antibody 
conveniently. Purification can be carried out with the histidine tag in combination 
with metal affinity chromatography (IMAC) (see chapter 6) and the antibody 
fragment can be detected by a second tag, such as the myc tag (Evans, 1985).
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Outside the expression cassette, the vector must code for an antibiotic resistance. In 
phage display, the expression of the antibiotic resistance gene must not be too high, or 
low phage titre will be observed, perhaps because of interference between the single­
strand production and transcription (Spada et al., 1997).
The scFv cloning cassettes and the different vectors used here are summarised in Fig. 
5.9. Attempting to express soluble GlaMor, the scFv gene was initially cloned from 
the fd-tet-DOGl phage vector (Hoogenboom et al., 1991) into the pKK322 expression 
vector. This was facilitated by the Gloop2 scFv pre-cloned in this vector.
As described in the following chapter, the expression studies using the pKK322 vector 
resulted in very low yields of soluble scFv although several expression experiments 
were set up and different conditions were tested.
The p7>*c99A vector was the second vector (Amann et al., 1988), tested due to the 
very strong trc promoter that would minimize the risk of leakiness prior to induction. 
During expression experiments this vector was found to be interacting with the host 
cells resulting in background expression of a 30kD non-specific protein after 
induction. Additionally, the p7>c99A vector contained an extra ATG start codon in 
the Ncol cloning site, upstream of the pelB leader sequence. Due to the fact that the 
second ATG start codon at the beginning of the pelB was in a different reading frame 
to the first ATG, the transcription of the scFv gene could not proceed normally.
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The Mung bean Nuclease, used to knock out the first ATG codon, seemed to digest 
single stranded DNA at a rate difficult to control, even though the reactions were 
carried out over a range of time intervals.
The last vector tried was the pUC119HismycXba (Griffiths et al., 1994) which was 
provided by Prof. R. Hawkins and had been used successfully for the expression of 
soluble antibody fragments (Griffiths et al., 1994). The additional advantage of this 
vector was the existence of the c-myc tag sequence upstream of the His tag that 
allowed detection of scFv expression using the anti-myc tag antibody, 9E10 (Evans, 
1985).
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Fig. 5.9: Schematic drawing of the scFv cloning cassettes in different vectors.




Two basic strategies can be employed to obtain antibody fragments from E. coli. The 
first is the functional expression of correctly folded fragments by secretion into the 
periplasmic space, (Skerra et al., 1991) and the second is the in vitro refolding of 
protein obtained from inclusion bodies, either from the cytoplasm or the periplasm. 
There are several advantages to this secretory expression system. First it directly leads 
to an assembled functional product with correctly formed disulphide bonds without 
the need to refold the protein in vitro (Glockshuber et al., 1992) Second the problem 
of protease degradation is greatly diminished, as there are fewer proteases in the 
periplasm than in the cytoplasm. However, there are studies where soluble functional 
scFv expressed in the cytoplasm was about five times higher that that in the 
periplasmic extracts from identical numbers of E. coli cells (He et al., 1995).
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The periplasmic space is a subcellular compartment located outside the cytoplasmic 
membrane, but retained within an outer cell wall which is impermeable to molecules 
greater than 600-800kDa (Nikaido and Rosenberg, 1981). Bacterial leaders are 
employed to direct the protein beyond the cytoplasmic membrane into the periplasmic 
space which may serve as a functional equivalent to the eukaryotic endoplasmic 
reticulum (Skerra and Pliickthun, 1988a). This is to be distinguished from the proteins 
that are destined for export beyond the outer cell wall and require specific gene 
systems the least complex of which needs three separate genes (David, 1990). A 
variety of bacterial signal sequences have been shown to direct transport and correct 
cleavage (Pliickthun, 1991). The signal peptide sequence, bacterial pedate lyase (pelB 
leader) from Erwinia carotovora (Lei et al., 1987) has been fused at the amino termini 
of antibody fragments and facilitated their transport through the inner bacterial 
membrane (Dubel et al., 1993). Somerville and coworkers (1994) found that scFv 
directed against human carcinomas was not folded correctly in the absence of a 
bacterial leader segment. It is often reported that active material can be found in the 
culture supernatant of E. coli expressing an Ig fragment with a bacterial leader 
segment (Better, M. et al., 1988). This has been mistakenly referred to as bacterial 
secretion but careful analysis reveals that appearance of the heterologous protein in 
the supernatant coincides precisely with cell death and lysis (Takkinen et al., 1991). 
Recently, Kirpriyanov et al. (1997a) found that the scFv could be made to accumulate 
in the periplasm or secreted into the medium by simply changing the incubation 
conditions and the concentration of the inducer.
Chapter 6: Bacterial expression and purification o f soluble scFv 138
6.1.2 Transcriptional regulation of the lac promoter
Different expression vectors (see chapter 5) with a variety of promoters have been 
used to direct transcription of antibody fragments in E. coli. The transcription of the 
foreign gene is repressed to avoid a potential lethal effect on the cells until the 
appropriate time, then induced at the optimal level. However, upon induction, it 
appears that the level of expression is difficult to regulate. The lac promoter from the 
E. coli lactose operon is one of the promoters most commonly used to regulate the 
expression of recombinant genes in bacteria (Auger and Bennet, 1987). The lac 
promoter can be induced by lactose or iso-propyl p-D-thiogalactopyranoside (IPTG), 
and thus, incremental regulation of transcription can be effected by graded 
concentration of the inducer. This promoter is also subject to repression by the lac I 
gene product (Beckwith, 1987). However, since a chemical equilibrium exists 
between bound and unbound repressor molecules, the operator site is not continuously 
occupied by the lac repressor and thus there is generally a low basal level of 
transcription of the lac genes. Trancription from the lac promoter is regulated by the 
binding of the catabolite activator (CAP) to the promoter region (Beckwith, 1987). 
When CAP binds to the promoter, it increases the affinity of the promoter for RNA 
polymerase, thereby increasing transcription of the lac genes. The affinity of CAP for 
the promoter is enhanced by its association with cyclic adenosine monophosphate 
(cAMP). Cellular levels of cAMP are higher when the amount of glucose in the 
medium is lowest (Fig. 6.1).
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Low High Promoter Operator lacZ High
(^RNA polymerase^)---------------------------------- ►
Fig. 6.1: The effect of glucose concentration in the growth medium on the level of transcription 
from the lac promoter in E. coli
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6.1.3 Factors that influence the expression of antibody fragments in 
E. coli
The amount of EPTG concentration, temperature, composition of the growth medium, 
the duration of the induction phase and the host cell strain, are factors that influence 
the expression of antibody fragments in E. coli.
Induction temperature and IPTG concentration
Dtibel et a l (1993) studied the effect of different induction temperatures and IPTG 
concentrations on the production of scFv in E.coli and concluded that concentrations 
above lOOpM IPTG or induction at temperatures above 30°C, led to substantially 
decreased growth rate and finally to cell death. They suggested that the amount of 
processed expressed protein was limited by the capacity of the membrane transport 
system. While the maximum specific growth rate for E. coli occurs at a temperature of 
37-39°C (Ingraham, 1987) and this coincides with the maximal activity of the lac 
promoter (Auger Benett, 1987) the use of suboptimal growth temperatures in some 
cases can reduce unwanted metabolic responses to the synthesis of a foreign protein. 
As a consequence, this improves the yield and/or solubility of the target protein 
product. For example, total and functional yields of Fv and Fab fragments, were 
consistently greater at 20-30°C compared to those at 37°C (Skerra et a l, 1991). In 
other studies, functional yields of scFv and Fab fragments were also substantially 
improved by reducing the culture temperature (Somerville et a l, 1994 and Takkinen 
etal., 1991).
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Induction duration
A number of studies have been reported that secreted foreign proteins can be isolated 
from the culture medium (Better et al., 1988, Skerra and Pluckthun, 1988, and 
Takkinen et a l , 1991). While E. coli does not normally secrete proteins to the 
medium, increasing the duration of the induction phase enhances the release of 
periplasmic proteins to the surrounding environment. For example, periplasmic Fab 
fragments leaked into the culture media as the induction phase was extended beyond 
10 hours (Shibui and Nagahari, 1992). For the production of a scFv fragment, 10% of 
the target protein was found in the culture medium after 4 hours, while the proportion 
of extracellular product increased to 40% after 8 hours and to 90% following 20 hours 
of induction (Takkinen et al., 1991). In other studies, long induction periods (16-24 
hours) have been used to produce 2-10 mg/L yields of antibody fragments in the 
culture medium (Better et al., 1988 and Takkinen et al., 1991). While in some cases 
the release of recombinant proteins to the medium has been associated with cell lysis 
(Somerville et al., 1994), periplasmic leakage has also been associated with actively 
growing cells (Chalmers et al., 1990). Knappik and Pluckthun (1995) studied the 
optimal induction period of three mutated Fv fragments of the phosphocholine 
antibody AbMCP603 (Sato et al., 1986) and found that it was dependent on cell 
stability during the induction periods that were varied between 3, 5 and 12 hours.
The release of periplasmic contents was unlikely to be due to de novo synthesis since 
the total amount of p-lactamase remained at a steady level while release was 
occurring, as reported by Sommerville and coworkers (1994).
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Composition of the growth medium
Studies examining the expression of recombinant proteins under the trancriptional 
control of the lac promoter have shown that the composition of the growth medium at 
or during the induction phase can significantly affect foreign protein expression 
(Sambrook et a l , 1989). Providing additional amino acids by supplementing the 
medium with casamino acids, peptone or yeast extract during induction has been 
shown to improve foreign protein expression (Nancib et al., 1991) and stability 
(Whitney et a l, 1989). In addition, enhancing cell yields, by supplementing complex 
LB medium with a 0.5-1.5% (w/v) yeast extract during induction improved specific 
and/or overall recombinant protein expression in some strains of E. coli (Li et a l, 
1990). The addition of sucrose to the growth media was demonstrated to inhibit the 
aggregation of secreted scFv (Kipriyanov et a l, 1997a).
The effect of host cell strain
Different E. coli strains, including HB101, JM101, JM83, MC4100, MCI061 and 
DH5-a, have been assessed for their effectiveness in antibody expression studies 
(Darveau et a l, 1992). TGI (Anand et a l, 1991), XLl-Blue (Kipriyanov et a l, 
1997a) and TOPP2 (Ulrich, H., oral communication) are popular for the expression of 
recombinant antibody fragments in E. coli strains. Limited leakage or lysis before and 
after induction and low protease levels are features that characterise those E.coli 
strains useful for expression studies. Pluckthun et al (1995) have used successfully the 
JM83 strain (a K12 strain) and claim that it performs better than other strains. 
However, they could not suggest a genetic basis for this relative robustness or find 
any obvious correlation with the genetic markers indicated.
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The folding problem
To evaluate different expression systems, two points must be kept in mind. First, the 
only relevant quantity is the amount of correctly folded, purified protein obtainable at 
the end. Second, because of the individuality of the antibody variable domain primary 
sequences and their dramatic influences on the yield of in vivo and in vitro folding, a 
comparison of two expression systems with two different antibody fragments may be 
misleading. Folding in vivo can be a limiting process in the production of many 
recombinant proteins. The individuality of the primary sequence of the antibody 
variable domain and its importance on folding and subsequently on the expression 
yields was demonstrated by Knappik and Pluckthun in 1995, when different antibody 
fragments were expressed under identical conditions. Cell lysis, usually caused by the 
onset of antibody expression, was diminished by simple point mutations in the 
antibody protein sequence and this suggested that the most effective strategy to obtain 
high-yield folding of periplasmic proteins was to engineer the protein itself (Knappik 
and Pluckthun, 1995). In the same study, they proposed that the crucial determinants
are loops in the structure of p—barrel proteins and they described point mutations in
these regions that appeared to inhibit aggregation and stabilize the interaction of these 
regions with the rest of the protein.
Kipriyanov et a l (1997b) identified two amino acid residues that were critical for the 
high level production of scFv in E. coli without affecting the antigen binding. It is 
possible that these changes influence the correct folding of the VH domain via a 
folding intermediate, but not the affinity.
The scFv antibody fragments are usually correctly processed in the periplasm, contain 
intramolecular disulphide bonds and are soluble (Glockshuber, 1990). Focusing on
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disulphide formation, Proba et al., (1997) observed that under some refolding 
conditions an unpaired cysteine (when there is no other cysteine to form S-S bond) in 
the VH3 domain might form a wrong disulphide and result in a misfolded, 
aggregation-prone product. Interestingly, in the same report when the missing cysteine 
was derivatized by glutathione, expression levels of functional scFv increased to 
50mg/L. Experiments using air oxidation instead of glutathione produced 2,5 mg/L 
functional scFv fragment. In different studies, Samuelsson et al (1996) described that 
the requirement for proteins with disulphide bonds to break and reform these bonds, 
might account for the need to have a low molecular weight redox buffer present 
during expression in E. coli.
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6.2 Periplasmic Expression of soluble scFv
A general protocol is presented here, followed in most of the expression experiments
described. Departures from this protocol will be indicated where they occur.
Protocol:
1. TGI or TOPP2 cells freshly transformed with Gloop2 or GlaMor 
/pUC119His6MycXba respectively were transferred with a toothpick from a plate 
in 750ml XLM media (16gr yeast extract, 16gr tryptone and lOgr NaCl) containing 
the appropriate antibiotics (lOOpg/ml Ampicillin for the TGI cells and 100pg/ml 
Ampicillin and 15pg/ml Tetracyclin for the TOPP2 cells) and 0.1% (w/v) Glucose. 
Glucose helps suppress the lac promoter when strains were propagated for plasmid 
manipulation or long term storage.
2. Cells were grown at 30°C for 24hs shaking at 250rpm to A6OOnm=4.0 before 
induction.
3. IPTG was added to a final concentration of lmM and the induction continued for 
3hs at 26°C shaking
4. Cells were harvested by centrifugation at 5,000rpm, for lOmin at 4°C
5. Pellets were resuspended in 150ml periplasmic lysis buffer (30mMTris HC1, 20% 
(w/v) sucrose pH 8.0)
6. lmM EDTA was added and the lysate was incubated at room temperature for 
lOmin shaking
7. The lysate was centrifuged at 7,000rpm for lOmin at 4°C
8. To complex the EDTA from the previous step, the pellet was resuspended in 150ml 
MgS04 5mM and incubated at 4°C for lOmin, shaking
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9. The lysate was centrifuged again at 7,000ipm for lOmin at 4°C
10. The supernatant (“periplasmic fraction”) was passed through a filter of pore size
0.45pm, under vacuum before purification
6.3 Immobilised metal affinity chromatography 
(IMAC) of soluble scFv fragments
In the periplasmic secretion system, considerable enrichment of the antibody protein 
is possible by cell fractionation, which can be carried out on a preparative scale. The 
periplasm of E. coli contains only a small part of the total cell protein, and therefore 
subsequent purification is simplified.
A scFv fragment can be purified to homogeneity in a single step using IMAC, and 
only a minimal structural perturbation of three additional C-terminal residues is 
necessary. This affinity tail does not disturb the binding of the antibody fragment or 
interfere with secretion in E. coli (Fig. 6.2).
Skerra et a l (1991) tested several alternatives to the histidine tail and concluded that 
five or six consecutive histidine residues give the best binding and expression 
properties, with minimal structural perturbation.
Deonarain et al. (1997) reported that although six histidine residues at the c-terminus 
of the scFv fragment were used successfully for large-scale clinical production of 
antibodies this was not sufficient to separate it properly from all E. coli proteins. 
Protocol
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The scFv was purified from the “periplasmic fraction” by IMAC (Hochuli et al.,
1988) as follows:
1. 500pl of Ni-NTA resin (QIAGEN) were added to 100ml of periplasmic lysate and 
were incubated at 4°C under moderate shaking in a glass container, for 30min.
2. The beads were collected by centrifugation at l,000rpm for lmin, at 4°C at the 
bottom of a centrifuge tube.
3. The beads were transferred in a home-made column and were allowed to set for 
30min.
4. The column was washed extensively with wash buffer (50mM NaH2P04 pH 8.0, 
300mM NaCl, 20mM Imidazole) and the flow-through was measured 
spectrophotometrically at 280nm. The washed were carried out until the OD280 of 
the flow-through was equal to this of the wash buffer (approximately 30-40x of the 
bed volume).
5. The bound scFv was eluted by applying 10ml elution buffer (50mM NaH2P04 pH 
8.0, 300mM NaCl, 250mM Imidazole) and collected in 1ml fractions.
6. The fractions were measured spectrophotometrically at 280nm and fractions 
corresponding to A280 peaks were pooled, concentrated using centicon-10 
microconcentrators, buffer exchanged with PBS to a final volume of 200pl and 
analyzed by SDS-PAGE electrophoresis.
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N TA  resin
6xH is
Fig. 6.2: The IMAC mechanism using the N r  NTA resin (QIAGEN™)
6xHis-tagged scFv from crude lysate of E. coli cells binds efficienlty to Ni-NTA agarose. The resin can 
afterwards be collected and used for conventional column purification.
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6.4 Analysis of Gloop2 and GlaMor soluble scFv 
fragments.
6.4.1 SDS-PAGE Electrophoresis
15pl from each sample was analysed on a 12% SDS-PAGE gel. The gel was stained 
with Coomassie brilliant blue, dried under vacuum as described in Materials and 
Methods and retained (fig. 6.21).
6.4.2 Western Blot Analysis
For the western blot analysis, Gloop2 and GlaMor purified scFv’s were fractionated 
by electrophoresis and blotted onto cellulose. Detection was performed with 9E10 
(Evan et al., 1985) which binds the c-myc epitope as the primary antibody followed 
by a peroxidase- conjugated goat anti-mouse IgG as the second antibody.
Control experiments included E. coli cells carrying the wild-type pUCl 19HisMycXba 
plasmid (negative control, -ve) and cells transformed with a pre-tested Fab fragment 
cloned in pUCl 19HisMycXba (positive control, +ve) (Fig. 6.3II).
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Fig. 6.3: Reducing 12% SDS-PAGE (1.) and immunoblot analysis (II.) of the periplasmic 
expression of Gloop2 and GlaMor scFv.
Periplasmic lysates were subjected to IMAC purification and selected fractions were 
concentrated and buffer exchanged in PBS. 15pl from each sample was analyzed per lane.
I. Proteins were stained with Coomassie Brilliant Blue
1 and 2 two different fractions of purified Gloop2 scFv, 3; purified GlaMor scFv; +ve control; 
unpurified periplasmic scFv.
0. Western Blot Analysis was performed with 9E10 Ab as a primary and a peroxidase- 
conjugated goat anti-mouse polyclonal as a second Ab.
I; Gloop2 scFv, 2; GlaMor scFv, +ve; control scFv
The molecular weight markers (M) shown on the left have protein bands of relative molecular 
weights of 21.5; 31;and 45 kDa for the SDS-PAGE analysis, and 21.5; 30; and 46kDa for the 
immunoblotting.
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6.5 Optimisation studies of Gloop2 and GlaMor scFv 
expression.
6.5.1 The effect of induction duration
The effect of the induction duration on the expression was studied for the Gloop2 and 
GlaMor scFv's in the pUC119His6MycXba system. Experiments were performed for 
24 hours induction periods and the culture densities were recorded by measurements 
of the absorbance (A) at a wavelenght of 660nm. Both the periplasmic and the 
supernatant fractions were analysed for the appearance of a correctly folded scFv 
fragment by SDS-PAGE and Westen Immunoblotting after the 24 hour induction 
period (Fig. 6.4).
After 24hrs incubation, Gloop2 and GlaMor scFv fragments were detected only in the 
culture supernatant. No detectable amounts of scFv could be found in the periplamic 
fractions.
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Fig. 6.4: Immunoblot analysis of the periplasmic fraction and culture supernatants from E. coli 
cells expressing Gloop2 and GlaMor scFv.
Periplasmic lysates and culture supernatants were analysed after 24 hours of induction. Cells were 
harvested, lysed and 4ml from each sample was concentrated and analysed on a reducing 12% SDS- 
PAGE gel followed by Western Blot analysis.
1 and 2; Gloop2 2, 3; and 4 GlaMor scFv of the periplasmic fraction and culture supernatant 
respectively.
+ve control is an FabRef fragment periplasmic fraction after 3 hours induction.
The molecular weight markers (M) have protein bands of relative molecular weights in kDa shown on 
the left.
6.5.2 The effect of host cell strain
TGI and TOPP2 (Stratagene) strains of E. coli were used comparatively in the 
expression studies of each Gloop2 and GlaMor scFv in the pUCl 19His6MycXba 
system. The TGI strain has been used successfully for the expression of antibody
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fragments in E. coli (Griffiths et al, 1994) while the T0PP2 strain is recommended 
by Stratagene as a non-K-12 strain suitable for the expression of proteins that are 
otherwise difficult or impossible to produce in E. coli K-12 strain. Gloop2 scFv 
expression levels were higher in TGI cells while GlaMor yields were higher in 
TOPP2 E. coli cells.
6.5.3 Expression using a redox buffer system
It seemed worth investigating whether the low expression levels of GlaMor scFv 
could be attributed to the one extra cysteine (five in total) in CDRL3. The wild-type 
sequence of Gloop2 scFv that contained the normal complement of four cysteines 
gave significantly higher expression yields. Expression of GlaMor scFv was 
attempted in the presence of a glutathione redox buffer in the culture medium during 
induction.
Protocol:
1. 500ml of XL media containing lOOpg/ml Ampicillin, 15pg/ml Tetracyclin and 
0.1% glucose was inoculated with a GlaMor/pucll9His6mycXba/TOPP2 clone 
and the culure was incubated overnight at 30°C, shaking.
2. Reduced (GSH) and oxidised (GSSG) glutathione (SIGMA) was added to a final 
concentration of 0.2mM each, the pH of the media was adjusted to 6 and the 
culture was induced with lmM IPTG at 26°C for 3 hours, shaking.
As a control an identical culture was set up without the addition of glutathione.
3. The cells were harvested, lysed and the scFv was purified following the expression 
and purification protocols described previously in this Chapter. GlaMor scFv
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fragments were analysed by SDS PAGE electrophoresis and detected by Western 
Immunoblotting.
Results
As shown in Figure 6.5, no significant effect on the yield of soluble GlaMor scFv 
fragment was observed, indicating that the expression behaviour was probably not 
due to the aberrant behaviour of the free cysteine.
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Fig. 6.5: Reducing 12% SDS-PAGE (I.) and Immunoblot analysis (II.) of the periplasmic 
expression of GlaMor scFv using a redox buffer
0.2mM of each reduced (GSH) and oxidised (GSSG) glutathione was added to GlaMor scFv expression 
culture just before induction. The periplasmic lysates were subjected to IMAC purification and selected 
fractions were concentrated and buffer exchanged in PBS. 15pl from each sample was analysed per 
lane.
1. Proteins were stained with Coomassie Brilliant Blue
1 and 3, lysates before purification with and without glutathione during induction
2 and 4, purified lysates with and without glutathione during induction
II. Western Blot analysis.
Samples 1,2, 3 and 4 as described above.
The molecular weight markers (M) have protein bands of relative molecular weights of 21.5; 31;and 45 
kDa for the SDS-PAGE, and 21.5; 30; and 46kDa for the Western.
Chapter 6: Bacterial expression and purification o f soluble scFv 156
6.6 Bacterial expression of Gloop2 and GlaMor scFv.
The studies described in this chapter addressed several problems encountered when 
periplasmic expression was attempted in E. coli, associated mainly with the very low 
yields of the GlaMor construct. Gloop2 expression levels were also low with 2pg/ml 
of culture as the maximum concentration obtained. The optimisation trials that have 
been carried out aimed to maximise the expression yield and the results were 
consistent for the two constructs with the Gloop2 giving better yields than GlaMor. A 
lower amount of scFv in the periplasmic or culture supernatant led to less pure 
material after the EMAC purification. The process of concentrating the fractions 
obtained was laborious and extended the time of the experiments, which in turn 
increased the risk of proteolytic degradation.
Attempts to improve the expression yields of GlaMor included the addition of redox 
buffer in the media during induction as well as sucrose in a separate set of trials. Both 
methods were based on earlier studies by Proba et al.(\991) and Kipriyanov et al. 
(1997) respectively. The addition of a low concentration of redox buffer was tested in 
order to improve the folding of GlaMor scFv, which might have been affected by the 
fifth, unpaired cysteine introduced during PCR mutagenesis. The rationale was that 
normal formation of disulphide bonds between cysteine pairs involves membrane 
bound proteins that are displaced by the “normal” partners. If the second is missing 
the unpaired cysteine might form incorrect disulphide bonds with wrong cysteines 
from other proteins leading to an aggregation-prone product. Glutathione derivatises 
the unpaired cysteine, does not interfere with affinity purification and can be removed 
by mild reduction conditions (Samuelsson et al., 1996). However, these studies 
showed no effect of glutathione on the expression yields of GlaMor scFv.
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Sucrose added in the media has been proposed to stabilise the expressed scFv by 
inhibiting aggregation. The hypothesis is that sucrose increases the osmotic pressure 
and causes the periplasm to enlarge (Kiefhaber et al., 1991) decreasing the 
concentration of secreted protein and resulting in less aggregation. The studies 
reported here showed that although in the Gloop2 system the addition of sucrose 
increased the yield of the scFv that was directed into the medium after a 24-hour 
induction by up to 100%, it had no effect on the expression levels of GlaMor.
The large amount of material found of 31kDa in Fig. 6.5 might be attributed to 
material being trapped in cytoplasmic inclusion bodies. There are methods available 
that enable the extraction and refolding of inclusion body scFv’s. For example, 
Pantoliano et al. (1991). Conformational stability, folding and ligand binding affinity 
of single chain Fv immunoglobulin fragments expressed in E. coli.) describe the 
expression and renaturation of an anti-fluorescein scFv at levels of 26mg/L. By 
contrast, this scFv yields almost no protein during periplasmic expression (Jung & 
Pluckthun, 1997). However, since those early studies it is clear that i) not all scFv’s 
behave in the same manner during expression, either into the cytoplasm or the 
periplasm, and ii) that refolding from cytoplasmic inclusion bodies has fallen out of 
favour due to the ease with which secreted (periplasmic) antibody can be produced, 
and the absense of a single cytoplasmic protocol that will work for all scFv’s 
(J.Huston, pers.comm. and Proba et al (1995). Functional single chain antibody 
fragments from the cytoplasm of E.coli: influence of thioredoxin reductase). In fact, 
the majority of publications in scFv expression since those early experiments in the 
laboratories of Bird and Huston have almost exclusively centred on periplasmic 
expression. One of the factors that influences expression in E.coli seems to be the 
particular residues that occupy certain framework positions that are central to the
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refolding of scFv. Extensive studies by the Pluckthun group have established that E. 
coli expression is heavily influenced by sequence (Worn, A & Pluckthun,A, 1998). 
Mutual stabilisation of VL and VH in single chain antibody fragments, investigated 
by mutants engineered for stability (Worn & Pluckthun, 1999) Differential 
equilibrium stability behaviour of scFv fragments: Identification, classification and 
improvement by protein engineering (Wall,JG & Pluckthun,A, 1999). The heirarchy 
of mutations influencing the folding of antibody domains in E.coli.). The use of 
alternative expession sysems such as yeast were not considered in-house due to the 
complexity of evolving a new system in which little experience was held -  even 
expert groups have exerted a great deal of effort to develop such systems (Shusta et 
al, 1998).
In retrospect, attempting cytoplasmic expression and purification may have been an 
option that could have been explored. The decision not to do so was a fine balance 
between knowledge of the periplasmic system already used successfully by other 
laboratories and members of this laboratory, and the time remaining for the project. In 
the event, a decision was taken to undertake further E. coli studies with the aim of 
optimising GlaMor expression levels in collaboration with expert colleagues at the 
Institute of Applied Microbiology, University of Agricultural Sciences, Vienna (Dr. 
Randolf Kerschbaumer under the supervision of Professor Florian Rueker). These 
studies are discussed in Chapter 7.
7Expression Studies on a Critically Unstable 
scFv1
7.1 Introduction
Functional expression yields of antibody fragments in the periplasm of E. coli 
(Pluckthun, 1992), especially Fv or scFv fragments, vary widely over several orders of 
magnitude even when the cell density is accounted for or when fragments in the 
identical host-vector system are compared (Carter et al., 1992; Pluckthun et al., 1996). 
Despite numerous studies (reviewed by Pluckthun et a l , 1996), the factors influencing 
antibody expression are still poorly understood. In this Chapter expression trials on 
GlaMor scFv are described. Some unusual expression conditions (i.e high glucose 
media and 16°C induction temperature) that have been previously shown to decrease
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significantly plasmid loss and have been used successfully for expression of other 
scFv’s are attempted (Kerschbaumer et al., 1997).
Expression of protein-scFv fusion constructs has been used in cases where 
stabilisation of the expressed scFv fragment is required and in other studies where the 
signal peptide has not mediated efficient protein translocation through the inner 
membrane to the bacterial periplasm. In this study, the GlaMor scFv fragment was 
fused to the N-terminus of E. coli alkaline phosphatase (Kerschbaumer et a/., 1996).
Sequencing of the pUC119HisMycXba construct identified on GlaMor an additional 
mutation introduced either during PCR amplification procedures or during expression 
in the first residue of FW4 of the light chain (position 98) where the originally 
identified Phenylalanine has been mutated to Leucine. This mutation and its effect on 
the expression/binding profile of GlaMor scFv is also investigated in this chapter.
In addition, construction of an expression plasmid vector that normally ensures high 
levels of protein synthesis (Baibas and Bolivar, 1990) will be examined. GlaMor has 
been recloned into vectors with optimal architectures (optimised promoter, ribosomal 
binding site (RBS) and Shine-Dalgamo (SD) sequence and initiating AUG codon 
spacing; Makrides et al., 1996).
Primary sequence effects have also been analysed. It has already been shown that the 
presence of certain residues at particular positions in the V-region sequence can be a 
decisive factor in determining the yield of functional protein (Knappik and Pluckthun,
’Study carried out by Professor Florian Rueker and Dr. Randolf Kerschebaumer, Institute of Applied 
Microbiology, Unioverity of Agricultural Sciences, Vienna.
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1995 and Nieba et al., 1997). Also, Ulrich et al. (1995) found that point mutations in 
the CDRs can increase the yields in periplasmic antibody fragment expression.
The above factors: expression conditions, fusion partners, expression vectors and 
scFv primary sequence will be discussed in this chapter as a case study and will 
provide further confirmation of the unsuitable expression profile of the GlaMor scFv.
7.2 Expression and Purification of GlaMor scFv
Protocol
The pUC119/His/Xba clone of GlaMor (constructed as described in Chapter 6) was 
used to transform E. coli strain TGI. The expression and purification protocol is 
described in detail in Kerschbaumer et a/.(1997). According to this protocol the TGI 
cell culture is grown in high glucose medium (4g in lit). The culture is then 
centrifuged and the cells are resuspended in fresh medium without glucose. IPTG 
(ImM final concentration) is added for induction and the culture is shaken at 16°C for 
24hours. Cells are harvested and the periplasmic extract purified using Chelate 
Sepharose column (Pharmacia, Sweden), charged with Zn+2. Fractions are eluted using 
a step gradient of imidazole (maximum concentration used was 120mM) and analysed 
by ELISA. scFv was detected by anti-his or anti-myc 9E10 (Munro and Pelham, 1986) 
followed by an anti-IgG phosphatase conjugate. Colorimetric development indicated 
the levels of expression measured against a control Fv.
Observations
Using these conditions, no scFv was detected. Some material was eluted with the 
imidazole gradient but since the elution behaviour observed with GlaMor was 
different to that routinely seen with other his-tag containing scFv’s (Kerschbaumer et
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al., 1997) the possibility of an E. coli protein binding weakly to the column could not 
be excluded. ELISA using the anti-his and 9E10 antibodies to detect GlaMor scFv 
were also negative.
Conclusions
The presence of the pelQ leader sequence at the N-terminus, as well as the his and myc 
tags at the C-terminus were verified by sequencing of the GlaMor scFv clone. Protease 
action might have been responsible for the above observation if. For example, the his 
and myc tags had been clipped off the recombinant protein. However, the expression 
was carried out at 16°C and the time of purification minimal, reducing the likelihood 
of proteolytic action. The control scFv, Gloop2 did not exhibit similar problems.
The “apparent” absence of GlaMor scFv from the periplasmic fraction might also be 
explained by non-efficient translocation of the molecule through the inner membrane 
(although the leader sequence is intact) maybe related to folding efficiency and 
stability.
Further constructions
Selected fusion systems have been shown to have a direct impact on high level 
production and, in some cases secretion of the target proteins (for a review see 
Makrides et al., 1996). A simplified method has been designed for fusion of scFv 
fragments to the N-terminus of E. coli alkaline phosphatase (AP) and the resulting 
immunoconjugates can be produced by expression in E. coli and purified in a single 
step via metal affinity chromatography due to an added his-tag (Kerschbaumer et al., 
1996). Application of this method on GlaMor scFv will facilitate its detection through 
its phosphatase activity, as well as potentially stabilising the scFv (alkaline
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phosphatase is very stable and well expressed, Kerschbaumer, personal 
communication).
7.3 Expression and Purification of Alkaline 
Phosphatase (AP) Fusion GlaMor scFv
The pDAP2 vector (Fig. 7.1) constructed by Kerschebaumer et al. (1996) was 
designed for simple and rapid construction of scFv -AP fusion proteins. Genes of scFv 
can be cloned into the polylinker site, thus linking them to the 5* end of the ecphoAl- 
gene. The /ac-operator allows induction of expression by IPTG, while the N-terminal 
pe/B-leader directs the product to the periplasmic space to allow simple harvesting of 
concentrated fusion protein. Additionally, a hexa-histidine-tag fused to the C- 
terminus of AP, facilitates purification by metal affinity chromatography in one step.
Protocol
GlaMor scFv gene was subcloned into the pDAP2 vector using the Hindlll/Notl 
cloning sites (Fig. 7.1III). The resulting construct maintains the ORF of the 
pUCl 19HisXba parent clone, has no myc tag and has the old 6xhis tag replaced by the 
alkaline phosphatase gene followed by a 6xhis tag at its C- terminus. The expression 
and purification was performed as described by Kerschbaumer et al. (1996). All 
cytoplasmic, periplasmic and culture supernatant fractions were purified by metal 
affinity chromatography, eluted with imidazole (ImM final concentration) and tested 
for AP activity with p-nitrophenyl as substrate, the active fractions were pooled and 
analysed on SDS-PAGE followed by silver staining (Fig. 7.2).
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Observations
Using AP activity to trace AP-GlaMor scFv showed that it was located in the 
cytoplasmic fraction, despite the pelB leader sequence being present. The purified AP- 
GlaMor scFv fragment from the cytoplasmic fraction showed as a single band 
approximately 8-10kDa smaller than the expected size of 78kDa (Fig. 7.2). For 
comparison, expression results using other scFv’s are also shown.
Conclusions
Various possible explanations of the above result can be proposed. For example, a 
premature stop codon may have been introduced during the vector construction. 
However, the fact that the protein can purify using the his-tag as well as extensive 
sequencing checks argue against this.
The most probable explanation is that the cytoplasmic location of the fusion protein 
exposed it to proteolytic degradation - the cytoplasm of E.coli contains a greater 
number of proteases than the periplasm. (Swamy and Goldberg, 1981 and 1982). 
Strategies for minimising proteolysis of recombinant proteins in E. coli include 
protein targeting to the periplasm or the culture medium, use of protease deficient host 
strains, growth of host cells at low temperature and construction of N-and/or C- 
terminal fusion proteins (see Makrides et a l , 1996 for a review). However, Wall and 
Pluckthun (1995) have suggested that when using protease-deficient strains, 
low efficiency expression may result due to the accumulation of abnormal proteins 
and the resulting toxicity.
Again, the configuration of the procaryotic expression vector has been suggested as a 
key factor that influences the levels of protein synthesis (Baibas and Bolivar, 1990). 
The essential architecture of an E. coli expression vector needs to fulfil some
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minimum requirements: the promoter is positioned approximately 10-100bp upstream 
of the ribosome-binding site (RBS) and it is under the control of a regulatory gene. 
The RBS spans a region of approximately 54 nucleotides and includes part of the 
promoter, the shine-Dalgamo (SD) sequence, part of the coding sequence and the 
spacings between them. The SD sequence interacts with the 16S rRNA during 
translation initiation. The spacing between the SD site and the initiating AUG codon 
ranges from 5 to 13 nucleotides and influences the efficiency of translational initiation 
(Gold, 1988). The distance between the LacZ-RBS and the ATG of the pelB leader 
sequence in GlaMor pUC119HisXba and in initial pDAP2 constructs is somewhat 
longer than 13 nucleotides.However, when GlaMor scFv was recloned into the pDAP2 
vector at SfiUNotl maintaining the ORF of the pDAP2 vector, no improvement was 
seen.
Future Constructions
One possible cause of the low expression behaviour, not yet examined, is the presence 
of the non-designed mutation, Phenylalanine to Leucine, at the start of FW4 of the 
light chain. This position is highly conserved among all FW4 light chain antibody 
sequences and is not present in the Gloop2 parent sequence whose expression is more 
normal. It has been suggested (Knappik and Pluckthun, 1995) that the primary 
sequence of a particular antibody variable region emerges as the most decisive factor 
determining the yield of functional protein and that very minor changes can have a 
dramatic effect on the in vitro aggregation properties of these molecules.
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The back mutation of Leucine to Phenylalanine and the use of the pD AP2 vector with
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Fig. 7.1: Cloning of GlaMor scFv in pDAP2 vector
I. Map of the pDAP2 vector (Kerschabumer et al., 1996)
II. GlaMor scFv cloning cassette in the pDAP2 vector
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Fig. 7.2: SDS PAGE of AP-GlaMor scFv purified periplasmic extract (3).
Silver staining gel showing the purified periplasmic fraction in lane 3 and other control expressed 
scFv’s in lanes 1 and 2. Proteins of known molecular weight are shown in lane M
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7.4 Back Mutagenesis of Leucine to Phenylalanine
using PCR
Protocol
Two primers and inverse PCR were used for making the leucine to phenylalanine
mutation of the GlaMor FW4 light chain. The sequences of the two primers
GMFKORR-BA and GMFKORR-FO as well as the region on the scFv that these
prime are shown below:
GMFKORR-FO
^  NarI GMFKORR-BA
  1 ►___________________
GlaMor scFv FW4
TTC (Phe)
GMFKORR-FO: 5‘CGTGTCCGGA AAACTAAGAT CTTGG 
GMFKORR-BA: 5‘TTCGGCGCCG GGACCAAGCT CGAGCTGAAA C
The GMFKORR-BA primer contains the correct TTC phenylalanine codon, the NarI 
site and primes clockwise while the GMFKORR-FO primer primes anticlockwise. The 
NarI site (shown underlined) was introduced as a silent mutation to facilitate 
screening. Inverse PCR using this set of primers results in a linear PCR product which 
can be closed by ligation. The respective ends of the primers when ligated together as 
blunt ends give the correct reading frame. DNA from the resulting clones was 
screened for digestion with NarI and positive clones were thereafter sequenced. DNA 
from six clones was prepared and sequenced. Each of the six clones was found to 
contain either the old mutation or different mutations (insertions, deletions or 
duplications). All six clones and the mutations identified in each are listed below.
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Observations
Clone1
GMSEQ3: has retained the old mutation
GLAMOR -  CAGACTATTATTGTTGCCAAGATCTTAGTTTTCCGGACACGTTCGGTGCT - 7 5 0
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I  I I I N I  I I
GM SEQ3_IC -  CAGACTATTATTGTTGCCAAGATCTTAGTTTTCCGGACACGCTCGGCGCC - 2 2 7  
GLAMOR -  GGGACCAAGCTCGAGCTGAAACGGGCGGCCGCAGAACAAAAACTCATCTC - 8 0 0
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
GMSEQ3 IC  -  GGGACCAAGCTCGAGCTGAAACGGGCGGCCGCAGAACAAAAACTCATCTC - 2 7 7
Clone2:
GMSEQ5: contains the correct mutation but lacks one base upstream
▼
GLAMOR -  TTTGCAGACTATTATTGTTGCCAAGATCTTAGTTTTCCGGACACGTTCGG - 7 4 6
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l  I I I I I I I I I I I I I I
G M SC FV 5_IC - TTTGCAGACTATTATTGTTGCCAAGATCTTAGTTT- CCGGACACGTTCGG - 5 4 2  
GLAMOR -  TGCTGGGACCAAGCTCGAGCTGAAACGGGCGGCCGCAGAACAAAAACTCA - 7 9 6
II l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
GMSCFV5 I C -  CGCCGGGACCAAGCTCGAGCTGAAACGGGCGGCCGCAGAACAAAAACTCA - 5 9 2
Clone 3:
GMSEQ8: retains the old mutation and contains a single base insertion upstream
T
GLAMOR -  TTTTGCAGACTATTATTGTTGCCAAGATCTTAGTTTTCCGGACAC- GTTC - 7 4 4
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l  I II
GMSEQ8 -  TTTTGCAGACTATTATTGTTGCCAAGATCTTAGTTTTCCGGACACTGCTC - 3 6 5
GLAMOR -  GGTGCTGGGACCAAGCTCGAGCTGAAACGGGCGGCCGCAGAACAAAAACT - 7 9 4
II II l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
GMSEQ8 -  GGCGCCGGGACCAAGCTCGAGCTGAAACGGGCGGCCGCAGAACAAAAACT - 4 1 5
Clone 4:
GMSEQ9: retains the old mutation and an additional point mutation downstream
GLAMOR -  TTGCAGACTATTATTGTTGCCAAGATCTTAGTTTTCCGGACACGTTCGGT - 7 4 7
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l  I N I
GMSEQ9 IC  -  TTGCAGACTATTATTGTTGCCAAGATCTTAGTTTTCCGGACACGCTCGGC - 4 0 2
GLAMOR -  GCTGGGACCAAGCTCGAGCTGAAACGGGCGGCCGCAGAACAAAAACTCAT - 7 9 7
I I  l l l l l l l l l l l l l l l l l l l l  I I '  I I I I I I I I  I I I I I I I I I  I I I I
GMSEQ9 IC  -  GCCGGGACCAAGCTCGAGCTGAACCGGGCGGCCGCAGAACAAAAACTCAT - 4 5 2
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Clone 5:
GMSEQ10:conatins the correct mutation, but has duplicated bases downstream (126 
bases)of GlaMor (see complete sequencing result for GMSEQ10 below)
GLAMOR -  GCAGACTATTATTGTTGCCAAGATCTTAGTTTTCCGGACACGTTCGGTGC - 7 4 9
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l  II
G M SE Q 10_IC - GCAGACTATTATTGTTGCCAAGATCTTAGTTTTCCGGACACGTTCGGCGC - 4 0 9  
GLAMOR -  TGGGACCAAGCTCGAGCTGAAACGGGCGGCCGCAGAACAAAAACTCATCT - 7 9 9
l l l l l l l l l l l l l l l l l l l l l i l l l l l l l l l l l l l l l l l l l l l l l l l l l
G M SE Q 10_IC - CGGGACCAAGCTCGAGCTGAAACGGGCGGCCGCAGAACAAAAACTCATCT - 4 5 9
Dublicated Bases (shown in italics and underlined)
CCAGTTNCAT CTCNTATGGC CTCTNTGGAA AANGTCAGTC TCACTGTGGG CAGTCAAGAA
ATTAGTGGTT CTTAAGCTGG CTTGGCAGAA CCAGATGAAC TATTAAACGC CTATCTACGC
NGCATCCACT TTAGATTCTG GTGTCCCAAA AAGGTTCAGT GGCAGAAGGT CTGGGTCAGA
TTATTACTCA CCATCAGCAA G CCTTGAGTC T G A A G A TT TT  G C A G AC TA TT A TTG TTG C C A  <
A G A T C T T A G T  TTTCCG GACA CGTTCGGCGC CGGGACCAAG CTCGAGCTGA AACGGCGGCC
GCAG AACAAA A A C TC A G A TT  ATTCACTCAC CATCAGCAAG CCTTGAGTCT GAAGATTTTG .
CAGACTATTA TTGTTGCCAA GATCTTAGTT TTCCGGACAC GTTCGGCGCC GGGACCAAGC
TCGAGCTGAA ACGGGCGGCC GCAGAACAAA AACTCATCTC AGAAGAGGAT CTGAATGGGG
CCGCACATCA CCATCATCAC CATTAATAAG AATCCANTGG CCGTCNTTAT ACAACGTCGT
GGCTNNAAAA A
Clone6:
GMSEQ11: contains additional mutatons around the NarI site
GLAMOR -  CTGGGTCAGATTATTCACTCACCATCAGCAGCCTTGAGTCTGAAGATTTT - 6 9 9
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
G M SE Q 11_IC - CTGGGTCAGATTATTCACTCACCATCAGCAGCCTTGAGTCTGAAGATTTT - 3 5 3
T T T
GLAMOR -  GCAGACTATTATTGTTGCCAAGATCTTAGTTTTCCGGACACGTTC- GGTG - 7 4 8
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l  I II I
GMSEQ11 I C -  GCAGACTATTATTGTTGCCAAGATCTTAGTTTTCCGGACACGCTATGGCG - 4 0 3
GLAMOR -  CTGGGACCAAGCTCGAGCTGAAACGGGCGGCCGCAGAACAAAAA - 7 9 7
I 1 1 1 1 1 1 1 1 1  M  1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1  M  M  1 1 1 1 !
G M SE Q 11_IC - CCGGGACCAAGCTCGAGCTGAAACGGGCGGCCGCAGAACAAAAA - 4 5 3
Conclusions
Inverse PCR worked to repair Leucine back to Phenylalanine. However, it introduced 
other mutations into the GlaMor scFv gene. Although, the PCR process itself might be 
causing this problem, some instability deriving from the GlaMor scFv gene cannot be 
excluded. This is particularly strengthened by the fact the Pfu polymerase (Stratagene) 
used for these experiments has a much lower error rate and is unlikely to have been 
responsible for the observed mutations.
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The above GlaMor sequences were screened (50bp-lbp) either side of the problematic 
region against the EMBL database, to identify possible matches with other unstable 
sequences of other ‘difficult’ Fv’s. The search revealed antibody-related sequences 
none of which have been catalogued as giving rise to instability or problematic 
expression.
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7.5 Non-PCR Back Mutagenesis of Leucine to 
Phenylalanine.
Protocol
GlaMor/pUC119his6mycXba was double digested with Bglll and Notl and the large 
piece of DNA was gel purified. The two primers:
• GM-KORR-CO (56mer): gat ctt agt ttt ccg gac acg ttc gee gcc ggg acc aag etc gag 
ctg aaa egg gc and
• GM-KORR-IC (56mer): ggc ege ccg ttt cag etc gag ctt ggt ccc ggc gcc gaa cgt gtc 
egg aaa act aa
when annealed yield BglU and Notl overhangs (in italics) and were ligated with the cut 
plasmid (Fig.7.3) This step replaced the piece containing the fault with a synthetic 
correct sequence (in bold). Positive clones were selected and characterised by 
restriction digest, using Bglll and Notl to cut out the insert and a newly created Narl 
site (unerlined) contained on the insert itself (silent mutation to facilitate screening). 
Positive clones were verified by sequencing the whole GlaMor sequence.
The GlaMor scFv gene was subcloned in the pDAP2 (Fig. 7.1). Briefly, pDAP2 vector 
was digested with Pstl and Not. The GlaMor gene was prepared by digesting the gene 
coding for the repaired GlaMor with the same enzymes and purifying using 
preparative gel electrophoresis. Then, the gene was inserted into pDAP2 and the 
construct was verified by restriction analysis. Positive constructs were used for 
expression as described in paragraph 7.3 It should be noted, that bacteria harboring 
GlaMor constructs were grown at less than 25°C, for both DNA preparation or protein 
expression to minimise the instability risk.
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The expression and purification were performed as follows:
E. coli strain TGI harboring the GlaMor/pDAP2 construct were grown up in M9ZB 
containing lOOpg/ml ampicillin and 2%(w/v) glucose to an OD600 of 0,8-0,9. Cultures 
were cooled down to 16°C, IPTG was added to ImM and cultures were shaken for 16- 
18 hours at 16°C. Cells were harvested by centrifugation (11,000 x g, 4°C, lOmin), 
resuspended in 0.2M borate pH 8.0 containing lmMNaCl and ImM EDTA and 
incubated on ice for 30min.
After centrifugation (13000 x g, 4°C, 20min) the supernatant was recovered and the 
pH was adjusted to 7.35 by adding 1M KH2P04. Imidazole was added to ImM final 
concentration. The phosphatase activity was determined in lOpl sample by adding 100 
pi substrate buffer (lmgPNPP/ml, 50mM Tris pHIO, 150mM NaCl, 2mM MgCl2), 
incubation for 45min at room temperature and measuring the OD at 405nm. 
Purification was performed by using HiTrap Chelating Sepharose:column (Pharmacia, 
Sweden). The column was loaded with 0.1M ZnCl2 and equilibrated with PBS/1 M 
NaCl. The periplasmic fraction was loaded on the column, then washed with 
equilibration buffer and eluted in 1ml fractions by increasing imidazole concentrations 
of lOmM up to 120mM.
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Cloning as Pst I/Not I cassette in the pDAP2 vector
Fig.7.3: Non-PCR mutagenesis of Leucine back to Phenylalanine.
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Observations
The OD405 measurements are shown at the table below.
Before IMAC Purification After IMAC Purification
M9ZB Blank 0.032 Periplasmic Extract 0.088
Buffer Blank 0.024 Flow Through 0.420
Supernatant 0.117 Wash (without Imidazole) 0.038








The four fractions marked with asterisks were pooled and frozen in liquid N2 at -80°C 
and analysed by silver staining (Fig. 7.4A). The protein corresponding to MW 75kD 
had no phosphatase activity, while phosphatase activity was present in a band at 
50kDa, possibly corresponding to alkaline phosphatase alone. After Western Blotting 
with anti-his tag antiboly (Fig.7.4C) both lanes gave a signal at the same MW of 
50kDa which was too low to be intact phosphatase-fusion protein, suggesting 
degradation.
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Conclusions
The non-PCR method used for correcting leucine back to phenylalanine succeeded to 
produce clones with the correct sequence avoiding other unwanted mutations. GlaMor 
scFv clones with the correct sequence were tried for expression but failed to provide 
scFv material. The hypothesis that the mutation of Phenylalanine to Leucine might 
have caused the problems with GlaMor scFv expression is therefore considered 
unlikely.








Fig. 7.4: Expression and purification of the repaired GlaMor scFv
Silver staining gel (A) with different fractions (lanes 1-4) after IMAC purification. Proteins of the correct 
molecular weight are shown at 75kDa. Two of these fractions (A2 and A3), which showed bands of the 
correct size and had phosphatase activity were pooled with their left and right neighbor (Aland A4) and are 
shown on gel B (silver staining gel) and gel C (anti-his tag western blot).
8Kinetic analysis of recombinant antibody- 
antigen interactions
8.1 Introduction
The relationship between domain structures of recombinant monoclonal antibody 
fragments and their reaction kinetics was studied for the first time using a biosensor 
based on surface plasmon resonance (SPR) by Borrebaeck et al. in 1992.
Evaluating newly engineered antibodies requires the measurement of their affinity 
constants for a given antigen. The biosensor based technology permits real-time mass 
measurements using either surface plasmon resonance (SPR, BIAcore) or a resonant 
mirror (Iasys, Fisons). In this chapter the preliminary results described were obtained 
from the SPR BIAcore™ system (BIAcore).
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The BIAcore™ system is built of a processing and a computer unit. The processing 
unit consists of an integrated fluidic cartridge, a sensorchip and a detector. The 
interaction between biomolecules takes place on the sensor chip, which consists of an 
optically flat glass slide covered with a thin layer of gold on one side. A hydrophilic 
dextran matrix is covalently bound to the gold film. (Fig. 8.1). Antibody or antigen is 
coupled to the matrix and allowed to react with its counterpart. The amount of protein 
bound to the gold surface is analysed by measuring the surface plasmon resonance 
(SPR). A change of 0.1 degree corresponds to lng bound protein/mm2 or 1000RU 
(RU= resonance unit which is an instrument specific unit). The SPR results are 
illustrated as a sensorgram, where resonance units (RU) are plotted against time 





Incident light Reflected light
Fig. 8.1: Schematic of biosensor optics
In SPR when a resonant coupling between the incident light energy and surface plasmons in 
the conducting film occurs at a specific angle of incident light, absorbing the light energy and 
causing a characteristic drop in the reflected light at that angle.
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8.2 Materials and Methods
BIAcore Sensor chip CM5 and the amine coupling kit containing NHS, EDC and a 
solution of 1M ethanolamine hydrochloride adjusted to pH 8.5 with sodium hydroxide 
were obtained from BIAcore. The studies described on this chapter were carried out 
on a BIAcore 2000 at BIAcore (Stevenage, U.K).
8.2.1 Immobilisation of 9E10 mAb on CM5 sensor chip
The general procedure for the conditioning of the sensor chip CM5 surface using HBS 
buffer was carried out before the activation of the carboxyl groups as described by the 
manufacturer (BIAcore). After the sensor chip was conditioned, the automated 
immobilisation cycle was performed at a flow rate of 20pl/min. 70pl each of 0.4M 
EDC and 0.1M NHS were mixed together and injected over the surface. 9E10 mAb 
(50pg/ml) was immobilized on all four flowcells of the Biacore 2000 system, in 
lOmM acetate buffer at pH 5.0 at a flow rate of lOpl/ml. Standard HBS buffer (lOmM 
Hepes pH 7 .4 ,150mM NaCl, 3.4 mM EDTA, 0.005% Surfactant P20) was used as the 
running buffer. The procedure was repeated one more time for all flow cells and a 
third time for flow cell four so as to obtain similar immobilisation levels of 9E10 (in 
RU) in the four flow cells. Any remaining reactive esters were inactivated by injection 
of 1M ethanolamine hydrochloride at pH 8.5.
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7,600 to 9,500 RU of 9E10 was immobilised on the carboxymethylated dextran 
surface of the CMS (BIAcore) on the four flowcells (Fig. 8.2).
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Fig. 8.2: Immobilisation of 9E10 anti-myc tag antibody on the CM sensor chip.
1. baseline of unmodified CM5 sensor chip surface with continuous flow of HBS buffer
2. injection of 140ul of NHS/EDC and activation
3. 1st injection of 50ul 9E10 (50ul/ml) in acetate buffer pH 5.0 over flowcells 1-4
4. 2nd injection (as in 3) over flowcells 1-4
5. 3rd injection (as in 3) over flowcell 4
6. ethanolamine capping of the unreacted esthers
7. immobilised level of9E10 on all four flowcells (9,500 RU on FC1, 8,300 RU on FC2, 7,800 RU 
on FC3 and 7,600 RU on FC4.)
8.2.2 Interaction analysis
Gloop2 and GlaMor scFv binding to the 9EI0.
Flow cell two (FC2) was kept as a negative control or blank for each experiment. 
Gloop2 scFv (2pg/ml) was injected at 5|il/min in HBS buffer over flowcell 
three. 1,400RU of Gloop2 was captured on 9E10. (Fig. 8.3). Similarly GlaMor scFv 
was injected at 5pl/min over flow cell three. Very little of this ligand was available for 
capture, typically less than 50RU. (Fig. 8.4).
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Peptides
40pl of Loop peptide (9pM) in HBS was injected at 20pl/min over flowcells two and 
three. Injecting 40pl of lOmM Glycine pH 2.2 at 20pl/min regenerated the surface of 
the sensor chip. (Fig. 8.5).
The same experiment with Gloop2 scFv bound to 9E10 was repeated and enkephalin 
was passed over flow cells two and three to detect any non-specific binding to Gloop2 
scFv.
The amino acid sequences of loop peptide and Leu-enkephalin are shown in Fig. 8.6
• Leu-enkephalin: Tyr-Gly-Gly-Phe-Leu
• Loop peptide: Gln-Ile-Asn-Ser-Arg-Trp-Trp-Cys-Asn-Asp-Gly-Arg-Thr-Pro-Gly- 
Ser-Arg-Asn-Leu-Ala-Asn-Ile-Pro-Cys-Ser-Ala-Leu-leu
Fig. 8.6: Amino acid sequences of Loop and enkephalin peptides.
Chapter 8: Kinetic analysis o f recombinant antibody-antigen interactions 183
Capture of Gloop2 scFv on 9E10 antibody
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Fig. 8.3: Capture of Gloop2 scFv on 9E10 antibody
1. Shared baseline showing the level of immobilised 9E10 on flowcells 2 and 3 (red and green 
respectively).
2. Capturing of Gloop2 scFv on flowcell 3 (green)
3. Equilibrium state of Gloop2 on 9E10
4. Wash with HBS buffer
5. Captured levels of Gloop2 scFv on 9E10; approximately 1,400RU of Gloop2 was captured.
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Fig. 8.4: Capture of GlaMor scFv on 9E10 antibody
1. Shared baseline showing the level of immobilised 9E10 on flowcells 2 and 3 (red and green 
respectively).
2. Capturing of GlaMor scFv on flowcell 3 (green)
3. Equilibrium state of GlaMor on 9E10
4. Wash with HBS buffer
5. Captured levels of GlaMor scFv on 9E10
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Fig. 8.5: Binding of peptide antigens on Gloop2 scFv
1. Baseline of immobilised 9E10 (blank surface, FC2, red) and captured Gloop2 scFv on 9E10 (FC3, 
green)
2. Decrease in the SPR signal due to the change of bulk refractive index
3. Wash under continuous flow of HBS of the bound loop peptide. Approximately 50 RU of peptide 
have been bound on Gloop2 scFv (left sensorgram) while non-detectable amount of enkephalin 
binds to Gloop2 scFv (right sensorgram).
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Fig. 8.7: Binding of peptide antigens on GlaMor scFv
4. Baseline of immobilised 9E10 (blank surface, FC2, red) and captured GlaMor scFv on 9E10 (FC3,
green)
5. Decrease in the SPR signal due to the change of bulk refractive index
6. Wash under continuous flow of HBS of the bound loop peptide. Non-detectable amounts of either
loop peptide (left sensorgram) or enkephalin (right sensorgram) bound on GlaMor scFv.
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8.3 Qualitative measurement of binding kinetics
8.3.1 Stoichiometric calculation of maximal binding levels of loop 
peptide on Gloop2 and GlaMor scFv
The molecular weight of the 9E10 antibody is 150kDa and that of the Goop2 and 
GlaMor scFv is approximately 32kDa. Hence, the maximal binding capacity of 
Gloop2 and GlaMor scFv on a sensor surface area with 7,800 RU of captured 9E10 
would be 3,120 RU, taking into account 1:2 stoichiometry of binding. For Gloop2 
scFv, approximately 1,400 RU was captured using 2pg/ml, which was the highest 
concentration available. Since the Loop peptide is 1.1 kDa the maximal binding 
capacity of this surface assuming 1:1 stoichiometry would have been 48 RU. For the 
Loop peptide 50 RU was captured using the 9pM concentration, which was estimated 
as saturating. Had the Gloop2 scFv shown any specificity for the enkephalin peptide, 
which has a molecular weight of 500Da, the Rmax (maximum binding capacity) 
would have been about 20 RU.
A typical binding curve on Biacore may run from 20-2000RUs. For GlaMor scFv in 
order to detect a 20RU signal of enkephalin bound on GlaMor scFv a minimum of 
1400RU of captured scFv is needed. This means that the concentration of expressed 
and purified GlaMor scFv required should be 2pg/ml. Given the very low amounts of 
GlaMor scFv expressed and captured on 9E10 no binding of enkephalin on GlaMor 
scFv could be detected.
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8.3.2 Specificity of interaction
The loop peptide bound to Gloop2 scFv with 50 RU when injected at 9pM while no 
binding of the enkephalin was observed at 9pM injection of the peptide over the 
Gloop2 scFv. The surface could be effectively regenerated with using lOmM glycine 
at pH 2.2 for repeated studies on the same sensor surface.
8.3.3 Problems with quantitative analysis
The quantitative analysis that would determine the affinity values of the above 
interactions was not performed. Low levels of GlaMor scFv expression did not 
produce enough material to perform complete quantitative analysis. Provided that 
enough GlaMor scFv was available and specific binding was detected on enkephalin 
against the loop peptide, assays would be repeated with 5-6 different concentrations 
of scFv’s in order to determine the Kon/Koff and affinity values.
Due to the low molecular weight of the loop and enkephalin peptides all interactions 
can only be monitored on Biacore 2000 instrument (available in BIAcore, Stevenage) 
which sensitivity detects low molecular weight analytes.
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8.4 Discussion
The Biacore technology offers a non-label tool for studying the antibody-antigen 
interactions in real time. The experiments described in this chapter aimed to 
investigate the specificity of Gloop2 scFv and GlaMor scFv’s against the loop and 
enkephalin peptides. The design of the assays took into account the low molecular 
weight of the peptide antigens and the very low expression yields of the GlaMor scFv 
as described in Chapter 6. Low molecular weight antigens used as analytes need to be 
detected by a high sensitivity instrument such as the BIAcore 2000. Alternatively, 
BSA conjugated forms of the antigens could increase the mass of the analytes but also 
might interfere with the binding epitope of such small molecules.
The 9E10 anti-myc antibody used for the immobilisation on the CM5 dextran had 
been used successfully for the detection of periplasmic Gloop2 and GlaMor scFv’s in 
Western Immunoblotting (seeChapter 6). Gloop2 and GlaMor scFv were expressed 
and purified as described in Chapter 6 and buffer-exchanged in PBS before the assays. 
Between 1,000 and 1,400 RU of Gloop2 scFv was captured on immobilised 9E10 
antibody over several trials that were carried out. This level of immobilised Gloop2 
scFv on 9E10 was sufficient to proceed with the binding of the loop and enkephalin 
peptide antigens. The assays carried out showed specific binding of the Loop peptide 
on Gloop2. The enkephalin peptide did not show specific binding when used at the 
highest (9pM) concentration. The GlaMor scFv expressed at very low levels and, 
when immobilised on 9E10, calculations indicated that insufficient peptide would be 
captured to allow detection, even by the ultrasensitive Biacore 2000 system. The 
background binding (Fig. 7.7) of the loop and enkephalin peptides detected on the
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blank flowcell with only the immobilised 9E10, was probably due to the fact that the 
9E10 antibody (gift from Dr G.Winter) was not completely pure. In addition, there 
was insufficient material to warrant purification. For this reason, further dose 
dependent Biacore experiments were not carried out and efforts focused on improving 
GlaMor scFv expression and obtaining more material which would then be used in 
binding assays and quantitative analysis.
9Discussion and Conclusions
9.1 Gloop2 and GlaMor CDR sequences
The CDR sequences predicted by the computational design (Chapter 3) and the 
sequences identified by phage selection and used thereafter in bacterial expression 
studies are summarised in Table 9.1. The mutations found in GlaMor after the phage 
Elisa’s showed highest similarity with the fourth ranked construct out of the ten 
lowest energy conformations shown in Table 3.3. From this table several conclusions 
can be drawn:
1. The residues selected by the ab initio design for the theoretical antibody 
combining site are mainly bifunctional residues which are defined as residues capable 
of more than one type of interaction, e.g Tyr which can engage in hydrophobic 
packing interactions and can hydrogen bond through its -OH group. These residue
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types were selected because the average distance between antibody and antigen is 
approximately the same as the side chain length (4.2-4.3A) of the selected residue 
types (His, Phe, Trp, Tyr, Gin, Asn).
2. Residues of the L2 CDR are not included in the design because small antigens 
tend to bind to those residues located at or near the centre of the combining site. By 
contrast, larger protein antigens whose interacting surfaces may be as much as 400A2 
will obligatorily be in contact distance from L2 residues (MacCallum et al., 1996). 
Notwithstanding this physical proximity, it has been reported that CDR-L2 only rarely 
contributes to antigen binding (Wilson and Stanfield, 1993).
3. The L3 89 position.
The primer conferring the mutation at this position was degenerate (Table 4.1) 
encoding for tryptophan, or tyrosine, or a stop codon or cysteine in that position. If a 
stop codon was introduced this would result in non-viable phage since the 
transcription/translation mechanism would terminate before the gill protein. With an 
additional cysteine the GlaMor scFv construct has an odd number of 5 cysteines, 
which as discussed later, may have contributed to the low expression yields of the 
soluble GlaMor scFv.
4. The HI 32 and 34 positions
These two residue positions differed between the computational and the experimental 
work (noted with asterisks in Table 8.1). The ab initio method predicted a F32K 
mutation and no mutation for position 34 which is an isoleucine in Gloop2 wild type 
sequence. The PCR mutagenesis primers did not encode for any of these mutations
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mutation and no mutation for position 34 which is an isoleucine in Gloop2 wild type 
sequence. The PCR mutagenesis primers did not encode for any of these mutations 
that were identified in the construct selected through phage ELISA (Chapter 3). These 
mutations might be attributable to errors of the DNA polymerase during the PCR 
cycles. Since isoleucine in position 34 is classified as a canonical residue (Chothia, 
1989) its replacement by an arginine may have affected the conformation of HI and 
hence the specificity of the GlaMor binding to enkephalin. Database searching 
indicated that Arginine at this position does not occur in any of the known antibody HI 
canonical classes.
Possible interactions between enkephalin and GlaMor are indicated in Fig.9.1
Phe U
Phe L94 His H9i
Fig.9.1 As Fig 3.5C but with residues from the 4th design sequence and showing arrows for CDR- 
enkephalin interactions suggested by the pharmacophore in Fig 3.2
Chapter 9: Discussion and Conclusions 192
In the orientation generated by the design process a number of plausible 
pharmacophoric interactions can be satisfied. For example, the tyrosine of enkephalin 
is flanked by phenylalanine H35 (threonine in Gloop 2), tryptophan H56 (lysine in 
Gloop 2) with a possible but more distant contact with phenylalanine L94 (tyrosine on 
Gloop 2). It is also in hydrogen bonding distance from histidine 50 of H2 and 
histidine 95 of H3, both of which are glutamic acid residues in Gloop2 and possibly 
either or both involved in the salt bridge interactions with the critical binding arginine 
of the loop peptide. Additionally, the phenylalanine sidechain of enkephalin is also 
close to phenylalanine L32 (tyrosine in Gloop 2). More distant, and hence less likely 
to be important, interactions were seen for D91 and D96 with the backbone of 
enkephalin (not shown for clarity). These plausible interactions at least are consistent 
with the requirement (see Fig.3.2) for three hydrophobic sites (H56, L94 and L32) 
plus an anionic site (H50 and H95). The lack of a clear phenolic site would be an 
obvious case for second round improvement.
A question that could be posed is : Why was the 4th ranked construct selected and no 
others? The top ranked, 4th ranked and wild type sequences at the design positions are 
summarised in Table 9.2 below:
LI L3 HI H2 H3
32 89 91 94 96 32 35 50 56 95 96 101
F W D F N K F H W H D F
F w/C D F D K F H W H D Y
Y L Y Y L F T E K E I R
Table 9.2
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This indicates that there are few differences between the two design sequences -  DvN 
at position L96 and YvF at position H I01. The process of modelling and energy 
calculations is not yet so precise that it can easily discriminate models with this type 
of subtle difference (although D is charged, N has the ability to hydrogen bond, both 
as a donor and acceptor). Since there are no positively charged residues in enkephalin 
the hydrogen bonding of N96 may have been more important than the charge, 
resulting in deselection of the top candidate.
In contrast, the differences from the Gloop 2 sequence are quite significant. LI and L3 
are essentially hydrophobic in Gloop 2, while the negative charges are located in the 
heavy chain (H2 and H3). This is essentially reversed in the GlaMor sequences where 
two histidines are found in the heavy chain, one in place of E50 and the other in place 
of E95. In addition, two negatively charged residues are located in LI and L3 
essentially altering that region of the groove from hydrophobic to hydrophilic.
A complicating factor was the presence of two unexpected mutations in the selected 
phage construct. The first at position L89, where a cysteine was present in place of the 
expected tryptophan, is not likely to have had a major impact since it would probably 
have been too short to engage in enkephalin contact. Of more consequence could have 
been the mutation of 134 to arginine in HI. This is a canonical position and is 
involved in HI packing. A change in conformation of HI may thus have occurred. 
However, position 34 is not a groove contact residue and since there is also a 
positively charged residue at position 32 (K) it is possible that even with a small 
conformational change, positive charge at or close to the groove would have been 
retained.
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The foregoing highlights the difficulties of interpreting binding data of mutants in the 
absence of x-ray structures. Had it been possible to generate accurate models of the 
selected designs, at least some attempt at rationalisation of the specificity change 
could have been made. Poor expression thwarted such attempts at full 
characterisation, and ultimately structural studies. It may be that any redesign project 
of this sort should only be attempted or pursued where a high chance of obtaining 
crystals of the mutants exists.




32 89 91 94 96 32 34 35 50 55 95 96 101
Gloop2
Sequence













F C D F D F R F H W H D Y
* *
Table 9.1: Summary table of the CDR sequences predicted computationally and identified 
experimentally.
The Gloop2 wild type sequence is shown on the first row. Asterisks mark the residue positions were 
the predicted and the observed sequence differ. The isoleucine at position H34 (marked in grey )was 
maintained at the design as it is a canonical position. The mutation of this position to arginine as seen 
on the phage selected construct can attributed to a PCR error.
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9.2 Bacterial expression of Gloop2 and GlaMor scFv.
This study defines several problems encountered when periplasmic expression is 
attempted in E. coli, associated mainly with the very low yields of the GlaMor 
construct. Gloop2 expression levels were also low with 2pg/ml of culture as the 
maximum concentration obtained. Several optimisation trials have been carried out to 
maximise the expression yield as described in Chapter 6. The results were consistent 
for the two constructs with the Gloop2 giving better yields than GlaMor. A lower 
amount of scFv in the periplasmic or culture supernatant led to less pure material after 
the IMAC purification. Trials aimed at concentrating the fractions obtained were 
laborious and extended the time of the experiments, which in turn increased the risk of 
proteolytic degradation.
Attempts to improve the expression yields of GlaMor included the addition of redox 
buffer in the media during induction as well as sucrose in a separate set of trials. Both 
methods were based on earlier studies by Proba el al.(\991) and Kipriyanov et al. 
(1997) respectively. The addition of a low concentration redox buffer was attempted 
to improve the folding of GlaMor scFv, which might have been affected by the fifth, 
unpaired cysteine introduced during PCR mutagenesis. Normal formation of 
disulphide bonds between cysteine pairs involves membrane bound proteins that are 
displaced by the “normal” partners. If the second is missing the unpaired cysteine 
might form incorrect disulphide bonds with wrong cysteines from other proteins 
leading to an aggregation-prone product. Glutathione derivatizes the unpaired 
cysteine, does not interfere with affinity purification and can be removed by mild
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reduction conditions. However, these studies showed no effect of glutathione on the 
expression yields of GlaMor scFv.
Sucrose added in the media has been proposed to stabilise the expressed scFv by 
inhibiting aggregation. The hypothesis is that sucrose increases the osmotic pressure 
and causes the periplasm to enlarge (Kiefhaber et al., 1991) decreasing the 
concentration of secreted protein and resulting in less aggregation. The studies 
reported here showed that although in the Gloop2 system the addition of sucrose 
increased the yield of the scFv that was directed into the medium after a 24-hour 
induction by up to 100%, it had no effect on the expression levels of GlaMor.
It was concluded that the very low efficiency of expression for the GlaMor scFv 
construct was probably attributable to its highly engineered primary sequence. It has 
been shown that the degree of successful folding depends on the primary sequence of 
the variable domains (Pluctkthun, 1994; Knappik and Pluckthun, 1995).
Further engineering of the antibody sequence has been proposed as a strategy to 
obtain correctly folded periplasmic proteins in high yields (Knappik and Pluckthun, 
1995). Therefore it is possible that further mutagenesis of the GlaMor sequence could 
improve the expression yields and facilitate further characterisation.
The possibility of producing individually the ten GlaMor constructs as predicted in 
Chapter 3 using site-specific mutagenesis and further expression and binding analysis 
would be worth investigating. In vitro scanning saturation mutagenesis of an anti-
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digoxin antibody binding pocket has been demonstrated as a useful tool for protein 
structure-function and engineering studies (Burks et a l , 1997).
Yeast, insect and mammalian expression systems have been also exploited with 
relative advantages and disadvantages. The baculovirus mediated expression systems 
are the most popular of the insect cell expression systems and have already been used 
for the production of an anti-pancarcinoma antigen scFv and its IL-2 fusion protein 
(Bei et al, 1995). The main advantage of this system is that can provide high levels of 
the desired protein with most of the post-translational alterations which are used by 
higher eukaryotes. However, it has been shown that the nature of the gene to be 
expressed is able to affect the yields of the expressed protein (Ellis et a l , 1988).
The main advantage of yeast over other expression sytems are related to the fact that it 
both a microorganism and a eukaryot, providing an advanced folding protein pathway 
for heterologous proteins as well as rapid production on simple growth media. High 
levels of secreted recombinant antibody scFv’s have been achieved in yeast 
expression systems (Eldin et a l, 1997).
Mammalian cells have been also used for the production of a wide range of scFv, scFv 
fusion proteins in lower levels compared to the yield obtained from the bacterial 
expression system (Dorai et a l, 1994). The main advantage of this system is that the 
signals for synthesis, processing and secretion of eukaryotic proteins are properly and 
efficiently recognised.
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It should be noted that different antibodies pose their own problems and so no 
“universal” expression system can be used. Similarly to GlaMor, some antibodies 
might be inherently poor at being expressed. In such circumstances a choice should be 
made on investing more time on this particular molecule, in an attempt to improve the 
expression, or reselecting an alternative molecule that may prove superior. Given the 
amount of effort and time already expended, in Bath and Vienna, it may be more 
profitable to reselect an antibody sequence from the original design. This is clearly not 
an option for the present author.
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The Perkin Elmer Applied Biosystems (ABI) 373A Automated Sequencer was used for 
all the sequencing reactions described in this thesis. The termination at each of the four 
nucleotides is characterised by a different coloured dye and all four reactions can be run 
in a single lane, rather than four separate lanes. Using dy-labelled terminators 
(DyeDeoxyTerminators, ABI) all four reactions can be performed simultaneously in the 
same tube (according to the manufacturer’s instructions).
B. Software packages for sequencing analysis
There are several software packages for the anlysis of DNA sequences. If using an 
automated sequencer, the analysis software should be compatible with its output, so that 
the sequences can be directly imported. The ABI 373A automated sequencer software 
runs on an Apple Macintosh. The ABI sequence editor SeqEd ( the updated version is 
called Sequence Navigator) was used for sequence analysis. SeqEd allows multiple
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chromatograms from the same of different runs to be displayed simultaneously. The 
sequences can be compared and the differences between them highlighted. This was
particularly useful for comparing the Gloop2 and GlaMor scFv nucleotide sequences and 
identifying the mutated bases. SeqEd can also reverse complement sequences and 
produce amino acid translations. After performing the above manipulations using SeqEd 
the Gloop2 and GlaMor scFv full length sequences were saved and are shown below.
C. The Gloop2 and GlaMor scFv full sequences
The Gloop2 and GlaMor scFv sequences were translated in amino acid sequences. The 
protein sequences were compared and the different amino acids were marked with 
asterisks. In the format below all four nucleotide and protein sequences are shown as well 
as the differences between them. Both scFv constructs start with a pelB leader sequence 
at the N’-end followed by the VH, the linker, the VL, the myc-tag and the 6xhistine tag at 
the C’-end.
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TCTAGAATGA AATACCTATT GCCTACGGCA GCCGCTGGAT TGTTATTGCT 
S R M  K Y L L  P T A  A A G L L L L
TCTAGAATGA AATACCTATT GCCTACGGCA GCCGCTGGAT TGTTATTGCT 
S R M  K Y L L  P T A  A A G L L L L
60 70  80 90 IG0






AGCTGCCCAA CCAGCGATGG CCCAGGTGCA GCTGCAGCAG TCTGGAACTG 
A A Q P A M  A Q V Q  L Q Q  S G T
AGCTGCCCAA CCAGCGATGG CCCAGGTGCA GCTGCAGCAG TCTGGAACTG 
A A Q  P A M  A Q V Q  L Q Q  S G T
1 10  1 2 0  1 3 0  1 4 0  1 5 0  






AGTTGGCGAG GCCTGGGGCT TCAGTGAGGC TGTCCTGCAA GGCTTCTGGA 
E L A R  P G A  S V R  L S C K  A S G
AGTTGGCGAG GCCTGGGGCT TCAGTGAGGC TGTCCTGCAA GGCTTCTGGA 
E L A R  P G A  S V R  L S C K  A S G
16 0  1 7 0  18 0  1 9 0  2 0 0






TACACCTTCA CAACCTTTGG TATAACCTGG GTGAAGCAGA GAACTGGACA
Y T F  T T F G  I T W  V K Q  R T G Q
* *
TATACCTTCA CAACCTTTGG TAGATTCTGG GTGAAGCAGA GAACGGGACA 
Y T F  T T F G  R F W  V K Q  R T G Q
2 1 0  2 2 0  2 3 0  2 4 0  2 5 0






GGGCCTTGAG TGGATTGGAG AAATTTTTCC TGGAAATAGT AAGACTTACT 
G L E  W I G  E I F P  G N S  K T Y
GGGCCTTGAG TGGATTGGAC ATATTTTTCC TGGAAATAGT TGGACTTACT 
G L E  W I G  H I F P  G N S  W T Y
2 6 0  2 7 0  2 8 0  2 9 0  3 0 0






ACGCTGAGAG GTTCAAGGGC AAGGCCACAC TGACCGCAGA CAAATCCTCC 
Y A E R  F K G  K A T  L T A D  K S S
ACGCTGAGAG GTTCAAGGGC AAGGCCACAC TGACCGCAGA CAAATCCTCC 
Y A E R  F K G  K A T  L T A D  K S S
3 1 0  3 2 0  3 3 0  3 4 0  3 5 0






ACCACAGCCT ACATGCAGCT CAGCAGCCTG ACATCTGAGG ACTCTGCCGT 
T T A Y M Q L  S S L  T S E  D S A V
ACCACAGCCT ACATGCAGCT CAGCAGCCTG ACATCTGAGG ACTCCGCCGT 
T T A Y M Q L  S S L  T S E  D S A V
3 6 0  3 7 0  3 8 0  3 9 0  4 0 0






CTATTTCTGT GCAAGAGAGA TCCGCTACTG GGGCCAAGGG ACCAAGGTCA
Y F C  A R E  I R Y W  G Q G  T K V
* * *
CTATTTCTGT GCAAGACATG ACTACTACTG GGGCCAAGGC ACCAAGGTCA 













CCGTCTCCTC AGGTGGAGGC GGTTCAGGCG GAAGTGGCTC TGGCGGTGGC i 
T V S S  G G G  G S G  G S G S  G G G
CCGTCTCCTC AGGTGGAGGC GGTTCAGGCG GAAGTGGCTC TGGCGGTGGC 
T V S S  G G G  G S G  G S G S  G G G







GGATCGGACA TCGAGCTCAC CCAGTCTCCA TCCTCCTTAT CTGCCTCTCT 
G S D  I E L T  Q S P  S S L  S A S L
GGATCGGACA TCGAGCTCAC CCAGTCTCCA TCCTCCTTAT CTGCCTCTCT 
G S D  I E L T  Q S P  S S L  S A S L
510 5 2 0
1







GGGAGAAAGA GTCAGTCTCA CTTGTCGGGC AAGTCAAGAA ATTAGTGGTT 
G E R V S L  T C R A  S Q E  I S G
GGGAGAAAGA GTCAGTCTCA CTTGTCGGGC AAGTCAAGAA ATTAGTGGTT 
G E R V S L  T C R A  S Q E  I S G






ACTTAAGCTG GCTTCAGCAG AAACCAGATG GAACTATTAA ACGCCTGATC 
Y L S W  L Q Q  K P D  G T I K  R L I
■k_________________   ;______________________ ____________________
TCTTAAGCTG GCTTCAGCAG AAACCAGATG GAACTATTAA ACGCCTGATC 
F L S W  L Q Q  K P D  G T I K  R L I










TACGCCGCAT CCACTTTAGA TTCTGGTGTC CCAAAAAGGT TCAGTGGCAG 
Y A A  S T L D  S G V  P K R  F S G R
TACGCCGCAT CCACTTTAGA TTCTGGTGTC CCAAAAAGGT TCAGTGGCAG 
Y A A  S T L D  S G V  P K R  F S G R
660 6 70
_1_











AAGGTCTGGG TCAGATTATT CACTCACCAT CAGCAGCCTT GAGTCTGAAG 













S S L  E S E
7 4 0 I
ATTTTGCAGA 






L S Y P L T F
ATTTTGCAGA 









L S F P D T F




























810 820 830_L_ 8 4 0 8 5 01
CATCTCAGAA GAGGATCTGA ATGGGGCCGC ACATCACCAT CATCACCATT 
I S E E D L  N G A A H H H  H H H
CATCTCAGAA GAGGATCTGA ATGGGGCCGC ACATCACCAT CATCACCATT 
I S E E D L  N G A A H H H  H H H
86 0
_L_














A. Immobilisation, binding and regeneration on the BIAcore
SPR analysis depends on immobilising (convalent binding) sufficient amounts of the 
ligand to the carboxymethyl dextran hydrogel. In the case of protein ligands, proteins 
usually possess sufficient surface lysine residues so that coupling to the carboxyl groups 
of the hydrogel can be accomplished without completely destroying the
ligand’s antibody binding activity. Johnson et al (1991) have shown that maximum 
protein binding to the hydrogel occurs at a pH below the protein’s isoelectric point and at 
low ionic strength (lOmM or less) where ionic interactions between the protein and 
hydrogel are favoured. Amine coupling of protein to EDC/NHS activated carboxyl 
groups of the hydrogel, the standard BIAcore activation chemistry, occurs best at the pH 
where the matrix amount of protein electrostatically interacts with the hydrogel. For most 
proteins, even those of low pi, the optimum pH is from 4.0-4.5, the optimum pH for EDC 
activation of carboxyl groups. The entire process is monitored by a sensorgram and the 
net target value of net covalent binding to the hydrogel should be from a minimum of
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1000 to a maximum of 10000 RUs. At the lower end, there may not be sufficient range 
(in RUs) to cover the binding kinetics of 4-5 times concentrations of ligate. At the upper 
end, too much ligand (immobilised part) may be present on the biosensor, causing 
problems with mass transport at low analyte (injected part) concentrations.
The amount of ligand to be immobilised for a given application also depends on the 
relative sizes of ligand and analyte. For a large ligand, a given level in RU will represent 
a smaller number of analyte binding sites giving a correspondingly smaller maximum 
binding capacity in RU. Similarly, a large analyte will give a larger response than a small 
analyte for the same number of binding sites.
The apparent stoichiometry of the surface complex may be calculated from the saturating 
binding capacity of the surface if the molecular weights of analyte and ligand are known:
_ . 7 . analyte response ligand M W
Stoichiometry = -----     x -----------------
ligand responsel analyte M W
Ethanolamine is added after the ligand to deactivate any remaining active esthers. 
Regeneration solution may be added to condition the surface before analyte interaction 
analysis. Regeneration refers to removal of non-covalenlty bound analyte: the covalently 
immobilized ligand cannot normally be removed without destroying the sensor chip 
surface. For antibody-antigen interaction, the surface can usually be regenerated by 
lowering the pH.
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The analyte, introduced to the surface with the immobilised ligand, can be analyzed in 
crude sample, such as serum and cell culture supernatants. However, it should be free 
from free particles. Sample concentration and the required amount of substance varies 
between applications. Typical concentration of injected analyte is 2-100pg/ml.
B. Measuring association and dissociation rate constants.
When the analyte is injected in a discrete pulse across a ligand surface, the resulting 
sensorgram can be divided into three essential phases.
1. Association of analyte with ligand during sample injection
2. Equilibrium or steady state during sample injection, where the rate of analyte binding 
is balanced by dissociation from the complex.
3. Dissociation of analyte from the surface during buffer flow.
The three phases are illustrated in Fig. II.2.
The association and dissociation phase provides information on the kinetics of the 
analyte-ligand interaction (i.e. the rates of complex formation and dissociation). The 
equilibrium phase provides information on the affinity of the analyte-ligand interaction. 
The basic kinetic measurements are shown in Table II.l.
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Fig. n.l: Typical sensorgram from immobilisation of monoclonal antibodies to sensor chip CM5
using standard amine coupling chemistry.
1. Baseline for unmodified sensor chip surface with continuous flow buffer.
2. Injection of NHS/EDC to activate the surface gives an increase in the SPR signal due to the change of 
bulk refractive index.
3. Baseline after activation. Activation of the surface has itself only a very slight effect on the SPR signal.
4. Injection of ligand (IgG) leads to electrostatic attraction and coupling to the surface matrix. At this 
point the ligand solution is still in contact with the sensor chip surface and the response includes both 
immobilised and non-covalently bound ligand.
5. Immobilised ligand before deactivation. The ligand solution has passed the sensor surface, and most of 
the protein that is not covalently bound is eluted.
6. Deactivation of unreacted NHS-esthers using 1M ethanolamine hydrochloride, adjusted to pH 8.5 with 
NaOH. The increased SPR signal is due to change in the bulk refractive index. The deactivation 
process also removes any remaining electrostatically bound ligand.







Fig. n.2: Schematic sensorgram, showing association, equilibrium and dissociation phases.
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Basic Kinetic Measurements
A homogeneous 1:1 interaction on the sensor chip surface may be described by the 
equation:
Kon
A + B < j: AB
Koff
Where A is the analyte, B is the surface-bound ligand, Ko„ the association constant and 
Koff the dissociation constant.
Assuming first order interaction kinetics, the rate of association phase during sample 
injection is given by:
d[AB]/dt = K™ [A] [B] -  [AB]
which may be expressed in terms of the SPR signal as:
dR/dt = Ka C Rmax -  (K^ C+Koff) R
Respectively the dissociation phase is described by:
dR/dt = -Kd R
Where dR/dt is the rate of change of the SPR signal 
C is the concentration of the analyte 
Rmax is the maximum analyte binding capacity in RU 
and R is the SPR signal in RU at time t.
Table I I .l : The basic kinetic measurements.
